{"PMC7538175": [["In general, the worse is the adherence, the worse are the health outcomes and patients\u2019 quality of life [1].", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86]]], ["These effects also take place in the management of obstructive lung diseases\u2014asthma and chronic obstructive pulmonary disease (COPD).", [["lung", "ANATOMY", 63, 67], ["pulmonary", "ANATOMY", 108, 117], ["obstructive lung diseases\u2014asthma", "DISEASE", 51, 83], ["chronic obstructive pulmonary disease", "DISEASE", 88, 125], ["COPD", "DISEASE", 127, 131], ["lung", "ORGAN", 63, 67], ["pulmonary", "ORGAN", 108, 117], ["obstructive lung diseases\u2014asthma", "PROBLEM", 51, 83], ["chronic obstructive pulmonary disease", "PROBLEM", 88, 125], ["COPD)", "PROBLEM", 127, 132], ["obstructive", "OBSERVATION_MODIFIER", 51, 62], ["lung", "ANATOMY", 63, 67], ["diseases\u2014asthma", "OBSERVATION", 68, 83], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["obstructive", "OBSERVATION_MODIFIER", 96, 107], ["pulmonary", "ANATOMY", 108, 117], ["disease", "OBSERVATION", 118, 125], ["COPD", "OBSERVATION", 127, 131]]], ["In course of these two conditions, the primary clinical role is attributed to inhaled medications, which are important in management of disease symptoms and natural course of the diseases.IntroductionAs asthma and COPD are frequent and most often chronic conditions, the key to their successful management comes with systematic drug use, particularly those inhaled.", [["asthma", "DISEASE", 203, 209], ["COPD", "DISEASE", 214, 218], ["inhaled medications", "TREATMENT", 78, 97], ["disease symptoms", "PROBLEM", 136, 152], ["the diseases", "PROBLEM", 175, 187], ["IntroductionAs asthma", "PROBLEM", 188, 209], ["COPD", "PROBLEM", 214, 218], ["chronic conditions", "PROBLEM", 247, 265], ["diseases", "OBSERVATION", 179, 187], ["COPD", "OBSERVATION", 214, 218]]], ["Specific drug selection depends on the diagnosis and indication, previous treatment response, disease severity, patient\u2019s individual needs and preferences and various other patient-related factors.", [["patient", "ORGANISM", 112, 119], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 112, 119], ["patient", "SPECIES", 173, 180], ["disease severity", "PROBLEM", 94, 110]]], ["The inhaled drugs used in these two indications include: inhaled corticosteroids (ICS), short-acting beta-agonists (SABA), long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA) [3].IntroductionAsthma and COPD symptoms\u2014their type and severity\u2014often vary among patients and also may change over time.", [["SABA", "CHEMICAL", 116, 120], ["LABA", "CHEMICAL", 150, 154], ["IntroductionAsthma", "DISEASE", 206, 224], ["COPD", "DISEASE", 229, 233], ["corticosteroids", "CHEMICAL", 65, 80], ["inhaled corticosteroids", "SIMPLE_CHEMICAL", 57, 80], ["short-acting beta-agonists", "SIMPLE_CHEMICAL", 88, 114], ["SABA", "SIMPLE_CHEMICAL", 116, 120], ["long-acting beta-agonists", "SIMPLE_CHEMICAL", 123, 148], ["LABA", "SIMPLE_CHEMICAL", 150, 154], ["long-acting muscarinic antagonists", "SIMPLE_CHEMICAL", 160, 194], ["LAMA", "SIMPLE_CHEMICAL", 196, 200], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292], ["The inhaled drugs", "TREATMENT", 0, 17], ["inhaled corticosteroids (ICS", "TREATMENT", 57, 85], ["short-acting beta-agonists", "TREATMENT", 88, 114], ["long-acting beta-agonists (LABA", "TREATMENT", 123, 154], ["long-acting muscarinic antagonists (LAMA)", "TREATMENT", 160, 201], ["IntroductionAsthma", "PROBLEM", 206, 224], ["COPD symptoms\u2014their type and severity\u2014often", "PROBLEM", 229, 272], ["COPD", "OBSERVATION", 229, 233]]], ["Although these diseases are life-threatening conditions\u2014especially during an exacerbation or severe breathlessness attack\u2014in course of chronic treatment patients still have some degree of freedom in self-management during stable, controlled periods of their disase.", [["breathlessness", "DISEASE", 100, 114], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["these diseases", "PROBLEM", 9, 23], ["life-threatening conditions", "PROBLEM", 28, 55], ["an exacerbation", "PROBLEM", 74, 89], ["severe breathlessness", "PROBLEM", 93, 114], ["chronic treatment", "TREATMENT", 135, 152], ["self-management", "TREATMENT", 199, 214], ["their disase", "PROBLEM", 252, 264], ["diseases", "OBSERVATION", 15, 23], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["chronic", "OBSERVATION_MODIFIER", 135, 142]]], ["Despite that, efficient long-term asthma and COPD treatment comes from the proper and regular use of inhaled medications.", [["asthma", "DISEASE", 34, 40], ["COPD", "DISEASE", 45, 49], ["efficient long-term asthma", "PROBLEM", 14, 40], ["COPD treatment", "TREATMENT", 45, 59], ["inhaled medications", "TREATMENT", 101, 120], ["long-term", "OBSERVATION_MODIFIER", 24, 33], ["asthma", "OBSERVATION", 34, 40], ["COPD", "OBSERVATION", 45, 49]]], ["In this case, adherence to treatment, and primary adherence in particular, greatly contributes to the therapeutic success.IntroductionDefined in the ABC European consensus, medication adherence is as an active, cooperative and voluntary participation of the patient in following recommendations from a healthcare provider.", [["patient", "ORGANISM", 258, 265], ["patient", "SPECIES", 258, 265], ["treatment", "TREATMENT", 27, 36], ["medication adherence", "TREATMENT", 173, 193]]], ["The process involves three crucial steps:Initiation\u2014defined as the moment the first dose is taken by the patient;Implementation\u2014defined by the extent of prescription regimen fulfilment;Discontinuation\u2014that is when the patient discontinues taking the prescribed drugs [4].IntroductionIn general, primary non-adherence is a situation when a patient does not obtain the prescribed drug from the pharmacy during the prescription\u2019s validity [5].", [["patient", "ORGANISM", 105, 112], ["patient", "ORGANISM", 218, 225], ["patient", "ORGANISM", 339, 346], ["patient", "SPECIES", 105, 112], ["patient", "SPECIES", 218, 225], ["patient", "SPECIES", 339, 346], ["prescription regimen", "TREATMENT", 153, 173], ["the prescribed drugs", "TREATMENT", 246, 266]]], ["Having assumed that a prescription for an individual drug is a proof that the need for pharmacotherapy has been confirmed by a medical professional, primary non-adherence is a major discordance from the treatment schedule.", [["pharmacotherapy", "TREATMENT", 87, 102], ["the treatment schedule", "TREATMENT", 199, 221]]], ["Many studies have covered aspects of primary non-adherence, particularly in terms of chronic diseases\u2019 management (e.g. hypertension, diabetes mellitus and other) [6\u20139].", [["hypertension", "DISEASE", 120, 132], ["diabetes mellitus", "DISEASE", 134, 151], ["Many studies", "TEST", 0, 12], ["primary non-adherence", "PROBLEM", 37, 58], ["chronic diseases", "PROBLEM", 85, 101], ["hypertension", "PROBLEM", 120, 132], ["diabetes mellitus", "PROBLEM", 134, 151], ["primary non-adherence", "OBSERVATION", 37, 58], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["diseases", "OBSERVATION", 93, 101]]], ["However, data on primary non-adherence in treatment of asthma and COPD is limited.", [["asthma", "DISEASE", 55, 61], ["COPD", "DISEASE", 66, 70], ["asthma", "PROBLEM", 55, 61], ["COPD", "PROBLEM", 66, 70], ["asthma", "OBSERVATION", 55, 61], ["COPD", "OBSERVATION", 66, 70]]], ["Moreover, the issue of general primary non-adherence and of that for inhaled medications, has yet not been properly studied in Poland because reliable data was lacking.", [["inhaled medications", "TREATMENT", 69, 88]]], ["Fortunately, the recent implementation of nationwide e-Health solutions in Poland created new and unique opportunities for studying primary non-adherence in asthma and COPD.MethodsThe aim was to study the primary non-adherence to all of the inhaled medications available in Poland (as of December 2018) with indication for asthma and/or COPD\u2014overall and for individual drugs.", [["asthma", "DISEASE", 157, 163], ["COPD", "DISEASE", 168, 172], ["asthma", "DISEASE", 323, 329], ["COPD", "DISEASE", 337, 341], ["nationwide e-Health solutions", "TREATMENT", 42, 71], ["asthma", "PROBLEM", 157, 163], ["COPD", "PROBLEM", 168, 172], ["Methods", "TREATMENT", 173, 180], ["the inhaled medications", "TREATMENT", 237, 260], ["asthma", "PROBLEM", 323, 329], ["COPD", "PROBLEM", 337, 341], ["asthma", "OBSERVATION", 157, 163], ["COPD", "OBSERVATION", 168, 172], ["COPD", "OBSERVATION", 337, 341]]], ["Additionally, the impact of patients\u2019 demographics on this phenomenon was analysed.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["this phenomenon", "TREATMENT", 54, 69]]], ["The variation of primary non-adherence across different types of inhalers\u2014(dry powder inhalers (DPIs) vs metered dose inhalers (MDIs)) and presence of a dosage counter within the inhaler was also studied.MethodsWe retrospectively analysed the data from all of the e-prescriptions issued in Poland in 2018 (n = 119,880) from the national e-prescription pilot.", [["DPIs", "CHEMICAL", 96, 100], ["inhalers\u2014", "TREATMENT", 65, 74], ["dry powder inhalers (DPIs)", "TREATMENT", 75, 101], ["metered dose inhalers (MDIs)", "TREATMENT", 105, 133], ["a dosage counter", "TREATMENT", 151, 167], ["the inhaler", "TREATMENT", 175, 186], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["primary", "OBSERVATION_MODIFIER", 17, 24]]], ["The e-prescriptions were prescribed by 190 doctors of various specialisations.MethodsThe study database was provided to the researchers by the Center of Information Systems for Healthcare (Centrum System\u00f3w Informacyjnych Ochrony Zdrowia, CSIOZ)\u2014a Polish governmental institution working on the Polish healthcare system digitalization.MethodsA recent task of this institution was the implementation of the nationwide system of e-prescriptions, which is fully operational as of January 2020.MethodsThe data used in the analysis was fully anonymized.", [["Healthcare (Centrum System\u00f3w Informacyjnych Ochrony Zdrowia", "TREATMENT", 177, 236], ["the analysis", "TEST", 513, 525]]], ["Thus, the study was not subject to ethical approval, according to the Ethical Commission of Medical University of Lodz.", [["the study", "TEST", 6, 15]]], ["The records included basic patient characteristics (age and gender), the date of prescription issuing, prescription details (drug trade name, dosage, packages number), and details and date of drug dispensation (only if it happened).", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]], ["In the literature, primary non-adherence is generally defined as not obtaining the medication within the defined number of days after prescribing [5].", [["the medication", "TREATMENT", 79, 93]]], ["However, the database used in this study did not include exact clinical data (that is individual patient\u2019s diagnosis) and the long-term, individual prescription histories were not possible to be studied.", [["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104], ["this study", "TEST", 30, 40]]], ["Therefore, for this study purpose, we defined primary non-adherence as not obtaining an individual e-prescription from the pharmacy within 30 days, as it is the general prescription validity in Poland\u2014including inhalable medications prescriptions.MethodsIn our analysis, we included all of the inhaled medications available in Poland as of December 2018, with all of their available doses and formulations (21 compound combinations, over 100 available preparations - the full list of analysed ATC codes is available in Table 1).", [["this study purpose", "TEST", 15, 33], ["inhalable medications prescriptions", "TREATMENT", 211, 246], ["the inhaled medications", "TREATMENT", 290, 313], ["formulations", "TREATMENT", 393, 405], ["ATC codes", "TREATMENT", 493, 502]]], ["Each of the available inhaled medications was categorized by the authors according to their characteristics as either DPI, MDI, metered dose liquid inhaler (MDLI) or nebulization.MethodsFirst, the descriptive statistics of overall prevalence of primary non-adherence were calculated.", [["DPI", "CHEMICAL", 118, 121], ["DPI", "CHEMICAL", 118, 121], ["DPI", "SIMPLE_CHEMICAL", 118, 121], ["the available inhaled medications", "TREATMENT", 8, 41], ["DPI", "TREATMENT", 118, 121], ["MDI", "TREATMENT", 123, 126], ["metered dose liquid inhaler (MDLI)", "TREATMENT", 128, 162], ["nebulization", "TREATMENT", 166, 178], ["primary non-adherence", "PROBLEM", 245, 266]]], ["Categorical variables were expressed as proportions and compared between the groups using the \u03c72 test.", [["Categorical variables", "TEST", 0, 21], ["the \u03c72 test", "TEST", 90, 101]]], ["A p value of < 0.05 was considered significant.ResultsOut of all (119,880) individual drugs prescribed on e-prescriptions in Poland in 2018, 1973 (1.6%) were inhalable medicines of interest for this study.", [["A p value", "TEST", 0, 9], ["individual drugs", "TREATMENT", 75, 91], ["this study", "TEST", 194, 204]]], ["The primary non-adherence for inhalable medicines reached 15.3%, as 1671 (84.7%) of e-prescriptions on those drugs were obtained by the patients.Results995 (50.4%) e-prescriptions for inhalable drugs were prescribed for males.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["inhalable medicines", "TREATMENT", 30, 49], ["those drugs", "TREATMENT", 103, 114], ["inhalable drugs", "TREATMENT", 184, 199]]], ["Primary non-adherence among males reached 16.7% and it was not significantly different from that among females (13.9%, p = 0,086) (Table 2).", [["significantly different", "OBSERVATION_MODIFIER", 63, 86]]], ["Moreover, none of the analysed inhaled medications was significantly more often redeemed by either of genders.ResultsThe patients who obtained their inhalable medicine e-prescriptions were slightly, but significantly older on average than those who did not (65.8 \u00b1 18.0 vs. 64.1 \u00b1 17.1 years, respectively, p < 0.05).", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["the analysed inhaled medications", "TREATMENT", 18, 50], ["their inhalable medicine", "TREATMENT", 143, 167]]], ["The further analysis of age-related primary non-adherence dependencies has shown significant differences between age groups.", [["The further analysis", "TEST", 0, 20], ["primary non-adherence dependencies", "PROBLEM", 36, 70], ["primary", "OBSERVATION_MODIFIER", 36, 43], ["non-adherence dependencies", "OBSERVATION", 44, 70], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["differences", "OBSERVATION_MODIFIER", 93, 104]]], ["The highest primary non-adherence (18.0%) was observed among patients aged 65-74, whilst the highest primary adherence (89.2%) was among the 75 + years-old patients (Fig. 1).ResultsThe extents of primary non-adherence to individual inhaled medication drug classes is shown in Table 3.", [["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 156, 164], ["individual inhaled medication", "TREATMENT", 221, 250], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["primary", "OBSERVATION_MODIFIER", 12, 19]]], ["The most commonly prescribed groups were LABAs (422 e-prescriptions, 16.82% non-adherent) and ICSs (419, 13.37% non-adherent).ResultsFor drugs of interest in this study, the mostly prescribed (346) was a LABA\u2014formoterol.", [["LABA", "CHEMICAL", 204, 208], ["formoterol", "CHEMICAL", 209, 219], ["LABA", "CHEMICAL", 204, 208], ["formoterol", "CHEMICAL", 209, 219], ["LABA", "SIMPLE_CHEMICAL", 204, 208], ["formoterol", "SIMPLE_CHEMICAL", 209, 219], ["LABAs", "TEST", 41, 46], ["e-prescriptions", "TEST", 52, 67], ["ICSs", "TEST", 94, 98], ["this study", "TEST", 158, 168], ["a LABA\u2014formoterol", "TREATMENT", 202, 219]]], ["Primary non-adherence to this drug was 19.08%.", [["this drug", "TEST", 25, 34]]], ["Among SABAs, the most frequently prescribed was salbutamol\u2014274 e-prescriptions, 14.6% primary non-adherence.", [["salbutamol", "CHEMICAL", 48, 58], ["salbutamol", "CHEMICAL", 48, 58], ["salbutamol", "SIMPLE_CHEMICAL", 48, 58], ["salbutamol", "TREATMENT", 48, 58]]], ["The most frequently prescribed LAMA was tiotropium\u2014115 e-prescriptions, 16.52% primary non-adherence.", [["LAMA", "CHEMICAL", 31, 35], ["tiotropium", "CHEMICAL", 40, 50], ["LAMA", "CHEMICAL", 31, 35], ["tiotropium", "CHEMICAL", 40, 50], ["LAMA", "SIMPLE_CHEMICAL", 31, 35], ["tiotropium", "SIMPLE_CHEMICAL", 40, 50], ["LAMA", "TREATMENT", 31, 35], ["tiotropium", "TREATMENT", 40, 50]]], ["The values for all of the analysed inhalable drugs are presented in Table 4.ResultsFurther analysis was focused on differences in primary non-adherence in relation to inhaler type (DPI vs MDI) and characteristics (presence of dosage counter).", [["DPI", "CHEMICAL", 181, 184], ["The values", "TEST", 0, 10], ["the analysed inhalable drugs", "TREATMENT", 22, 50], ["ResultsFurther analysis", "TEST", 76, 99], ["inhaler type (DPI vs MDI", "TREATMENT", 167, 191]]], ["A statistically significant difference was found between DPIs (995 e-prescriptions) and MDIs (759 e-prescriptions), for which the extents of primary non-adherence were 17.0% and 13.4% respectively.", [["DPIs", "TREATMENT", 57, 61], ["MDIs", "TREATMENT", 88, 92], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["difference", "OBSERVATION", 28, 38]]], ["Within drug class groups, where comparison was possible (ICSs, ICS + LABAs, LABAs and LAMAs), that is for which both types of inhalers within a group were available, there were no statistically significant differences in primary non-adherence.", [["LABAs", "TREATMENT", 69, 74], ["LABAs", "TREATMENT", 76, 81], ["inhalers", "TREATMENT", 126, 134]]], ["Among MDIs and DPIs, the inhalers without a dosage counter had significantly lower primary non-adherence than those with it - 13.4% vs. 17.0% respectively (chi2 = 4145; p = 0,0415).", [["Among MDIs", "TREATMENT", 0, 10], ["DPIs", "TREATMENT", 15, 19], ["the inhalers", "TREATMENT", 21, 33], ["a dosage counter", "TREATMENT", 42, 58], ["it", "TEST", 121, 123], ["chi2", "TEST", 156, 160]]], ["Within MDI and DPI groups such differences were not significant.DiscussionInhalable medicines are the established basis of asthma and COPD management according to GINA and GOLD recommendations [3, 10].", [["asthma", "DISEASE", 123, 129], ["COPD", "DISEASE", 134, 138], ["MDI", "TREATMENT", 7, 10], ["Inhalable medicines", "TREATMENT", 74, 93], ["asthma", "PROBLEM", 123, 129], ["COPD management", "TREATMENT", 134, 149], ["asthma", "OBSERVATION", 123, 129]]], ["Depending on the diseases\u2019 course and severity, a proper treatment scheme of asthma/COPD should be implemented, yet still a common part of these treatments are always inhaled drugs.", [["asthma", "DISEASE", 77, 83], ["COPD", "DISEASE", 84, 88], ["severity", "PROBLEM", 38, 46], ["asthma", "PROBLEM", 77, 83], ["COPD", "PROBLEM", 84, 88], ["these treatments", "TREATMENT", 139, 155], ["inhaled drugs", "TREATMENT", 167, 180], ["asthma", "OBSERVATION", 77, 83], ["COPD", "OBSERVATION", 84, 88]]], ["Those drugs are effective in reducing the respiratory symptoms and in long-term disease management.", [["respiratory", "ANATOMY", 42, 53], ["Those drugs", "TREATMENT", 0, 11], ["the respiratory symptoms", "PROBLEM", 38, 62], ["long-term disease management", "TREATMENT", 70, 98], ["respiratory symptoms", "OBSERVATION", 42, 62], ["long-term", "OBSERVATION_MODIFIER", 70, 79]]], ["Moreover, their effects are crucial in exacerbation prevention and reduction of life-threatening incidents and mortality rate.", [["exacerbation prevention", "TREATMENT", 39, 62], ["mortality rate", "TEST", 111, 125], ["exacerbation", "OBSERVATION_MODIFIER", 39, 51]]], ["Nonetheless, in proper management of asthma and COPD patient adherence is a greatly contributing factor [11, 12].", [["asthma", "DISEASE", 37, 43], ["COPD", "DISEASE", 48, 52], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["asthma", "PROBLEM", 37, 43], ["COPD", "PROBLEM", 48, 52], ["asthma", "OBSERVATION", 37, 43], ["COPD", "OBSERVATION", 48, 52]]], ["Medication adherence is considered a major factor contributing to asthma/COPD exacerbations, mortality and disease course [13, 14].DiscussionAccording to the literature, adherence is modified by numerous factors: socio-economic (e.g. family and employment), healthcare system-related (e.g. drug information and administration), condition-related (e.g. symptoms or lack of them), drug-related (e.g. drug regimen, formulation and costs) and importantly\u2013patient-related (e.g. level of education, mental and psychological condition, health beliefs and concerns, cognitive functions) [15\u201317].", [["asthma", "DISEASE", 66, 72], ["COPD", "DISEASE", 73, 77], ["Medication adherence", "TREATMENT", 0, 20], ["asthma", "PROBLEM", 66, 72], ["COPD exacerbations", "PROBLEM", 73, 91], ["e.g. symptoms", "PROBLEM", 347, 360], ["drug regimen", "TREATMENT", 398, 410], ["mental and psychological condition", "PROBLEM", 493, 527], ["asthma", "OBSERVATION", 66, 72], ["COPD", "OBSERVATION", 73, 77]]], ["In particular, studies show that adherence in COPD is device-related, with the device design resulting in under- or overuse, depending on its technical characteristics (dosage counter, the possibility to load an inhalation dose without real inhalation) [18].", [["COPD", "DISEASE", 46, 50], ["COPD", "PROBLEM", 46, 50], ["the device", "TREATMENT", 75, 85], ["an inhalation dose", "TREATMENT", 209, 227], ["COPD", "OBSERVATION", 46, 50]]], ["Moreover, studies show that in asthma adherence is dependent on patient treatment beliefs and perception [19].DiscussionIn order to assess the patients\u2019 adherence, a number of methods may be implemented.", [["asthma", "DISEASE", 31, 37], ["patient", "ORGANISM", 64, 71], ["patients", "ORGANISM", 143, 151], ["patient", "SPECIES", 64, 71], ["patients", "SPECIES", 143, 151], ["studies", "TEST", 10, 17], ["asthma adherence", "PROBLEM", 31, 47], ["patient treatment beliefs", "TREATMENT", 64, 89], ["asthma", "OBSERVATION", 31, 37], ["dependent", "OBSERVATION_MODIFIER", 51, 60]]], ["These include direct (e.g. drug or biomarker blood concentration) or indirect methods (e.g. pill counts, database research, self-reports) [20].", [["blood", "ANATOMY", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["biomarker blood concentration", "TREATMENT", 35, 64], ["indirect methods", "TEST", 69, 85], ["pill counts", "TEST", 92, 103]]], ["The use of e-prescription databases is subject to minimized bias in assessment of primary non-adherence, since the prescription drugs may legally only be obtained when a patient possesses a prescription and fills it at a pharmacy.", [["patient", "ORGANISM", 170, 177], ["patient", "SPECIES", 170, 177], ["the prescription drugs", "TREATMENT", 111, 133]]], ["Pill or dosage counts possibly overestimate the exact doses taken, as patients may influence the amount of those left in the package [21\u201323].", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["Pill", "TREATMENT", 0, 4], ["dosage counts", "TEST", 8, 21], ["left", "ANATOMY_MODIFIER", 113, 117]]], ["However, to properly assess the primary adherence in community setting, no other method than database search provides the most accurate data [24].DiscussionDepending on the definition, setting and methodology used, primary non-adherence to various drugs reaches different levels.", [["database search", "TEST", 93, 108], ["various drugs", "TREATMENT", 240, 253]]], ["In accordance to definition used in this study, it reaches a wide range of extents in different settings.", [["this study", "TEST", 36, 46], ["wide", "OBSERVATION_MODIFIER", 61, 65], ["range", "OBSERVATION_MODIFIER", 66, 71], ["extents", "OBSERVATION_MODIFIER", 75, 82]]], ["In an analysis performed in the USA by Rutherford et al. four important drug groups\u2014antihypertensives, lipid-lowering agents, hypoglycemics, and antidepressants\u2014were found to reach a mean level of 14.6% primary non-adherence [25], whereas e.g. for dermatological drugs primary non-adherence reached 24.7% [26].DiscussionFew studies have covered the issue of inhaled medications primary non-adherence.", [["antidepressants", "CHEMICAL", 145, 160], ["groups\u2014antihypertensives", "SIMPLE_CHEMICAL", 77, 101], ["lipid", "SIMPLE_CHEMICAL", 103, 108], ["hypoglycemics", "SIMPLE_CHEMICAL", 126, 139], ["an analysis", "TEST", 3, 14], ["drug groups\u2014antihypertensives", "TREATMENT", 72, 101], ["lipid-lowering agents", "TREATMENT", 103, 124], ["hypoglycemics", "TREATMENT", 126, 139], ["antidepressants", "TREATMENT", 145, 160], ["dermatological drugs", "TREATMENT", 248, 268], ["Few studies", "TEST", 320, 331], ["inhaled medications", "TREATMENT", 358, 377]]], ["Yet some examples addressing this phenomenon may be found in the literature.", [["this phenomenon", "PROBLEM", 29, 44]]], ["For \u201casthma medications\u201d, the primary non-adherence level reached 19.9% in adults aged 19 + and 11.4% in children.", [["asthma", "DISEASE", 5, 11], ["children", "ORGANISM", 105, 113], ["children", "SPECIES", 105, 113], ["\u201casthma medications", "TREATMENT", 4, 23], ["the primary non-adherence level", "TEST", 26, 57]]], ["For newly prescribed drugs in this field it reached 25.1% in adults and 11.3% in children.", [["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89], ["newly prescribed drugs", "TREATMENT", 4, 26]]], ["Similarly to our approach, the authors of that study analysed only the population of patients that used the e-prescriptions.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["that study", "TEST", 42, 52], ["the e-prescriptions", "TREATMENT", 104, 123]]], ["In another study, also by Fischer et al., primary non-adherence to \u201cAntiasthmatic and bronchodilator agents\u201d medications reached 17.9% [27, 28].DiscussionA meta-analysis of 31 articles on primary non-adherence published in 2019 by Cheen et al. summarized the results of 6 studies in asthma/COPD area published in years 2009\u20132014.", [["Antiasthmatic", "CHEMICAL", 68, 81], ["asthma", "DISEASE", 283, 289], ["COPD", "DISEASE", 290, 294], ["another study", "TEST", 3, 16], ["Antiasthmatic", "TREATMENT", 68, 81], ["bronchodilator agents", "TREATMENT", 86, 107], ["medications", "TREATMENT", 109, 120], ["6 studies", "TEST", 270, 279], ["asthma/COPD area", "PROBLEM", 283, 299], ["COPD", "OBSERVATION", 290, 294]]], ["The levels of primary non-adherence to the asthma/COPD medications ranged between 9 to 25%, with an average of 14.0%.", [["asthma", "DISEASE", 43, 49], ["COPD", "DISEASE", 50, 54], ["primary non-adherence", "PROBLEM", 14, 35], ["the asthma", "PROBLEM", 39, 49], ["COPD medications", "TREATMENT", 50, 66], ["COPD", "OBSERVATION", 50, 54]]], ["In comparison, for other therapeutic areas covered in this meta-analysis, the primary non-adherence reached 25.0% for osteoporosis, 16.0% for hypertension, 10.0% for diabetes, 25.0% for hyperlipidemia and 12.0% for depression (17.0% across all groups).", [["osteoporosis", "DISEASE", 118, 130], ["hypertension", "DISEASE", 142, 154], ["diabetes", "DISEASE", 166, 174], ["hyperlipidemia", "DISEASE", 186, 200], ["depression", "DISEASE", 215, 225], ["this meta-analysis", "TEST", 54, 72], ["osteoporosis", "PROBLEM", 118, 130], ["hypertension", "PROBLEM", 142, 154], ["diabetes", "PROBLEM", 166, 174], ["hyperlipidemia", "PROBLEM", 186, 200], ["depression", "PROBLEM", 215, 225]]], ["The authors also indicated several factors significantly associated with primary non-adherence, in particular in asthma/COPD, of which positively correlated older age and male gender and higher co-payment.", [["asthma", "DISEASE", 113, 119], ["COPD", "DISEASE", 120, 124], ["asthma", "PROBLEM", 113, 119], ["COPD", "PROBLEM", 120, 124], ["asthma", "OBSERVATION", 113, 119], ["COPD", "OBSERVATION", 120, 124]]], ["Interestingly, the authors did not confirm a dependence resulting from differences in dosage forms [29].DiscussionThe impact of inhaler type (MDI vs DPI) on primary non-adherence has been subject of only few analyses up to date.", [["DPI", "CHEMICAL", 149, 152], ["a dependence", "PROBLEM", 43, 55], ["inhaler type (MDI vs DPI", "TREATMENT", 128, 152]]], ["In 2014 van Boven et al. used a Dutch pharmacy dispensing data from 1994 to 2012 in order to analyse LABA persistence in COPD patients.", [["LABA", "CHEMICAL", 101, 105], ["COPD", "DISEASE", 121, 125], ["LABA", "SIMPLE_CHEMICAL", 101, 105], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["COPD", "OBSERVATION", 121, 125]]], ["The authors of that study found no significant differences between MDIs and DPIs [30].", [["DPIs", "CHEMICAL", 76, 80], ["that study", "TEST", 15, 25], ["MDIs", "TREATMENT", 67, 71], ["DPIs", "TREATMENT", 76, 80], ["no", "UNCERTAINTY", 32, 34], ["significant", "OBSERVATION_MODIFIER", 35, 46]]], ["We believe the differences observed in our study might be a result of generally lower out-of-pocket costs of MDIs, as compared to DPIs.", [["our study", "TEST", 39, 48], ["MDIs", "TREATMENT", 109, 113], ["DPIs", "TREATMENT", 130, 134], ["lower", "OBSERVATION_MODIFIER", 80, 85], ["MDIs", "OBSERVATION", 109, 113]]], ["Of a note is that in Polish healthcare system, patients pay various drugs co-payments (with varying drug reimbursement levels: 100%, 70%, 50%, 0% or a standard co-payment of 3.20 PLN per package), that are dependent on the drug, indication, patient\u2019s age and other.DiscussionA number of interesting results on primary non-adherence to inhaled medications have been presented in this paper.", [["patients", "ORGANISM", 47, 55], ["patient", "ORGANISM", 241, 248], ["patients", "SPECIES", 47, 55], ["patient", "SPECIES", 241, 248], ["inhaled medications", "TREATMENT", 335, 354]]], ["Using the data of highest possible quality available to date, that originated from a nationwide e-prescription database, a specific level of primary non-adherence to inhaled medications in Poland was proven.", [["inhaled medications", "TREATMENT", 166, 185]]], ["The non-adherence to these drugs was lower than obtained in our previous study on drivers of general non-adherence in Poland, where for drugs in 6 major areas (antidiabetic, antithrombotic, cardiovascular, cholesterol medications, antibiotics and psychiatric drugs) the primary non-adherence was 20.8% [31].", [["cardiovascular", "ANATOMY", 190, 204], ["cholesterol", "CHEMICAL", 206, 217], ["psychiatric", "DISEASE", 247, 258], ["cholesterol", "CHEMICAL", 206, 217], ["cholesterol", "SIMPLE_CHEMICAL", 206, 217], ["these drugs", "TREATMENT", 21, 32], ["drugs", "TREATMENT", 136, 141], ["antidiabetic", "TREATMENT", 160, 172], ["antithrombotic", "TREATMENT", 174, 188], ["cardiovascular, cholesterol medications", "TREATMENT", 190, 229], ["antibiotics", "TREATMENT", 231, 242], ["psychiatric drugs", "TREATMENT", 247, 264]]], ["Also, it was lower than of that for antihistamine drugs, for which the level of primary non-adherence was 21% [32].DiscussionImportantly, this is the very first study that covered primary non-adherence to inhaled medications in Poland and also one of the very few such studies worldwide.", [["antihistamine", "CHEMICAL", 36, 49], ["antihistamine drugs", "TREATMENT", 36, 55], ["inhaled medications", "TREATMENT", 205, 224]]], ["A certain limitation of this study came from the database structure, as it was not possible to study the exact clinical reasons of each e-prescription.", [["this study", "TEST", 24, 34]]], ["The data was anonymous and no additional clinical data (in particular, the patient\u2019s diagnosis) were available.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["The data", "TEST", 0, 8]]], ["However, this study can still be considered an objective measure of adherence in obstructive diseases, since the analysed drugs\u2019 approved indications (as reflected in their Summaries of Product Characteristics) include only asthma and COPD management.", [["obstructive diseases", "DISEASE", 81, 101], ["asthma", "DISEASE", 224, 230], ["COPD", "DISEASE", 235, 239], ["this study", "TEST", 9, 19], ["obstructive diseases", "PROBLEM", 81, 101], ["the analysed drugs", "TREATMENT", 109, 127], ["asthma", "PROBLEM", 224, 230], ["COPD management", "TREATMENT", 235, 250], ["obstructive", "OBSERVATION_MODIFIER", 81, 92], ["diseases", "OBSERVATION", 93, 101], ["asthma", "OBSERVATION", 224, 230], ["COPD", "OBSERVATION", 235, 239]]], ["Also noteworthy is the fact that during data collection, the new e-healthcare system in Poland was a pilot solution, and thus the primary non-adherence results may have been influenced.", [["a pilot solution", "TREATMENT", 99, 115]]], ["Despite that, we believe the data used in this study is still of the highest possible quality and minimally biased.", [["the data", "TEST", 25, 33], ["this study", "TEST", 42, 52]]], ["It was not self-reported nor dependent on any physicians\u2019 opinion on patients\u2019 non-adherence.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77]]], ["As the lowest degree of primary non-adherence concerned patients aged 75 + , the common perception of a possible technological barrier of an e-prescription system for the eldest cannot be proven.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["an e-prescription system", "TREATMENT", 138, 162]]], ["The study database originated from a nationwide pilot e-prescription programme, thus it can be considered complete.DiscussionA further study limitation was that it was only possible to analyse the primary non-adherence, that is studying the act of obtaining/not obtaining a particular e-prescription.", [["The study database", "TEST", 0, 18], ["a nationwide pilot e-prescription programme", "TREATMENT", 35, 78], ["further study", "TEST", 127, 140]]], ["The number of doses a patient took or skipped was also not measured.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29]]], ["This issue could not be analysed with the data used in this study and, in fact, this was not an objective of this study.", [["this study", "TEST", 55, 65], ["this study", "TEST", 109, 119]]], ["A longitudinal analysis of a particular patient was also not possible to be performed with the analysed dataset.DiscussionFinally, we could not analyse the exact reasons behind the primary non-adherence, which could have been diverse: disbelief in diagnosis or physician, drug characteristics and other [15].", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["A longitudinal analysis", "TEST", 0, 23]]], ["We also could not analyse the impact of patients\u2019 out-of\u2013pocket costs (in Poland these are dependent on indication, age and having a national health insurance) on primary non-adherence, since the database did not include the data on that subject.DiscussionThe use of e-prescription is rising recently, both in Europe and worldwide.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["the database", "TEST", 192, 204]]], ["Studies on e-prescription systems in Europe show their multi area benefits: health, economic, social, patient-oriented and other.", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["Studies on e-prescription systems", "TEST", 0, 33]]], ["Major health benefits include reduced medication errors, better medicine accessibility and, what we recognize as crucial in therapy\u2014increased monitoring of adherence.", [["reduced medication errors", "PROBLEM", 30, 55]]], ["The economic benefits include efficiency gains for healthcare professionals, better transparency, reduced frauds and printing costs.", [["reduced frauds and printing costs", "PROBLEM", 98, 131]]], ["The social profits concentrate around patient satisfaction, financial relief and assistance for the elderly [33].", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45]]], ["Patients using e-prescriptions gain a possibility to trace their medication history better via a patient on-line portal.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 97, 104], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 97, 104], ["a patient on-line portal", "TREATMENT", 95, 119], ["portal", "ANATOMY", 113, 119]]], ["Finally, e-prescriptions help patients to adapt to other tele-health solutions, such as teleconsultations, and are of great help in case of limited physical access to healthcare facilities (e.g. recent coronavirus outbreak).DiscussionRegardless of why patients are non-adherent to inhaled medications or other drugs, some corrective solutions are described.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 252, 260], ["recent coronavirus outbreak", "PROBLEM", 195, 222], ["inhaled medications", "TREATMENT", 281, 300], ["other drugs", "TREATMENT", 304, 315], ["some corrective solutions", "TREATMENT", 317, 342]]], ["In a randomized trial of allergic rhinitis treatment with intranasal corticosteroid treatment, a daily short message service reminder improved patient adherence [34].", [["allergic rhinitis", "DISEASE", 25, 42], ["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150], ["allergic rhinitis treatment", "TREATMENT", 25, 52], ["intranasal corticosteroid treatment", "TREATMENT", 58, 93], ["allergic rhinitis", "OBSERVATION", 25, 42]]], ["Another SMS service for asthma patients that reminded about their daily inhaled medications was effective and increased adherence by 17.8% [35].", [["asthma", "DISEASE", 24, 30], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["asthma", "PROBLEM", 24, 30], ["their daily inhaled medications", "TREATMENT", 60, 91]]], ["As the e-prescription solution in Poland in fact includes SMS service, this approach could be simply implemented with a reminder of a particular e-prescription expiration date approaching.DiscussionA study of improving adherence to ICSs in asthma by Vollmer et al. has shown a small, yet significant improvement with an interactive voice recognition phone calls system that reminded patients of their medication refills and continuous ICS treatment.", [["ICSs", "DISEASE", 232, 236], ["asthma", "DISEASE", 240, 246], ["patients", "ORGANISM", 383, 391], ["patients", "SPECIES", 383, 391], ["the e-prescription solution", "TREATMENT", 3, 30], ["DiscussionA study", "TEST", 188, 205], ["asthma", "PROBLEM", 240, 246], ["their medication refills", "TREATMENT", 395, 419], ["continuous ICS treatment", "TREATMENT", 424, 448], ["small", "OBSERVATION_MODIFIER", 277, 282], ["significant", "OBSERVATION_MODIFIER", 288, 299], ["improvement", "OBSERVATION", 300, 311]]], ["Other approaches described in the literature include mobile apps that stress the significance of proper clinical allergy diagnosis and further encourage patients\u2019 adherence [37\u201339].DiscussionIn order to better picture the observed phenomenon, in our future research we intend to further broaden the analysis spectrum.", [["allergy", "DISEASE", 113, 120], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["the analysis spectrum", "TEST", 295, 316]]], ["Since from January 2020 the e-prescription is the applicable standard of drug prescribing in Poland, in near future we hope to provide even more objective and fully-nationwide results.ConclusionsIn our study more than 1 out of 7 e-prescriptions to inhaled medications were not obtained by the Polish patients.", [["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 300, 308], ["our study", "TEST", 198, 207], ["inhaled medications", "TREATMENT", 248, 267]]], ["The degree of primary non-adherence to these drugs was influenced by age and not by gender.", [["primary non-adherence", "PROBLEM", 14, 35], ["these drugs", "TREATMENT", 39, 50], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["primary", "OBSERVATION_MODIFIER", 14, 21], ["non-adherence", "OBSERVATION", 22, 35]]], ["The highest non-adherence was observed for ICS + LABA combinations (18.86%).", [["ICS", "CHEMICAL", 43, 46], ["LABA", "CHEMICAL", 49, 53], ["ICS + LABA combinations", "TREATMENT", 43, 66]]], ["Particular compounds had different primary non-adherence levels reaching 34.09% for budesonide + formoterol combination.", [["budesonide", "CHEMICAL", 84, 94], ["formoterol", "CHEMICAL", 97, 107], ["budesonide", "CHEMICAL", 84, 94], ["formoterol", "CHEMICAL", 97, 107], ["budesonide", "SIMPLE_CHEMICAL", 84, 94], ["formoterol", "SIMPLE_CHEMICAL", 97, 107], ["budesonide", "TREATMENT", 84, 94], ["formoterol combination", "TREATMENT", 97, 119]]], ["Significant differences in primary non-adherence between MDI and DPI inhalers and between inhalers with/without a dosage counter were found.", [["DPI", "CHEMICAL", 65, 68], ["DPI", "CHEMICAL", 65, 68], ["MDI", "TREATMENT", 57, 60], ["DPI inhalers", "TREATMENT", 65, 77], ["inhalers", "TREATMENT", 90, 98], ["a dosage counter", "TREATMENT", 112, 128]]], ["To authors\u2019 knowledge, this study is the first to cover primary non-adherence to inhaled medications in Poland and one of the very few such studies worldwide.", [["this study", "TEST", 23, 33], ["inhaled medications", "TREATMENT", 81, 100]]]], "PMC7134557": [["Identification of potential RNA-binding residues ::: ResultsThe BaMV helicase-like domain, generated as a fusion protein with a thioredoxin/hexahistidine/S-tag fused at the N-terminus, has been used to characterize associated enzymatic activities (Li et al., 2001, Han et al., 2007).", [["N", "CHEMICAL", 173, 174], ["BaMV", "GENE_OR_GENE_PRODUCT", 64, 68], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 128, 139], ["BaMV helicase-like domain", "PROTEIN", 64, 89], ["fusion protein", "PROTEIN", 106, 120], ["thioredoxin", "PROTEIN", 128, 139], ["hexahistidine/S-tag", "PROTEIN", 140, 159], ["N-terminus", "PROTEIN", 173, 183], ["a fusion protein", "TREATMENT", 104, 120], ["a thioredoxin/hexahistidine/S-tag fused", "TREATMENT", 126, 165], ["binding residues", "OBSERVATION", 32, 48]]], ["Purification of the recombinant domain involved protein denaturation and refolding.", [["recombinant domain", "PROTEIN", 20, 38], ["the recombinant domain", "PROBLEM", 16, 38], ["protein denaturation", "PROBLEM", 48, 68], ["protein denaturation", "OBSERVATION", 48, 68]]], ["To examine the oligomerization state of the refolded protein, a gel filtration step was included in the present study.", [["refolded protein", "PROTEIN", 44, 60], ["a gel filtration step", "TREATMENT", 62, 83], ["the present study", "TEST", 100, 117]]], ["According to the estimated molecular sizes, most refolded protein was in a monomeric form, while some associated with each other and formed dimers or probably even dodecamers (Fig. 1A).", [["refolded protein", "PROTEIN", 49, 65], ["monomeric form", "PROTEIN", 75, 89], ["sizes", "OBSERVATION_MODIFIER", 37, 42]]], ["Activity assays indicated that the monomer has optimal RTPase and ATPase activities (Figs.", [["RTPase", "GENE_OR_GENE_PRODUCT", 55, 61], ["ATPase", "GENE_OR_GENE_PRODUCT", 66, 72], ["RTPase", "PROTEIN", 55, 61], ["ATPase", "PROTEIN", 66, 72], ["Activity assays", "TEST", 0, 15]]], ["Activity for unwinding duplex RNA was also surveyed for each of the protein forms since many viral helicases have been shown to function as hexa- or oligomers (Goregaoker and Culver, 2003, Levin and Patel, 1999, Uhlmann-Schiffler et al., 2002).", [["unwinding duplex RNA", "RNA", 13, 33], ["viral helicases", "PROTEIN", 93, 108], ["unwinding duplex RNA", "TEST", 13, 33], ["many viral helicases", "PROBLEM", 88, 108], ["hexa", "TEST", 140, 144]]], ["However, no RNA unwinding activity was observed for any protein forms (data not shown).Identification of potential RNA-binding residues ::: ResultsReversible formaldehyde crosslinking is frequently utilized in protocols for assaying protein\u2013DNA interactions in vivo, e.g. chromatin immunoprecipitation (Perez-Romero and Imperiale, 2007).", [["chromatin", "ANATOMY", 272, 281], ["formaldehyde", "CHEMICAL", 158, 170], ["formaldehyde", "CHEMICAL", 158, 170], ["formaldehyde", "SIMPLE_CHEMICAL", 158, 170], ["protein\u2013DNA", "SIMPLE_CHEMICAL", 233, 244], ["chromatin", "CELLULAR_COMPONENT", 272, 281], ["chromatin", "DNA", 272, 281], ["RNA unwinding activity", "PROBLEM", 12, 34], ["ResultsReversible formaldehyde crosslinking", "TREATMENT", 140, 183], ["chromatin immunoprecipitation", "TREATMENT", 272, 301], ["no", "UNCERTAINTY", 9, 11], ["binding residues", "OBSERVATION", 119, 135], ["formaldehyde crosslinking", "OBSERVATION", 158, 183]]], ["It has also been adopted in the mapping of amino acid residues involved in the direct binding of proteins to nucleic acids (Kim et al., 2005).", [["amino acid", "CHEMICAL", 43, 53], ["nucleic acids", "CHEMICAL", 109, 122], ["amino acid", "CHEMICAL", 43, 53], ["amino acid", "AMINO_ACID", 43, 53], ["nucleic acids", "SIMPLE_CHEMICAL", 109, 122], ["amino acid residues", "TREATMENT", 43, 62], ["nucleic acids", "TEST", 109, 122]]], ["This technique relies on the formation of methylene bridges between the side chains of Lys, Arg, His, Cys, aromatic amino acids and bases (A, G, and C) of nucleic acids (Bernard et al., 2004).", [["methylene", "CHEMICAL", 42, 51], ["Lys", "CHEMICAL", 87, 90], ["Arg, His, Cys, aromatic amino acids", "CHEMICAL", 92, 127], ["nucleic acids", "CHEMICAL", 155, 168], ["methylene", "CHEMICAL", 42, 51], ["Lys", "CHEMICAL", 87, 90], ["Arg", "CHEMICAL", 92, 95], ["His", "CHEMICAL", 97, 100], ["Cys", "CHEMICAL", 102, 105], ["aromatic amino acids", "CHEMICAL", 107, 127], ["A, G, and C", "CHEMICAL", 139, 150], ["methylene bridges", "SIMPLE_CHEMICAL", 42, 59], ["Lys", "AMINO_ACID", 87, 90], ["Arg", "AMINO_ACID", 92, 95], ["His", "AMINO_ACID", 97, 100], ["Cys", "AMINO_ACID", 102, 105], ["aromatic", "SIMPLE_CHEMICAL", 107, 115], ["amino acids", "AMINO_ACID", 116, 127], ["nucleic acids", "SIMPLE_CHEMICAL", 155, 168], ["methylene bridges", "TREATMENT", 42, 59], ["aromatic amino acids", "TEST", 107, 127], ["bases", "TEST", 132, 137], ["nucleic acids", "TEST", 155, 168]]], ["These crosslinks can be reversed via rehydration of the methylene bridges and release of formaldehyde by heating the sample; therefore, the binding partners can be characterized (Orlando et al., 1997).", [["methylene", "CHEMICAL", 56, 65], ["formaldehyde", "CHEMICAL", 89, 101], ["methylene", "CHEMICAL", 56, 65], ["formaldehyde", "CHEMICAL", 89, 101], ["methylene bridges", "SIMPLE_CHEMICAL", 56, 73], ["formaldehyde", "SIMPLE_CHEMICAL", 89, 101], ["rehydration", "TREATMENT", 37, 48], ["the methylene bridges", "TREATMENT", 52, 73], ["formaldehyde", "TREATMENT", 89, 101]]], ["To further understand the structure\u2013function relationship of the BaMV helicase-like domain, particularly with respect to its RNA-binding function, the protein in its monomeric form was incubated with a 3\u2032-biotinylated 15-nt RNA in the presence of formaldehyde as described in Materials and methods.", [["formaldehyde", "CHEMICAL", 247, 259], ["formaldehyde", "CHEMICAL", 247, 259], ["BaMV", "GENE_OR_GENE_PRODUCT", 65, 69], ["formaldehyde", "SIMPLE_CHEMICAL", 247, 259], ["BaMV helicase-like domain", "PROTEIN", 65, 90], ["3\u2032-biotinylated 15-nt RNA", "RNA", 202, 227], ["the BaMV helicase", "PROBLEM", 61, 78], ["the protein", "TEST", 147, 158], ["a 3\u2032-biotinylated 15-nt RNA", "TREATMENT", 200, 227], ["formaldehyde", "TREATMENT", 247, 259], ["formaldehyde", "OBSERVATION", 247, 259]]], ["After digestion with trypsin, the peptides covalently linked to biotinylated RNA were affinity purified with avidin resin.", [["trypsin", "GENE_OR_GENE_PRODUCT", 21, 28], ["avidin", "GENE_OR_GENE_PRODUCT", 109, 115], ["trypsin", "PROTEIN", 21, 28], ["biotinylated RNA", "RNA", 64, 80], ["trypsin", "TREATMENT", 21, 28], ["the peptides", "TREATMENT", 30, 42], ["biotinylated RNA", "TREATMENT", 64, 80], ["avidin resin", "TREATMENT", 109, 121]]], ["After extensive washes, the crosslinked adduct was heated at 70 \u00b0C for 60 min to release the conjugated peptides, which were then subjected to sequence analysis by LC-MS/MS. To enhance the reliability of the data, the above experiment was repeated four times.", [["extensive washes", "TREATMENT", 6, 22], ["the crosslinked adduct", "TREATMENT", 24, 46], ["the conjugated peptides", "TEST", 89, 112], ["sequence analysis", "TEST", 143, 160], ["MS", "PROBLEM", 170, 172], ["the data", "TEST", 204, 212], ["extensive", "OBSERVATION_MODIFIER", 6, 15], ["washes", "OBSERVATION", 16, 22]]], ["Peptides repeatedly found to bind biotinylated RNA were selected and listed in Table 1.", [["biotinylated RNA", "RNA", 34, 50], ["Peptides", "TREATMENT", 0, 8], ["bind biotinylated RNA", "TREATMENT", 29, 50], ["biotinylated RNA", "OBSERVATION", 34, 50]]], ["They are distributed over the helicase-like domain, including two regions encompassing motifs I and II, respectively (Fig. 2).", [["helicase-like domain", "PROTEIN", 30, 50], ["motifs I and II", "PROTEIN", 87, 102]]], ["No peptide fragments deriving from the BaMV helicase-like domain were obtained in the parallel control reaction, in which the addition of formaldehyde was omitted.", [["formaldehyde", "CHEMICAL", 138, 150], ["formaldehyde", "CHEMICAL", 138, 150], ["BaMV", "GENE_OR_GENE_PRODUCT", 39, 43], ["formaldehyde", "SIMPLE_CHEMICAL", 138, 150], ["BaMV helicase-like domain", "PROTEIN", 39, 64], ["peptide fragments", "PROBLEM", 3, 20], ["the BaMV helicase", "TEST", 35, 52], ["peptide fragments", "OBSERVATION", 3, 20]]], ["Several positively charged residues and a tyrosine within the selected peptidyl regions were then substituted with alanine for functional analysis based on their potential to interact with the RNA substrate.", [["tyrosine", "CHEMICAL", 42, 50], ["alanine", "CHEMICAL", 115, 122], ["tyrosine", "CHEMICAL", 42, 50], ["alanine", "CHEMICAL", 115, 122], ["tyrosine", "AMINO_ACID", 42, 50], ["alanine", "AMINO_ACID", 115, 122], ["peptidyl regions", "PROTEIN", 71, 87], ["RNA substrate", "PROTEIN", 193, 206], ["Several positively charged residues", "PROBLEM", 0, 35], ["a tyrosine", "TREATMENT", 40, 50], ["alanine", "TREATMENT", 115, 122], ["functional analysis", "TEST", 127, 146], ["positively", "OBSERVATION_MODIFIER", 8, 18], ["charged residues", "OBSERVATION", 19, 35]]], ["Eleven mutant proteins were expressed and purified.", [["mutant proteins", "PROTEIN", 7, 22], ["Eleven mutant proteins", "PROBLEM", 0, 22]]], ["All had similar gel filtration profiles compared to WT.Mutational effects on RNA binding ::: ResultsThe effects on RNA-binding ability of each mutation were first examined by Northwestern assay (Fig. 3).", [["WT", "TEST", 52, 54], ["each mutation", "PROBLEM", 138, 151], ["filtration", "OBSERVATION", 20, 30]]], ["After normalization to the amount of protein loaded, the mutant domains exhibited slightly decreased abilities to bind a 5\u2032-terminal 178-nt genomic transcript compared to WT (Fig. 3A).", [["mutant domains", "PROTEIN", 57, 71], ["5\u2032-terminal 178", "DNA", 121, 136], ["the mutant domains", "PROBLEM", 53, 71], ["slightly decreased abilities", "PROBLEM", 82, 110], ["slightly", "OBSERVATION_MODIFIER", 82, 90], ["decreased", "OBSERVATION", 91, 100]]], ["It should be noted that the thioredoxin/hexahistidine/S-tag did not bind the RNA probe (data not shown).", [["thioredoxin", "GENE_OR_GENE_PRODUCT", 28, 39], ["hexahistidine", "GENE_OR_GENE_PRODUCT", 40, 53], ["thioredoxin", "PROTEIN", 28, 39], ["hexahistidine/S-tag", "PROTEIN", 40, 59], ["the thioredoxin/hexahistidine/S-tag", "TREATMENT", 24, 59]]], ["The binding ability was also assayed based on the mobility shift of a 50-nt RNA probe on native PAGE (Fig. 3B).", [["50-nt RNA probe", "DNA", 70, 85]]], ["Adding more amounts of the helicase-like domain in the reaction mixture would restrain more RNA molecules from migration.", [["helicase-like domain", "PROTEIN", 27, 47], ["RNA molecules", "PROTEIN", 92, 105], ["the helicase", "TREATMENT", 23, 35], ["the reaction mixture", "TREATMENT", 51, 71], ["migration", "OBSERVATION_MODIFIER", 111, 120]]], ["Once again, only minor effects on RNA binding were observed in response to the mutations.", [["RNA binding", "PROBLEM", 34, 45], ["the mutations", "PROBLEM", 75, 88]]], ["These results could be due to RNA-binding forces being contributed by every individual interaction, thus any single mutation would not significantly affect the overall binding strength.", [["RNA-binding forces", "PROBLEM", 30, 48], ["any single mutation", "PROBLEM", 105, 124], ["binding strength", "OBSERVATION", 168, 184]]], ["Alternatively, it is a possibility that none of the selected residues actually plays a role in RNA binding, however, this is an unlikely case.", [["the selected residues", "PROBLEM", 48, 69], ["RNA binding", "PROBLEM", 95, 106]]], ["Previous studies showed that mutations at the consensus residues of motifs I and II abolished ATPase and RTPase activities (Han et al., 2007).", [["motifs I and II", "GENE_OR_GENE_PRODUCT", 68, 83], ["ATPase", "GENE_OR_GENE_PRODUCT", 94, 100], ["RTPase", "GENE_OR_GENE_PRODUCT", 105, 111], ["ATPase", "PROTEIN", 94, 100], ["RTPase", "PROTEIN", 105, 111], ["Previous studies", "TEST", 0, 16], ["mutations", "PROBLEM", 29, 38]]], ["The ability of the corresponding mutant proteins, K643A/S644A and D702A respectively, to bind RNA was also examined by gel mobility shift assay.", [["mutant proteins", "PROTEIN", 33, 48], ["K643A", "PROTEIN", 50, 55], ["S644A", "PROTEIN", 56, 61], ["D702A", "PROTEIN", 66, 71], ["K643A", "TEST", 50, 55]]], ["Mutations at motif I slightly reduced the RNA-binding ability, whereas that at motif II did not cause a significant change.Mutational effects on ATPase and RTPase activities ::: ResultsThe importance of the selected residues in the release of 5\u2032-\u03b3-phosphate from ATP (Fig. 4A) and RNA (Fig. 4B) was assayed.", [["5\u2032-\u03b3-phosphate", "CHEMICAL", 243, 257], ["ATP", "CHEMICAL", 263, 266], ["5\u2032-\u03b3-phosphate", "CHEMICAL", 243, 257], ["ATP", "CHEMICAL", 263, 266], ["ATPase", "GENE_OR_GENE_PRODUCT", 145, 151], ["RTPase", "GENE_OR_GENE_PRODUCT", 156, 162], ["5\u2032-\u03b3-phosphate", "SIMPLE_CHEMICAL", 243, 257], ["ATP", "SIMPLE_CHEMICAL", 263, 266], ["motif I", "DNA", 13, 20], ["ATPase", "PROTEIN", 145, 151], ["RTPase", "PROTEIN", 156, 162], ["Mutations at motif I", "PROBLEM", 0, 20], ["a significant change", "PROBLEM", 102, 122], ["Mutational effects", "PROBLEM", 123, 141], ["ATP (Fig. 4A", "TREATMENT", 263, 275], ["RNA (Fig. 4B", "TREATMENT", 281, 293], ["significant", "OBSERVATION_MODIFIER", 104, 115], ["change", "OBSERVATION", 116, 122]]], ["Mutations of Y704 or K706, both located in motif II, abrogated both activities, suggesting that the critical region of motif II extends beyond the consensus DE/D residues.", [["Y704", "GENE_OR_GENE_PRODUCT", 13, 17], ["K706", "GENE_OR_GENE_PRODUCT", 21, 25], ["Y704", "DNA", 13, 17], ["K706", "DNA", 21, 25], ["motif II", "DNA", 43, 51], ["motif II", "DNA", 119, 127], ["consensus DE/D residues", "DNA", 147, 170], ["motif II", "PROBLEM", 119, 127]]], ["Mutation of H636, which is just in front of motif I, also severely inhibited activity.", [["H636", "CHEMICAL", 12, 16], ["H636", "AMINO_ACID", 12, 16], ["H636", "DNA", 12, 16], ["motif I", "PROTEIN", 44, 51], ["Mutation of H636", "PROBLEM", 0, 16], ["severely inhibited activity", "PROBLEM", 58, 85]]], ["Substitution of alanine for R645, immediately downstream of the GKS signature of motif I, still retained approximately 50% activity.", [["alanine", "CHEMICAL", 16, 23], ["R645", "CHEMICAL", 28, 32], ["alanine", "CHEMICAL", 16, 23], ["alanine", "AMINO_ACID", 16, 23], ["R645", "AMINO_ACID", 28, 32], ["R645", "PROTEIN", 28, 32], ["GKS", "PROTEIN", 64, 67], ["motif I", "PROTEIN", 81, 88], ["Substitution of alanine", "TREATMENT", 0, 23]]], ["The mutational effects of R597A were around the same magnitude as R645A.", [["R597A", "AMINO_ACID", 26, 31]]], ["K843A differentially affected ATPase and RTPase with the former decreased to 42% and the latter to 17% of WT.", [["K843A", "GENE_OR_GENE_PRODUCT", 0, 5], ["ATPase", "GENE_OR_GENE_PRODUCT", 30, 36], ["RTPase", "GENE_OR_GENE_PRODUCT", 41, 47], ["K843A", "PROTEIN", 0, 5], ["ATPase", "PROTEIN", 30, 36], ["RTPase", "PROTEIN", 41, 47], ["ATPase", "TEST", 30, 36], ["RTPase", "TEST", 41, 47], ["WT", "TEST", 106, 108], ["decreased", "OBSERVATION_MODIFIER", 64, 73]]], ["The rest of the mutant proteins were comparable to WT for both activities.", [["mutant proteins", "PROTEIN", 16, 31]]], ["The similar effects on ATPase and RTPase of mutations corroborate a previous hypothesis that the catalytic sites of the two activities overlap extensively.Mutational effects on viral accumulation in vivo ::: ResultsThe involvement of the potential RNA-binding residues in viral replication was then examined by introducing pCBG, or its mutant derivatives, into protoplasts of Nicotiana benthamiana and measuring accumulation of the viral coat protein (Fig. 5A) and genomic RNA (Fig. 5B).", [["protoplasts", "ANATOMY", 361, 372], ["ATPase", "GENE_OR_GENE_PRODUCT", 23, 29], ["RTPase", "GENE_OR_GENE_PRODUCT", 34, 40], ["pCBG", "GENE_OR_GENE_PRODUCT", 323, 327], ["Nicotiana benthamiana", "ORGANISM", 376, 397], ["Fig. 5A", "GENE_OR_GENE_PRODUCT", 452, 459], ["ATPase", "PROTEIN", 23, 29], ["RTPase", "PROTEIN", 34, 40], ["catalytic sites", "PROTEIN", 97, 112], ["pCBG", "PROTEIN", 323, 327], ["viral coat protein", "PROTEIN", 432, 450], ["Fig. 5A", "PROTEIN", 452, 459], ["genomic RNA", "RNA", 465, 476], ["Nicotiana benthamiana", "SPECIES", 376, 397], ["Nicotiana benthamiana", "SPECIES", 376, 397], ["ATPase", "TEST", 23, 29], ["mutations", "PROBLEM", 44, 53], ["a previous hypothesis", "PROBLEM", 66, 87], ["Mutational effects", "PROBLEM", 155, 173], ["viral accumulation", "PROBLEM", 177, 195], ["the potential RNA-binding residues", "PROBLEM", 234, 268], ["viral replication", "TREATMENT", 272, 289], ["its mutant derivatives", "TREATMENT", 332, 354], ["Nicotiana benthamiana", "PROBLEM", 376, 397], ["the viral coat protein", "TEST", 428, 450], ["viral accumulation", "OBSERVATION", 177, 195], ["binding residues", "OBSERVATION", 252, 268], ["viral replication", "OBSERVATION", 272, 289], ["Nicotiana benthamiana", "OBSERVATION", 376, 397], ["viral coat protein", "OBSERVATION", 432, 450]]], ["In general, effects on the two measurements in response to a given mutation were similar, suggesting that the changes in coat protein accumulation mainly resulted from changes in the efficiency of viral replication.", [["coat protein", "PROTEIN", 121, 133], ["mutation", "PROBLEM", 67, 75], ["the changes in coat protein accumulation", "PROBLEM", 106, 146], ["viral replication", "TREATMENT", 197, 214], ["protein accumulation", "OBSERVATION", 126, 146], ["viral replication", "OBSERVATION", 197, 214]]], ["Virus carrying H636A, Y704A, or K706A failed to accumulate viral RNA and coat protein above detectable levels.", [["Virus", "ORGANISM", 0, 5], ["H636A", "GENE_OR_GENE_PRODUCT", 15, 20], ["K706A", "GENE_OR_GENE_PRODUCT", 32, 37], ["viral RNA", "RNA", 59, 68], ["coat protein", "PROTEIN", 73, 85], ["viral RNA", "PROBLEM", 59, 68], ["coat protein", "TEST", 73, 85], ["viral RNA", "OBSERVATION", 59, 68]]], ["The lack of the 5\u2032 cap, due to the disabled RTPase, is enough to cause failure of the virus.", [["RTPase", "GENE_OR_GENE_PRODUCT", 44, 50], ["5\u2032 cap", "DNA", 16, 22], ["RTPase", "PROTEIN", 44, 50], ["the 5\u2032 cap", "TREATMENT", 12, 22], ["the disabled RTPase", "PROBLEM", 31, 50], ["failure of the virus", "PROBLEM", 71, 91], ["virus", "OBSERVATION", 86, 91]]], ["By contrast, viruses with K603A, R628A, H794A, or R799A were able to reproduce, at an efficiency within \u223c 35\u201365% of WT, as their ATPase and RTPase activities were approximately equal to that of WT.Mutational effects on viral accumulation in vivo ::: ResultsSurprisingly, K610A could only replicate to a very limited extent, although it had > 90% enzymatic activities of WT.", [["K603A", "GENE_OR_GENE_PRODUCT", 26, 31], ["ATPase", "GENE_OR_GENE_PRODUCT", 129, 135], ["RTPase", "GENE_OR_GENE_PRODUCT", 140, 146], ["ATPase", "PROTEIN", 129, 135], ["RTPase", "PROTEIN", 140, 146], ["K603A", "TEST", 26, 31], ["WT", "TEST", 116, 118], ["their ATPase", "TEST", 123, 135], ["Mutational effects", "PROBLEM", 197, 215], ["viral accumulation", "PROBLEM", 219, 237], ["viral accumulation", "OBSERVATION", 219, 237]]], ["R597A and R645A both retained approximately half of the enzymatic activity of WT.", [["R597A", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["R597A barely reproduced in protoplasts, however R645A could reproduce with efficiency consistent with its ATPase and RTPase activities.", [["protoplasts", "ANATOMY", 27, 38], ["R597A", "GENE_OR_GENE_PRODUCT", 0, 5], ["protoplasts", "CELL", 27, 38], ["ATPase", "GENE_OR_GENE_PRODUCT", 106, 112], ["RTPase", "GENE_OR_GENE_PRODUCT", 117, 123], ["R597A", "PROTEIN", 0, 5], ["ATPase", "PROTEIN", 106, 112], ["RTPase", "PROTEIN", 117, 123]]], ["K843A mutation had similar effects on RTPase activity and replication efficiency, suggesting that RTPase activity as low as 20% of WT is enough to sustain viral replication.", [["K843A", "GENE_OR_GENE_PRODUCT", 0, 5], ["RTPase", "GENE_OR_GENE_PRODUCT", 38, 44], ["RTPase", "GENE_OR_GENE_PRODUCT", 98, 104], ["RTPase", "PROTEIN", 38, 44], ["RTPase", "PROTEIN", 98, 104], ["RTPase activity", "TREATMENT", 38, 53], ["replication efficiency", "PROBLEM", 58, 80], ["replication efficiency", "OBSERVATION", 58, 80]]], ["A previous study using the Q826A mutation suggested that greatly enhanced ATP-binding ability might deteriorate viral RTPase activity in vivo due to the mutual exclusion of the two substrates (Han et al., 2007).", [["ATP", "CHEMICAL", 74, 77], ["ATP", "CHEMICAL", 74, 77], ["Q826A", "GENE_OR_GENE_PRODUCT", 27, 32], ["ATP", "SIMPLE_CHEMICAL", 74, 77], ["RTPase", "GENE_OR_GENE_PRODUCT", 118, 124], ["Q826A", "DNA", 27, 32], ["RTPase", "PROTEIN", 118, 124], ["A previous study", "TEST", 0, 16], ["the Q826A mutation", "TEST", 23, 41], ["greatly enhanced ATP-binding ability", "PROBLEM", 57, 93]]], ["Could this also be an explanation for the unexpected results of the R597A and K610A mutations?", [["R597A", "GENE_OR_GENE_PRODUCT", 68, 73], ["K610A", "GENE_OR_GENE_PRODUCT", 78, 83]]], ["Kinetic analysis of ATPase activity based on an enzyme-coupled assay was selectively carried out on WT, R597A, K603A, and K610A (Table 2).", [["ATPase", "GENE_OR_GENE_PRODUCT", 20, 26], ["ATPase", "PROTEIN", 20, 26], ["Kinetic analysis", "TEST", 0, 16], ["ATPase activity", "PROBLEM", 20, 35], ["an enzyme", "TEST", 45, 54], ["WT", "TEST", 100, 102], ["K603A", "TEST", 111, 116]]], ["The magnitudes of Km and kcat were not changed significantly due to the mutations.", [["Km", "GENE_OR_GENE_PRODUCT", 18, 20], ["Km", "TEST", 18, 20], ["kcat", "TEST", 25, 29], ["the mutations", "PROBLEM", 68, 81]]], ["Collectively, the results implied that in addition to its involvement in ATPase and RTPase activities, the BaMV helicase-like domain may have other functions required for replication.Mutational effects on viral accumulation in vivo ::: ResultsThe helicase-like domain was previously reported to have preferential binding to the rABC structural domain of the viral 3\u2032UTR based on a UV-induced crosslinking (Chen et al., 2003).", [["UV", "CHEMICAL", 381, 383], ["ATPase", "GENE_OR_GENE_PRODUCT", 73, 79], ["RTPase", "GENE_OR_GENE_PRODUCT", 84, 90], ["BaMV", "GENE_OR_GENE_PRODUCT", 107, 111], ["ATPase", "PROTEIN", 73, 79], ["RTPase", "PROTEIN", 84, 90], ["BaMV helicase-like domain", "PROTEIN", 107, 132], ["helicase-like domain", "PROTEIN", 247, 267], ["rABC structural domain", "PROTEIN", 328, 350], ["viral 3\u2032", "DNA", 358, 366], ["UTR", "DNA", 366, 369], ["the BaMV helicase", "TREATMENT", 103, 120], ["Mutational effects", "PROBLEM", 183, 201], ["viral accumulation", "PROBLEM", 205, 223], ["preferential binding", "PROBLEM", 300, 320], ["UTR", "PROBLEM", 366, 369], ["a UV-induced crosslinking", "TREATMENT", 379, 404], ["viral accumulation", "OBSERVATION", 205, 223]]], ["This specific protein\u2013RNA interaction has been proposed to account for the structural requirement of the rABC domain for an efficient replication of BaMV.", [["rABC", "GENE_OR_GENE_PRODUCT", 105, 109], ["BaMV", "GENE_OR_GENE_PRODUCT", 149, 153], ["rABC domain", "PROTEIN", 105, 116], ["BaMV", "PROTEIN", 149, 153], ["This specific protein\u2013RNA interaction", "PROBLEM", 0, 37], ["an efficient replication of BaMV", "TREATMENT", 121, 153]]], ["Thus, binding of the three mutant proteins to the 3\u2032UTR was assayed with the same technique in this study (Fig. 6).", [["mutant proteins", "PROTEIN", 27, 42], ["3\u2032UTR", "DNA", 50, 55], ["this study", "TEST", 95, 105]]], ["These results showed that R597A, K603A, K610A, and WT exhibited similar binding strength to the 3\u2032UTR, suggesting that this specific interaction is not the basis for the replication incompetence of R597A and K610A.Mutational effects on viral accumulation in vivo ::: ResultsThe influence of the mutated residues in viral infectivity was examined by inoculating the corresponding pCBG derivatives into leaves of N. benthamiana.", [["leaves", "ANATOMY", 401, 407], ["pCBG", "CHEMICAL", 379, 383], ["pCBG", "GENE_OR_GENE_PRODUCT", 379, 383], ["leaves", "ORGANISM_SUBDIVISION", 401, 407], ["N. benthamiana", "ORGANISM", 411, 425], ["3\u2032UTR", "DNA", 96, 101], ["N. benthamiana", "SPECIES", 411, 425], ["N. benthamiana", "SPECIES", 411, 425], ["K603A", "TEST", 33, 38], ["K610A", "TEST", 40, 45], ["WT", "TEST", 51, 53], ["Mutational effects", "PROBLEM", 214, 232], ["viral accumulation", "PROBLEM", 236, 254], ["the mutated residues", "PROBLEM", 291, 311], ["viral infectivity", "PROBLEM", 315, 332], ["viral accumulation", "OBSERVATION", 236, 254], ["viral infectivity", "OBSERVATION", 315, 332], ["N. benthamiana", "OBSERVATION", 411, 425]]], ["The expression of GFP in inoculated and systemic leaves was used as an index for viral replication in plant (Fig. 7).", [["leaves", "ANATOMY", 49, 55], ["GFP", "GENE_OR_GENE_PRODUCT", 18, 21], ["GFP", "PROTEIN", 18, 21], ["GFP", "PROBLEM", 18, 21], ["systemic leaves", "TREATMENT", 40, 55], ["an index", "TEST", 68, 76], ["viral replication", "TREATMENT", 81, 98]]], ["With respect to inoculated leaves, inoculation with WT gave high GFP expression after 20 days post-inoculation (dpi).", [["leaves", "ANATOMY", 27, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 65, 68], ["GFP", "PROTEIN", 65, 68]]], ["Sufficient GFP expression was also observed with R645A, H794A, and R799A.", [["GFP", "GENE_OR_GENE_PRODUCT", 11, 14], ["GFP", "PROTEIN", 11, 14], ["GFP expression", "OBSERVATION", 11, 25]]], ["By contrast, only limited fluorescence was observed with K603A, R628A, and K843A.", [["K603A", "GENE_OR_GENE_PRODUCT", 57, 62], ["K603A", "TEST", 57, 62]]], ["Furthermore, GFP expression was very restricted in response to R597A, K610A, H636A, Y704A, and K706A mutations.", [["GFP", "GENE_OR_GENE_PRODUCT", 13, 16], ["R597A", "GENE_OR_GENE_PRODUCT", 63, 68], ["K610A", "GENE_OR_GENE_PRODUCT", 70, 75], ["H636A", "GENE_OR_GENE_PRODUCT", 77, 82], ["Y704A", "GENE_OR_GENE_PRODUCT", 84, 89], ["K706A", "GENE_OR_GENE_PRODUCT", 95, 100], ["GFP", "PROTEIN", 13, 16], ["GFP expression", "TEST", 13, 27], ["K610A", "TEST", 70, 75]]], ["GFP accumulation in systemic leaves at 20 dpi was also recorded, which showed that only WT and R799A spread significantly.", [["leaves", "ANATOMY", 29, 35], ["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["GFP", "PROTEIN", 0, 3], ["GFP accumulation", "PROBLEM", 0, 16], ["systemic leaves", "PROBLEM", 20, 35], ["WT", "TEST", 88, 90], ["systemic", "OBSERVATION_MODIFIER", 20, 28], ["leaves", "OBSERVATION_MODIFIER", 29, 35]]], ["Infectivity of the BaMV variants in Chenopodium quinoa was also examined (Fig. 8).", [["BaMV", "GENE_OR_GENE_PRODUCT", 19, 23], ["Chenopodium quinoa", "ORGANISM", 36, 54], ["BaMV variants", "DNA", 19, 32], ["Chenopodium quinoa", "SPECIES", 36, 54], ["Chenopodium quinoa", "SPECIES", 36, 54], ["the BaMV variants in Chenopodium quinoa", "PROBLEM", 15, 54], ["Chenopodium quinoa", "OBSERVATION", 36, 54]]], ["Many fluorescent spots appeared on the leaves infected by WT, R645A, H794A, and R799A at 7 dpi.", [["leaves", "ANATOMY", 39, 45], ["Many fluorescent spots", "PROBLEM", 0, 22], ["fluorescent spots", "OBSERVATION", 5, 22]]], ["By contrast, the fluorescent spots on leaves inoculated with K603A, and R628A were few and dim.", [["leaves", "ANATOMY", 38, 44], ["K603A", "GENE_OR_GENE_PRODUCT", 61, 66], ["K603A", "TEST", 61, 66], ["few", "OBSERVATION_MODIFIER", 83, 86], ["dim", "OBSERVATION", 91, 94]]], ["The rest of the mutants did not give rise to notable GFP expression.DiscussionThe majority of helicases can be categorized into three superfamilies based on the presence of defined helicase motifs.", [["GFP", "GENE_OR_GENE_PRODUCT", 53, 56], ["GFP", "PROTEIN", 53, 56], ["helicase motifs", "PROTEIN", 181, 196], ["GFP expression", "OBSERVATION", 53, 67]]], ["The GKS/T signature of motif I is highly conserved across all the three superfamilies, whereas the consensus sequences of motif II are slightly different, with DE/D in SF1 and SF3 and DEAD, DEAH, or DExH in different subfamilies of SF2.", [["SF1", "GENE_OR_GENE_PRODUCT", 168, 171], ["SF3", "GENE_OR_GENE_PRODUCT", 176, 179], ["DEAD", "GENE_OR_GENE_PRODUCT", 184, 188], ["DEAH", "GENE_OR_GENE_PRODUCT", 190, 194], ["DExH", "GENE_OR_GENE_PRODUCT", 199, 203], ["SF2", "GENE_OR_GENE_PRODUCT", 232, 235], ["GKS", "PROTEIN", 4, 7], ["motif I", "PROTEIN", 23, 30], ["consensus sequences", "DNA", 99, 118], ["motif II", "DNA", 122, 130], ["SF1", "DNA", 168, 171], ["SF3", "DNA", 176, 179], ["DEAD", "PROTEIN", 184, 188], ["DEAH", "PROTEIN", 190, 194], ["DExH", "DNA", 199, 203], ["SF2", "DNA", 232, 235], ["The GKS", "TEST", 0, 7], ["DE/D in SF1", "PROBLEM", 160, 171], ["DEAD", "PROBLEM", 184, 188], ["DEAH", "PROBLEM", 190, 194], ["SF2", "ANATOMY", 232, 235]]], ["Other motifs including III, V, and VI are specific to each superfamily or subfamily.", [["III, V", "GENE_OR_GENE_PRODUCT", 23, 29], ["VI", "GENE_OR_GENE_PRODUCT", 35, 37], ["VI", "DNA", 35, 37]]], ["Comparison between the structures of SF1 helicases, e.g. Rep bound to ss-DNA (Korolev et al., 1997) and PcrA (Subramanya et al., 1996), and SF2 helicase, e.g. HCV NS3 (Yao et al., 1997), revealed that the core domains of the helicases have similar folds, characteristic of a large central parallel \u03b2-sheet flanked by \u03b1-helices, although there is little sequence homology between the SF1 and SF2 helicases (Korolev et al., 1998).", [["SF1", "GENE_OR_GENE_PRODUCT", 37, 40], ["Rep", "GENE_OR_GENE_PRODUCT", 57, 60], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["SF2", "GENE_OR_GENE_PRODUCT", 140, 143], ["HCV NS3", "ORGANISM", 159, 166], ["\u03b1-helices", "GENE_OR_GENE_PRODUCT", 317, 326], ["SF1", "GENE_OR_GENE_PRODUCT", 383, 386], ["SF2", "GENE_OR_GENE_PRODUCT", 391, 394], ["SF1 helicases", "PROTEIN", 37, 50], ["Rep", "PROTEIN", 57, 60], ["SF2 helicase", "PROTEIN", 140, 152], ["HCV NS3", "PROTEIN", 159, 166], ["helicases", "PROTEIN", 225, 234], ["\u03b2-sheet", "PROTEIN", 298, 305], ["\u03b1-helices", "PROTEIN", 317, 326], ["SF1", "PROTEIN", 383, 386], ["SF2 helicases", "PROTEIN", 391, 404], ["HCV", "SPECIES", 159, 162], ["PcrA", "TEST", 104, 108], ["SF2 helicase", "TREATMENT", 140, 152], ["the core domains of the helicases", "PROBLEM", 201, 234], ["similar folds", "PROBLEM", 240, 253], ["helicases", "OBSERVATION", 225, 234], ["similar folds", "OBSERVATION", 240, 253], ["large", "OBSERVATION_MODIFIER", 275, 280], ["central", "ANATOMY_MODIFIER", 281, 288], ["SF1", "ANATOMY", 383, 386]]], ["Together with structures of other RNA-bound helicases, including eIF4AIII (Andersen et al., 2006) and DEAD-box protein Vasa (Sengoku et al., 2006), the functions of helicase motifs have been concluded as follows: motifs I, II, and VI for ATP binding and hydrolysis, motifs III and V for coordinating nucleic acid binding and ATPase activity, and the less conserved motifs including motif IV and motifs Ia, Ib, Ic, Id, IVa, IVb, and Va, when present, for nucleic acid binding (Lee and Yang, 2006, Jankowsky and Fairman, 2007).DiscussionThe helicase-like domain of BaMV replicase possesses NTPase and RTPase activities (Li et al., 2001).", [["ATP", "CHEMICAL", 238, 241], ["nucleic acid", "CHEMICAL", 300, 312], ["nucleic acid", "CHEMICAL", 454, 466], ["ATP", "CHEMICAL", 238, 241], ["DEAD-box protein Vasa", "GENE_OR_GENE_PRODUCT", 102, 123], ["ATP", "SIMPLE_CHEMICAL", 238, 241], ["ATPase", "GENE_OR_GENE_PRODUCT", 325, 331], ["Ia", "GENE_OR_GENE_PRODUCT", 402, 404], ["Ib", "GENE_OR_GENE_PRODUCT", 406, 408], ["Id", "GENE_OR_GENE_PRODUCT", 414, 416], ["IVa", "GENE_OR_GENE_PRODUCT", 418, 421], ["IVb", "GENE_OR_GENE_PRODUCT", 423, 426], ["Va", "GENE_OR_GENE_PRODUCT", 432, 434], ["nucleic acid", "SIMPLE_CHEMICAL", 454, 466], ["BaMV", "GENE_OR_GENE_PRODUCT", 563, 567], ["NTPase", "GENE_OR_GENE_PRODUCT", 588, 594], ["RTPase", "GENE_OR_GENE_PRODUCT", 599, 605], ["RNA-bound helicases", "PROTEIN", 34, 53], ["eIF4AIII", "PROTEIN", 65, 73], ["DEAD-box protein Vasa", "PROTEIN", 102, 123], ["helicase motifs", "PROTEIN", 165, 180], ["I, II, and VI", "PROTEIN", 220, 233], ["motifs III and V", "PROTEIN", 266, 282], ["ATPase", "PROTEIN", 325, 331], ["motif IV", "PROTEIN", 382, 390], ["Ia", "PROTEIN", 402, 404], ["Ib", "PROTEIN", 406, 408], ["Ic", "PROTEIN", 410, 412], ["Id", "PROTEIN", 414, 416], ["IVa", "DNA", 418, 421], ["IVb", "DNA", 423, 426], ["Va", "DNA", 432, 434], ["helicase-like domain", "PROTEIN", 539, 559], ["BaMV replicase", "PROTEIN", 563, 577], ["NTPase", "PROTEIN", 588, 594], ["RTPase", "PROTEIN", 599, 605], ["other RNA-bound helicases", "PROBLEM", 28, 53], ["helicase motifs", "TREATMENT", 165, 180], ["ATP binding", "PROBLEM", 238, 249], ["hydrolysis", "PROBLEM", 254, 264], ["coordinating nucleic acid binding", "PROBLEM", 287, 320], ["ATPase activity", "PROBLEM", 325, 340], ["motif IV", "TREATMENT", 382, 390], ["IVb", "TREATMENT", 423, 426], ["nucleic acid binding", "PROBLEM", 454, 474], ["The helicase", "TREATMENT", 535, 547], ["BaMV replicase", "TREATMENT", 563, 577]]], ["It is known that motifs I, II, and VI are essential for both of the activities (Han et al., 2007); however, the regions responsible for RNA binding remained largely unclear before this study.", [["II", "GENE_OR_GENE_PRODUCT", 27, 29], ["VI", "GENE_OR_GENE_PRODUCT", 35, 37], ["I, II, and VI", "PROTEIN", 24, 37], ["RNA binding", "PROBLEM", 136, 147], ["this study", "TEST", 180, 190]]], ["In the present study, formaldehyde crosslinking between the viral helicase-like domain and RNA identified several peptidyl regions that could potentially contact RNA.", [["formaldehyde", "CHEMICAL", 22, 34], ["formaldehyde", "CHEMICAL", 22, 34], ["formaldehyde", "SIMPLE_CHEMICAL", 22, 34], ["viral helicase-like domain", "PROTEIN", 60, 86], ["peptidyl regions", "PROTEIN", 114, 130], ["the present study", "TEST", 3, 20], ["formaldehyde crosslinking", "TREATMENT", 22, 47], ["the viral helicase", "PROBLEM", 56, 74], ["several peptidyl regions", "PROBLEM", 106, 130], ["formaldehyde crosslinking", "OBSERVATION", 22, 47], ["viral helicase", "OBSERVATION", 60, 74], ["several", "OBSERVATION_MODIFIER", 106, 113], ["peptidyl regions", "OBSERVATION", 114, 130]]], ["The finding of motif I- and II-containing regions in association with RNA is understandable, as the two motifs play essential roles in cleaving the 5\u2032 \u03b3-phosphate off the RNA substrate.", [["5\u2032 \u03b3-phosphate", "CHEMICAL", 148, 162], ["5\u2032 \u03b3-phosphate", "CHEMICAL", 148, 162], ["motif I- and II-containing regions", "DNA", 15, 49], ["RNA substrate", "PROTEIN", 171, 184], ["motif I- and II-containing regions in association with RNA", "PROBLEM", 15, 73], ["the 5\u2032 \u03b3-phosphate", "TREATMENT", 144, 162], ["the RNA substrate", "TREATMENT", 167, 184]]], ["Three other non-conserved peptidyl regions were also found to bind RNA.", [["non-conserved peptidyl regions", "PROTEIN", 12, 42], ["Three other non-conserved peptidyl regions", "PROBLEM", 0, 42], ["peptidyl regions", "OBSERVATION", 26, 42], ["bind RNA", "OBSERVATION", 62, 70]]], ["Compared with the bona fide helicases described above, the BaMV helicase seems to bind RNA by using different peptidyl regions.", [["BaMV", "GENE_OR_GENE_PRODUCT", 59, 63], ["bona fide helicases", "PROTEIN", 18, 37], ["BaMV helicase", "PROTEIN", 59, 72], ["peptidyl regions", "PROTEIN", 110, 126], ["the BaMV helicase", "TREATMENT", 55, 72], ["different peptidyl regions", "TREATMENT", 100, 126], ["helicases", "OBSERVATION", 28, 37]]], ["Specifically, the sequence of the BaMV helicase-like domain, along with several homologues from other plant viruses, aligns with the well-characterized DNA helicase PcrA (Fig. 9).", [["BaMV", "GENE_OR_GENE_PRODUCT", 34, 38], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["BaMV helicase-like domain", "PROTEIN", 34, 59], ["DNA helicase", "PROTEIN", 152, 164], ["PcrA", "PROTEIN", 165, 169], ["Fig. 9", "PROTEIN", 171, 177], ["the BaMV helicase", "TREATMENT", 30, 47], ["other plant viruses", "PROBLEM", 96, 115], ["plant viruses", "OBSERVATION", 102, 115]]], ["As members of SF1, all the proteins have similar consensus sequences within motifs I, II, III, V, and VI.", [["SF1", "GENE_OR_GENE_PRODUCT", 14, 17], ["SF1", "PROTEIN", 14, 17], ["consensus sequences", "DNA", 49, 68], ["VI", "DNA", 102, 104]]], ["However, the helicase-like domains of plant viruses are shorter than PcrA and lack motifs Ia, Ib, Ic, Id, IVa, IVb, and Va, which are responsible for DNA binding in PcrA (Lee and Yang, 2006).DiscussionThe importance of the mapped peptidyl regions in the enzymatic activities and viral replication was assayed by substituting alanine for the arginine, lysine, histidine, and tyrosine residues within the regions based on the preferential reactivity of these amino acids to formaldehyde and ability to link RNA.", [["alanine", "CHEMICAL", 325, 332], ["arginine", "CHEMICAL", 341, 349], ["lysine", "CHEMICAL", 351, 357], ["histidine", "CHEMICAL", 359, 368], ["tyrosine", "CHEMICAL", 374, 382], ["amino acids", "CHEMICAL", 457, 468], ["formaldehyde", "CHEMICAL", 472, 484], ["alanine", "CHEMICAL", 325, 332], ["arginine", "CHEMICAL", 341, 349], ["lysine", "CHEMICAL", 351, 357], ["histidine", "CHEMICAL", 359, 368], ["tyrosine", "CHEMICAL", 374, 382], ["amino acids", "CHEMICAL", 457, 468], ["formaldehyde", "CHEMICAL", 472, 484], ["plant viruses", "ORGANISM", 38, 51], ["PcrA", "GENE_OR_GENE_PRODUCT", 69, 73], ["Ia", "GENE_OR_GENE_PRODUCT", 90, 92], ["Ib", "GENE_OR_GENE_PRODUCT", 94, 96], ["Ic", "GENE_OR_GENE_PRODUCT", 98, 100], ["Id", "GENE_OR_GENE_PRODUCT", 102, 104], ["IVa", "GENE_OR_GENE_PRODUCT", 106, 109], ["IVb", "GENE_OR_GENE_PRODUCT", 111, 114], ["Va", "GENE_OR_GENE_PRODUCT", 120, 122], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["alanine", "AMINO_ACID", 325, 332], ["arginine", "AMINO_ACID", 341, 349], ["lysine", "AMINO_ACID", 351, 357], ["histidine", "AMINO_ACID", 359, 368], ["tyrosine", "AMINO_ACID", 374, 382], ["amino acids", "AMINO_ACID", 457, 468], ["formaldehyde", "SIMPLE_CHEMICAL", 472, 484], ["helicase-like domains", "PROTEIN", 13, 34], ["PcrA", "PROTEIN", 69, 73], ["Ib", "PROTEIN", 94, 96], ["Ic", "PROTEIN", 98, 100], ["Id", "PROTEIN", 102, 104], ["IVa", "DNA", 106, 109], ["IVb", "DNA", 111, 114], ["Va", "DNA", 120, 122], ["peptidyl regions", "PROTEIN", 230, 246], ["RNA", "RNA", 505, 508], ["plant viruses", "PROBLEM", 38, 51], ["IVb", "TREATMENT", 111, 114], ["DNA binding", "PROBLEM", 150, 161], ["the mapped peptidyl regions", "PROBLEM", 219, 246], ["viral replication", "TREATMENT", 279, 296], ["alanine", "TREATMENT", 325, 332], ["the arginine, lysine", "TREATMENT", 337, 357], ["histidine", "TREATMENT", 359, 368], ["tyrosine residues", "TREATMENT", 374, 391], ["these amino acids", "TREATMENT", 451, 468], ["plant viruses", "OBSERVATION", 38, 51], ["Va", "ANATOMY", 120, 122]]], ["Eleven mutant proteins were thus created and purified.", [["mutant proteins", "PROTEIN", 7, 22], ["Eleven mutant proteins", "PROBLEM", 0, 22]]], ["The capability of the BaMV helicase-like domain to bind RNA was not significantly affected by any single mutation.", [["BaMV", "GENE_OR_GENE_PRODUCT", 22, 26], ["BaMV helicase-like domain", "PROTEIN", 22, 47], ["the BaMV helicase", "TREATMENT", 18, 35], ["any single mutation", "PROBLEM", 94, 113]]], ["Similar results had been observed in a previous HCV NS5B-RNA binding study, in which a less than two-fold decrease in the affinity for RNA was seen in response to single point mutation (Kim et al., 2005).", [["HCV", "SPECIES", 48, 51], ["a previous HCV NS5B", "TEST", 37, 56], ["RNA binding study", "TEST", 57, 74], ["RNA", "PROBLEM", 135, 138], ["decrease", "OBSERVATION_MODIFIER", 106, 114]]], ["In addition, the magnitudes of Km of mutant proteins, R597A, K603A, and K610A, toward ATP were not altered significantly.", [["ATP", "CHEMICAL", 86, 89], ["ATP", "CHEMICAL", 86, 89], ["ATP", "SIMPLE_CHEMICAL", 86, 89], ["mutant proteins", "PROTEIN", 37, 52], ["R597A", "PROTEIN", 54, 59], ["K603A", "PROTEIN", 61, 66], ["K610A", "PROTEIN", 72, 77], ["mutant proteins", "TEST", 37, 52], ["K603A", "TEST", 61, 66], ["K610A", "TEST", 72, 77], ["ATP", "TEST", 86, 89]]], ["Collectively, these results suggest that the mutations should not cause significant changes in the structure of BaMV helicase-like domain.", [["BaMV", "GENE_OR_GENE_PRODUCT", 112, 116], ["BaMV helicase-like domain", "PROTEIN", 112, 137], ["the mutations", "PROBLEM", 41, 54], ["significant changes in the structure of BaMV helicase", "PROBLEM", 72, 125]]], ["Therefore, the effects on viral replication in vivo should be due to the inherent functions of the mutated residues, rather than the result of drastic changes of the protein structure.DiscussionThe mutational effects can be categorized into several classes (Table 3).", [["protein structure", "PROTEIN", 166, 183], ["viral replication", "TREATMENT", 26, 43], ["the mutated residues", "PROBLEM", 95, 115], ["drastic changes of the protein structure", "PROBLEM", 143, 183], ["drastic", "OBSERVATION", 143, 150], ["protein structure", "OBSERVATION", 166, 183]]], ["First, H636A, Y704A, and K706A caused severe or even deadly effects on not only in vitro ATPase and RTPase activities but also viral replication in protoplasts.", [["protoplasts", "ANATOMY", 148, 159], ["H636A", "GENE_OR_GENE_PRODUCT", 7, 12], ["ATPase", "GENE_OR_GENE_PRODUCT", 89, 95], ["RTPase", "GENE_OR_GENE_PRODUCT", 100, 106], ["protoplasts", "CELL", 148, 159], ["ATPase", "PROTEIN", 89, 95], ["RTPase", "PROTEIN", 100, 106], ["vitro ATPase", "TREATMENT", 83, 95], ["viral replication in protoplasts", "PROBLEM", 127, 159], ["severe", "OBSERVATION", 38, 44], ["viral replication", "OBSERVATION", 127, 144]]], ["Disabled enzymatic activities should be the cause for infertility of the mutant viruses in plant cells.", [["cells", "ANATOMY", 97, 102], ["infertility", "DISEASE", 54, 65], ["mutant viruses", "ORGANISM", 73, 87], ["plant cells", "CELL", 91, 102], ["plant cells", "CELL_TYPE", 91, 102], ["Disabled enzymatic activities", "PROBLEM", 0, 29], ["infertility", "PROBLEM", 54, 65], ["the mutant viruses in plant cells", "PROBLEM", 69, 102], ["viruses", "OBSERVATION", 80, 87], ["plant cells", "OBSERVATION", 91, 102]]], ["In theory, RNA helicase activity is important for viral survival by unwinding duplex RNA, e.g. stem-loop and hairpin structures, to facilitate the replication process or avoid RNA interference.", [["duplex RNA", "RNA", 78, 88], ["unwinding duplex RNA", "TEST", 68, 88], ["the replication process", "TREATMENT", 143, 166], ["RNA interference", "PROBLEM", 176, 192], ["helicase activity", "OBSERVATION", 15, 32]]], ["Although the possession of helicase activity remains uncertain, ATPase activity is a prerequisite for such a presumable activity.", [["ATPase", "GENE_OR_GENE_PRODUCT", 64, 70], ["helicase", "PROTEIN", 27, 35], ["ATPase", "PROTEIN", 64, 70], ["helicase activity", "PROBLEM", 27, 44], ["helicase activity", "OBSERVATION", 27, 44]]], ["Without the fuel provided by ATPase, the presumable helicase activity could not function normally.", [["ATPase", "GENE_OR_GENE_PRODUCT", 29, 35], ["ATPase", "PROTEIN", 29, 35], ["helicase activity", "OBSERVATION", 52, 69]]], ["RTPase is another essential function for viral replication.", [["RTPase", "GENE_OR_GENE_PRODUCT", 0, 6], ["RTPase", "PROTEIN", 0, 6], ["viral replication", "TREATMENT", 41, 58], ["viral replication", "OBSERVATION", 41, 58]]], ["If unable to form the 5\u2032-cap at plus sense viral RNAs, viral protein translation would be shut down.", [["5\u2032", "DNA", 22, 24], ["plus sense viral RNAs", "RNA", 32, 53], ["the 5\u2032-cap at plus sense viral RNAs", "TREATMENT", 18, 53], ["viral protein translation", "TREATMENT", 55, 80]]], ["Compared with the results of R645A and K843A, the remaining ATPase and RTPase activities of R597A and K610A should be able to support viral replication in protoplasts proportionally.", [["protoplasts", "ANATOMY", 155, 166], ["ATPase", "GENE_OR_GENE_PRODUCT", 60, 66], ["RTPase", "GENE_OR_GENE_PRODUCT", 71, 77], ["R597A", "GENE_OR_GENE_PRODUCT", 92, 97], ["K610A", "GENE_OR_GENE_PRODUCT", 102, 107], ["protoplasts", "CELL", 155, 166], ["ATPase", "PROTEIN", 60, 66], ["RTPase", "PROTEIN", 71, 77], ["K610A", "PROTEIN", 102, 107], ["the remaining ATPase", "TEST", 46, 66], ["RTPase activities", "TEST", 71, 88], ["K610A", "TREATMENT", 102, 107], ["viral replication in protoplasts", "TREATMENT", 134, 166]]], ["However, replication of the two mutant viruses in protoplasts was very limited.", [["protoplasts", "ANATOMY", 50, 61], ["mutant viruses", "ORGANISM", 32, 46], ["protoplasts", "CELL", 50, 61], ["the two mutant viruses in protoplasts", "PROBLEM", 24, 61], ["viruses", "OBSERVATION", 39, 46]]], ["This discrepancy suggests that the peptidyl region encompassing residues 597\u2013610 may be involved in the unproven helicase activity or some other unidentified functions required for replication.", [["597\u2013610", "CHEMICAL", 73, 80], ["peptidyl", "CHEMICAL", 35, 43], ["597\u2013610", "AMINO_ACID", 73, 80], ["peptidyl region", "PROTEIN", 35, 50], ["the peptidyl region encompassing residues", "PROBLEM", 31, 72]]], ["BMV 1a protein represents an example that demonstrates the involvement of a helicase-like domain in viral replication by additional mechanisms such as assembling the replication complex and regulating viral protein translation (Chen and Ahlquist, 2000, Chen et al., 2001, Yi et al., 2007).DiscussionThe third class includes K603A and R628A, which limited viral infectivity in plants despite some amount of viral replication in protoplasts.", [["protoplasts", "ANATOMY", 427, 438], ["BMV 1a", "GENE_OR_GENE_PRODUCT", 0, 6], ["K603A", "GENE_OR_GENE_PRODUCT", 324, 329], ["R628A", "GENE_OR_GENE_PRODUCT", 334, 339], ["protoplasts", "CELL", 427, 438], ["BMV 1a protein", "PROTEIN", 0, 14], ["helicase-like domain", "PROTEIN", 76, 96], ["replication complex", "PROTEIN", 166, 185], ["BMV", "SPECIES", 0, 3], ["a helicase", "TREATMENT", 74, 84], ["viral replication", "TREATMENT", 100, 117], ["viral infectivity in plants", "PROBLEM", 355, 382], ["viral replication in protoplasts", "PROBLEM", 406, 438], ["viral replication", "OBSERVATION", 100, 117], ["viral protein", "OBSERVATION", 201, 214], ["viral infectivity", "OBSERVATION", 355, 372], ["viral replication", "OBSERVATION", 406, 423]]], ["Accumulations of the coat protein and genomic RNA of the two mutant viruses in protoplasts were approximately 30\u201363% of WT.", [["protoplasts", "ANATOMY", 79, 90], ["mutant viruses", "ORGANISM", 61, 75], ["protoplasts", "CELL", 79, 90], ["coat protein", "PROTEIN", 21, 33], ["genomic RNA", "RNA", 38, 49], ["the coat protein", "TEST", 17, 33], ["the two mutant viruses in protoplasts", "PROBLEM", 53, 90], ["WT", "TEST", 120, 122], ["coat protein", "OBSERVATION", 21, 33], ["genomic RNA", "OBSERVATION", 38, 49], ["mutant", "OBSERVATION_MODIFIER", 61, 67], ["viruses", "OBSERVATION", 68, 75]]], ["Similar levels of accumulation also resulted from R645A, H794A, and R799A.", [["R645A", "GENE_OR_GENE_PRODUCT", 50, 55], ["accumulation", "OBSERVATION", 18, 30]]], ["However, there is an apparent disparity in viral infectivity between the two groups.", [["an apparent disparity in viral infectivity", "PROBLEM", 18, 60], ["apparent", "OBSERVATION_MODIFIER", 21, 29], ["disparity", "OBSERVATION_MODIFIER", 30, 39], ["viral infectivity", "OBSERVATION", 43, 60]]], ["The former accumulated much lower amounts of GFP than the latter in the inoculated leaves of C. quinoa and N. benthamiana, suggesting that viral cell-to-cell movement was somewhat restricted by K603A and R628A mutations.", [["leaves", "ANATOMY", 83, 89], ["cell", "ANATOMY", 145, 149], ["cell", "ANATOMY", 153, 157], ["GFP", "GENE_OR_GENE_PRODUCT", 45, 48], ["C. quinoa", "ORGANISM", 93, 102], ["N. benthamiana", "ORGANISM", 107, 121], ["cell", "CELL", 145, 149], ["cell", "CELL", 153, 157], ["K603A", "GENE_OR_GENE_PRODUCT", 194, 199], ["R628A", "GENE_OR_GENE_PRODUCT", 204, 209], ["GFP", "PROTEIN", 45, 48], ["C. quinoa", "SPECIES", 93, 102], ["N. benthamiana", "SPECIES", 107, 121], ["C. quinoa", "SPECIES", 93, 102], ["N. benthamiana", "SPECIES", 107, 121], ["C. quinoa and N. benthamiana", "PROBLEM", 93, 121], ["viral cell", "TEST", 139, 149], ["accumulated", "OBSERVATION_MODIFIER", 11, 22], ["much", "OBSERVATION_MODIFIER", 23, 27], ["lower amounts", "OBSERVATION_MODIFIER", 28, 41], ["benthamiana", "ANATOMY", 110, 121], ["viral cell", "OBSERVATION", 139, 149], ["cell movement", "OBSERVATION", 153, 166]]], ["The involvement of the helicase-like domain in viral cell-to-cell movement was also demonstrated previously in Tobacco mosaic virus (Hirashima and Watanabe 2003).", [["cell", "ANATOMY", 53, 57], ["cell", "ANATOMY", 61, 65], ["Tobacco mosaic virus", "DISEASE", 111, 131], ["cell", "CELL", 53, 57], ["cell", "CELL", 61, 65], ["Tobacco mosaic virus", "ORGANISM", 111, 131], ["helicase-like domain", "PROTEIN", 23, 43], ["Tobacco mosaic virus", "SPECIES", 111, 131], ["Tobacco mosaic virus", "SPECIES", 111, 131], ["the helicase-like domain", "PROBLEM", 19, 43], ["viral cell", "TEST", 47, 57], ["viral cell", "OBSERVATION", 47, 57], ["cell movement", "OBSERVATION", 61, 74], ["Tobacco mosaic virus", "OBSERVATION", 111, 131]]], ["Mutations of R645A and H794A constitute the fourth class.", [["R645A", "GENE_OR_GENE_PRODUCT", 13, 18], ["H794A", "AMINO_ACID", 23, 28], ["R645A", "DNA", 13, 18]]], ["Although virus carrying either mutation could reproduce properly in inoculated leaves of N. benthamiana, it could not move into systemic leaves as efficiently as WT and R799A.", [["leaves", "ANATOMY", 79, 85], ["leaves", "ORGANISM_SUBDIVISION", 79, 85], ["N. benthamiana", "ORGANISM", 89, 103], ["R799A", "GENE_OR_GENE_PRODUCT", 169, 174], ["N. benthamiana", "SPECIES", 89, 103], ["N. benthamiana", "SPECIES", 89, 103], ["virus", "PROBLEM", 9, 14], ["mutation", "PROBLEM", 31, 39], ["WT", "TEST", 162, 164], ["N. benthamiana", "OBSERVATION", 89, 103]]], ["R799A belongs to another class.", [["R799A", "PROTEIN", 0, 5]]], ["No adverse effect regarding replication and movement was noted due to the R799A mutation.DiscussionWith RNA-binding ability, helicases have evolved diverse functions to cope with the demands for the organism survival.", [["R799A", "GENE_OR_GENE_PRODUCT", 74, 79], ["R799A", "DNA", 74, 79], ["adverse effect", "PROBLEM", 3, 17], ["the R799A mutation", "PROBLEM", 70, 88], ["the organism survival", "TREATMENT", 195, 216], ["adverse effect", "OBSERVATION", 3, 17]]], ["For example, the RNA helicases Ded1 and NPH-II can displace protein from RNA in an ATP-dependent mode without duplex unwinding (Fairman et al., 2004, Jankowsky and Bowers, 2006).", [["ATP", "CHEMICAL", 83, 86], ["ATP", "CHEMICAL", 83, 86], ["Ded1", "GENE_OR_GENE_PRODUCT", 31, 35], ["NPH-II", "GENE_OR_GENE_PRODUCT", 40, 46], ["ATP", "SIMPLE_CHEMICAL", 83, 86], ["RNA helicases", "PROTEIN", 17, 30], ["Ded1", "PROTEIN", 31, 35], ["NPH-II", "PROTEIN", 40, 46], ["the RNA helicases", "TEST", 13, 30], ["NPH", "TEST", 40, 43], ["an ATP", "TEST", 80, 86]]], ["It is tempting to assume that such a protein-displaced activity would be useful for BaMV to control the opposite movements between ribosome and replicase complex along the viral RNA.", [["ribosome", "ANATOMY", 131, 139], ["BaMV", "GENE_OR_GENE_PRODUCT", 84, 88], ["ribosome", "CELLULAR_COMPONENT", 131, 139], ["BaMV", "PROTEIN", 84, 88], ["replicase complex", "PROTEIN", 144, 161], ["viral RNA", "RNA", 172, 181], ["a protein-displaced activity", "PROBLEM", 35, 63], ["BaMV", "TREATMENT", 84, 88], ["ribosome and replicase complex along the viral RNA", "PROBLEM", 131, 181], ["viral RNA", "OBSERVATION", 172, 181]]], ["Cellular DExH proteins RIG-I and MDA5 can even sense the presence of viral RNA in cytoplasm and initiate antiviral cellular responses (Pichlmair et al., 2006, Yoneyama et al., 2004, 2005).", [["Cellular", "ANATOMY", 0, 8], ["cytoplasm", "ANATOMY", 82, 91], ["cellular", "ANATOMY", 115, 123], ["DExH", "GENE_OR_GENE_PRODUCT", 9, 13], ["RIG-I", "GENE_OR_GENE_PRODUCT", 23, 28], ["MDA5", "GENE_OR_GENE_PRODUCT", 33, 37], ["cytoplasm", "ORGANISM_SUBSTANCE", 82, 91], ["cellular", "CELL", 115, 123], ["Cellular DExH proteins", "PROTEIN", 0, 22], ["RIG-I", "PROTEIN", 23, 28], ["MDA5", "PROTEIN", 33, 37], ["viral RNA", "RNA", 69, 78], ["Cellular DExH proteins", "TEST", 0, 22], ["viral RNA in cytoplasm", "PROBLEM", 69, 91], ["viral RNA", "OBSERVATION", 69, 78]]], ["With the potential versatility of helicases, it is not surprising to discover that the BaMV helicase-like domain may be involved in various biological functions, including 5\u2032-cap formation, replication, and viral movement.", [["BaMV", "GENE_OR_GENE_PRODUCT", 87, 91], ["BaMV helicase", "PROTEIN", 87, 100], ["5\u2032", "PROTEIN", 172, 174], ["the BaMV helicase", "PROBLEM", 83, 100], ["5\u2032-cap formation", "TREATMENT", 172, 188], ["replication", "TREATMENT", 190, 201], ["viral movement", "OBSERVATION", 207, 221]]], ["This study thus provides a base for future investigation on each of the mechanisms.Plasmids and site-directed mutagenesis ::: Materials and methodsThe plasmid pHWT was used as an expression vector for the BaMV helicase-like domain in Escherichia coli Novablue (DE3) cells as described previously (Li et al., 2001).", [["plasmid", "ANATOMY", 151, 158], ["DE3) cells", "ANATOMY", 261, 271], ["pHWT", "GENE_OR_GENE_PRODUCT", 159, 163], ["BaMV", "GENE_OR_GENE_PRODUCT", 205, 209], ["Escherichia coli", "ORGANISM", 234, 250], ["Novablue", "ORGANISM", 251, 259], ["DE3) cells", "CELL", 261, 271], ["plasmid pHWT", "DNA", 151, 163], ["BaMV helicase-like domain", "PROTEIN", 205, 230], ["Escherichia coli Novablue (DE3) cells", "CELL_LINE", 234, 271], ["Escherichia coli", "SPECIES", 234, 250], ["Escherichia coli", "SPECIES", 234, 250], ["This study", "TEST", 0, 10], ["future investigation", "TEST", 36, 56], ["Plasmids", "TREATMENT", 83, 91], ["The plasmid pHWT", "TEST", 147, 163], ["an expression vector", "TREATMENT", 176, 196], ["the BaMV helicase", "TREATMENT", 201, 218], ["Escherichia coli Novablue (DE3) cells", "TREATMENT", 234, 271], ["Escherichia coli", "OBSERVATION", 234, 250]]], ["Plasmid pCBG is an infectious clone of recombinant BaMV in which the green fluorescent protein (GFP) gene preceded by a duplicated coat protein promoter is inserted between triple gene block and coat protein-coding regions as described previously (Han et al., 2007). pUHel is a pUC18-based vector containing a SphI-digested fragment (4168 nts) isolated from pCBG.", [["pCBG", "GENE_OR_GENE_PRODUCT", 8, 12], ["BaMV", "GENE_OR_GENE_PRODUCT", 51, 55], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 69, 94], ["GFP", "GENE_OR_GENE_PRODUCT", 96, 99], ["pUC18", "GENE_OR_GENE_PRODUCT", 278, 283], ["SphI", "GENE_OR_GENE_PRODUCT", 310, 314], ["pCBG", "CANCER", 358, 362], ["pCBG", "DNA", 8, 12], ["recombinant BaMV", "PROTEIN", 39, 55], ["green fluorescent protein (GFP) gene", "DNA", 69, 105], ["coat protein promoter", "DNA", 131, 152], ["triple gene block", "DNA", 173, 190], ["coat protein-coding regions", "DNA", 195, 222], ["pUHel", "DNA", 267, 272], ["pUC18-based vector", "DNA", 278, 296], ["SphI-digested fragment", "DNA", 310, 332], ["4168 nts", "DNA", 334, 342], ["Plasmid pCBG", "TEST", 0, 12], ["an infectious clone of recombinant BaMV", "PROBLEM", 16, 55], ["the green fluorescent protein", "TEST", 65, 94], ["a duplicated coat protein promoter", "TREATMENT", 118, 152], ["triple gene block", "TREATMENT", 173, 190], ["coat protein", "TREATMENT", 195, 207], ["a pUC18-based vector", "TREATMENT", 276, 296], ["a SphI-digested fragment", "TREATMENT", 308, 332], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["protein promoter", "OBSERVATION", 136, 152], ["vector", "ANATOMY_MODIFIER", 290, 296], ["digested fragment", "OBSERVATION", 315, 332]]], ["Point mutations in pHWT and pUHel were created according to the protocol of the QuikChange site-directed mutagenesis kit (Stratagene).", [["pHWT", "GENE_OR_GENE_PRODUCT", 19, 23], ["pUHel", "GENE_OR_GENE_PRODUCT", 28, 33], ["pHWT", "DNA", 19, 23], ["pUHel", "DNA", 28, 33], ["QuikChange site", "DNA", 80, 95], ["Point mutations in pHWT and pUHel", "PROBLEM", 0, 33], ["the QuikChange site", "TREATMENT", 76, 95], ["directed mutagenesis kit (Stratagene)", "TREATMENT", 96, 133]]], ["After obtaining the desired mutations, the mutated SphI-digested fragment in pUHel was cloned back into pCBG.Protein expression and purification ::: Materials and methodsThe culture for inducing protein expression in E. coli and the initial purification, including steps for dissolution of inclusion bodies, protein refolding, and immobilized metal affinity chromatography, were performed as described previously (Li et al., 2001, Han et al., 2007).", [["SphI", "GENE_OR_GENE_PRODUCT", 51, 55], ["fragment", "CELLULAR_COMPONENT", 65, 73], ["pUHel", "GENE_OR_GENE_PRODUCT", 77, 82], ["E. coli", "ORGANISM", 217, 224], ["mutated SphI-digested fragment", "DNA", 43, 73], ["pUHel", "PROTEIN", 77, 82], ["pCBG", "DNA", 104, 108], ["E. coli", "SPECIES", 217, 224], ["E. coli", "SPECIES", 217, 224], ["the desired mutations", "PROBLEM", 16, 37], ["the mutated SphI-digested fragment in pUHel", "TREATMENT", 39, 82], ["The culture", "TEST", 170, 181], ["inducing protein expression", "PROBLEM", 186, 213], ["E. coli", "PROBLEM", 217, 224], ["the initial purification", "TEST", 229, 253], ["dissolution of inclusion bodies", "PROBLEM", 275, 306], ["protein refolding", "TEST", 308, 325], ["immobilized metal affinity chromatography", "TEST", 331, 372], ["fragment", "OBSERVATION_MODIFIER", 65, 73]]], ["Gel filtration chromatography using Hiprep 16/60 Sephacryl S-300 (Pharmacia) was included to further separate the refolded proteins based on their oligomerization states.", [["Hiprep 16/60 Sephacryl S-300", "CHEMICAL", 36, 64], ["refolded proteins", "PROTEIN", 114, 131], ["Gel filtration chromatography", "TEST", 0, 29], ["Hiprep", "TREATMENT", 36, 42]]], ["The purified protein was finally stocked in 50 mM Tris [pH 7.5], 150 mM KCl, 0.1% Brij-35, 10% glycerol, and 5 mM \u03b2-mercaptoethanol.", [["KCl", "CHEMICAL", 72, 75], ["Brij-35", "CHEMICAL", 82, 89], ["glycerol", "CHEMICAL", 95, 103], ["\u03b2-mercaptoethanol", "CHEMICAL", 114, 131], ["Tris", "CHEMICAL", 50, 54], ["KCl", "CHEMICAL", 72, 75], ["Brij-35", "CHEMICAL", 82, 89], ["glycerol", "CHEMICAL", 95, 103], ["\u03b2-mercaptoethanol", "CHEMICAL", 114, 131], ["KCl", "SIMPLE_CHEMICAL", 72, 75], ["Brij-35", "SIMPLE_CHEMICAL", 82, 89], ["glycerol", "SIMPLE_CHEMICAL", 95, 103], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 114, 131], ["The purified protein", "TEST", 0, 20], ["pH", "TEST", 56, 58], ["KCl", "TEST", 72, 75], ["Brij", "TEST", 82, 86], ["glycerol", "TREATMENT", 95, 103], ["5 mM \u03b2-mercaptoethanol", "TREATMENT", 109, 131]]], ["Thyroglobulin (669 kDa), apoferritin (443 kDa), \u03b2-amylase (200 kDa), alcohol dehydrogenase (150 kDa), albumin (66 kDa), and carbonic anhydrase (29 kDa) were used in gel filtration chromatography as markers for the molecular weight calibration of the eluted proteins.RNA preparation ::: Materials and methodsA double-stranded DNA template containing a T7 promoter followed by 15 nt similar to the 5\u2032 sequence of BaMV genomic RNA was prepared by annealing 5\u2032-TAATACGACTCACTATAGGGAAACCACGCCAT and 5\u2032-ATGGCGTGGTTTCCCTATAGTGAGTCGTATTA oligonucleotides.", [["Thyroglobulin", "CHEMICAL", 0, 13], ["alcohol", "CHEMICAL", 69, 76], ["apoferritin", "CHEMICAL", 25, 36], ["alcohol", "CHEMICAL", 69, 76], ["Thyroglobulin", "GENE_OR_GENE_PRODUCT", 0, 13], ["apoferritin", "GENE_OR_GENE_PRODUCT", 25, 36], ["\u03b2-amylase", "GENE_OR_GENE_PRODUCT", 48, 57], ["alcohol dehydrogenase", "GENE_OR_GENE_PRODUCT", 69, 90], ["albumin", "GENE_OR_GENE_PRODUCT", 102, 109], ["carbonic anhydrase", "GENE_OR_GENE_PRODUCT", 124, 142], ["DNA", "CELLULAR_COMPONENT", 325, 328], ["BaMV", "GENE_OR_GENE_PRODUCT", 411, 415], ["Thyroglobulin", "PROTEIN", 0, 13], ["apoferritin", "PROTEIN", 25, 36], ["\u03b2-amylase", "PROTEIN", 48, 57], ["alcohol dehydrogenase", "PROTEIN", 69, 90], ["150 kDa", "PROTEIN", 92, 99], ["albumin", "PROTEIN", 102, 109], ["carbonic anhydrase", "PROTEIN", 124, 142], ["eluted proteins", "PROTEIN", 250, 265], ["methodsA double-stranded DNA template", "DNA", 300, 337], ["T7 promoter", "DNA", 351, 362], ["5\u2032 sequence", "DNA", 396, 407], ["BaMV genomic RNA", "RNA", 411, 427], ["Thyroglobulin", "TEST", 0, 13], ["apoferritin", "TEST", 25, 36], ["\u03b2-amylase", "TEST", 48, 57], ["alcohol dehydrogenase", "TEST", 69, 90], ["albumin", "TEST", 102, 109], ["carbonic anhydrase (29 kDa)", "TREATMENT", 124, 151], ["gel filtration chromatography", "TEST", 165, 194], ["the molecular weight calibration", "TEST", 210, 242], ["the eluted proteins", "PROBLEM", 246, 265], ["Materials", "TREATMENT", 286, 295], ["methodsA double-stranded DNA template", "TREATMENT", 300, 337], ["a T7 promoter", "TREATMENT", 349, 362], ["BaMV genomic RNA", "TREATMENT", 411, 427], ["5\u2032-ATGGCGTGGTTTCCCTATAGTGAGTCGTATTA oligonucleotides", "TREATMENT", 494, 546]]], ["One \u03bcg template was then used to produce a 15-nt RNA with a biotin molecule attached at the 3\u2032 end in a 20-\u03bcl in vitro transcription reaction that also contained 3.75 mM ATP, 3.75 mM GTP, 3.75 mM CTP, 2 mM Bio-16-UTP (Ambion), 2 \u03bcl T7-MEGAshortscript enzyme mix (Ambion), and 1 \u00d7 T7 transcription buffer.", [["biotin", "CHEMICAL", 60, 66], ["ATP", "CHEMICAL", 170, 173], ["GTP", "CHEMICAL", 183, 186], ["CTP", "CHEMICAL", 196, 199], ["Bio-16-UTP", "CHEMICAL", 206, 216], ["biotin", "CHEMICAL", 60, 66], ["ATP", "CHEMICAL", 170, 173], ["GTP", "CHEMICAL", 183, 186], ["CTP", "CHEMICAL", 196, 199], ["Bio-16-UTP", "CHEMICAL", 206, 216], ["biotin", "SIMPLE_CHEMICAL", 60, 66], ["ATP", "SIMPLE_CHEMICAL", 170, 173], ["GTP", "SIMPLE_CHEMICAL", 183, 186], ["CTP", "SIMPLE_CHEMICAL", 196, 199], ["Bio-16-UTP", "SIMPLE_CHEMICAL", 206, 216], ["Ambion", "SIMPLE_CHEMICAL", 218, 224], ["\u03bcg template", "DNA", 4, 15], ["15-nt RNA", "RNA", 43, 52], ["One \u03bcg template", "TREATMENT", 0, 15], ["a 15-nt RNA", "TREATMENT", 41, 52], ["a biotin molecule", "TREATMENT", 58, 75], ["ATP", "TEST", 170, 173], ["GTP", "TEST", 183, 186], ["CTP", "TEST", 196, 199], ["mM Bio", "TEST", 203, 209], ["UTP (Ambion)", "TREATMENT", 213, 225], ["1 \u00d7 T7 transcription buffer", "TREATMENT", 276, 303]]], ["A control reaction with the same buffer except for the omission of Bio-16-UTP was performed in parallel.", [["Bio-16-UTP", "CHEMICAL", 67, 77], ["Bio-16-UTP", "CHEMICAL", 67, 77], ["Bio-16-UTP", "SIMPLE_CHEMICAL", 67, 77], ["A control reaction", "PROBLEM", 0, 18], ["Bio", "TEST", 67, 70]]], ["The biotin-labeled RNA was identified and recovered from a 15% acrylamide\u20137 M urea gel using RNA products produced in the control reaction as references.RNA preparation ::: Materials and methodsA 5\u2032-[\u03b3-32P]-labeled transcript corresponding to the first 50 nt of genomic RNA was used in the RTPase assay as described previously (Han et al., 2007).", [["biotin", "CHEMICAL", 4, 10], ["acrylamide\u20137 M urea", "CHEMICAL", 63, 82], ["5\u2032-[\u03b3-32P", "CHEMICAL", 196, 205], ["biotin", "CHEMICAL", 4, 10], ["urea", "CHEMICAL", 78, 82], ["5\u2032-[\u03b3-32P", "CHEMICAL", 196, 205], ["biotin", "SIMPLE_CHEMICAL", 4, 10], ["acrylamide\u20137 M urea", "SIMPLE_CHEMICAL", 63, 82], ["5\u2032-[\u03b3-32P", "SIMPLE_CHEMICAL", 196, 205], ["biotin-labeled RNA", "RNA", 4, 22], ["RNA products", "PROTEIN", 93, 105], ["methodsA 5\u2032-[\u03b3-32P]-labeled transcript", "RNA", 187, 225], ["genomic RNA", "RNA", 262, 273], ["RTPase", "PROTEIN", 290, 296], ["a 15% acrylamide\u20137 M urea gel", "TREATMENT", 57, 86], ["RNA products", "TREATMENT", 93, 105], ["Materials", "TEST", 173, 182], ["methodsA", "TEST", 187, 195], ["the RTPase assay", "TEST", 286, 302]]], ["A 5\u2032-terminally 178 nt genomic transcript, body-labeled with 32P, was prepared for Northwestern assay.", [["body", "ANATOMY", 43, 47], ["body", "ORGANISM_SUBDIVISION", 43, 47], ["32P", "SIMPLE_CHEMICAL", 61, 64], ["5\u2032-terminally 178 nt genomic transcript", "DNA", 2, 41], ["Northwestern assay", "TEST", 83, 101]]], ["A 32P-labeled 600 nt transcript complementary to the 3\u2032 end of the genomic RNA was prepared for the detection of genomic RNAs in Northern blot assay as described previously (Huang and Tsai, 1998).", [["32P", "SIMPLE_CHEMICAL", 2, 5], ["32P-labeled 600 nt transcript", "RNA", 2, 31], ["3\u2032 end", "DNA", 53, 59], ["genomic RNA", "RNA", 67, 78], ["genomic RNAs", "RNA", 113, 125], ["A 32P-labeled 600 nt transcript complementary", "TREATMENT", 0, 45], ["genomic RNAs", "PROBLEM", 113, 125], ["genomic RNAs", "OBSERVATION", 113, 125]]], ["Another 32P-labeled 100 nt RNA transcript, containing the rABC domains of the 3\u2032UTR, was synthesized for use in the UV-induced crosslinking assay as previously described (Chen et al., 2003).Enzymatic activity assay ::: Materials and methodsATPase and RTPase activities were determined by TLC based on the release of 32P from [\u03b3-32P]ATP and 5\u2032-[\u03b3-32P]RNA, respectively (Li et al., 2001).", [["[\u03b3-32P", "CHEMICAL", 325, 331], ["ATP", "CHEMICAL", 332, 335], ["5\u2032-[\u03b3-32P", "CHEMICAL", 340, 349], ["[\u03b3-32P]ATP", "CHEMICAL", 325, 335], ["5\u2032-[\u03b3-32P]RNA", "CHEMICAL", 340, 353], ["32P", "SIMPLE_CHEMICAL", 8, 11], ["methodsATPase", "GENE_OR_GENE_PRODUCT", 233, 246], ["RTPase", "GENE_OR_GENE_PRODUCT", 251, 257], ["32P", "SIMPLE_CHEMICAL", 316, 319], ["[\u03b3-32P]ATP", "SIMPLE_CHEMICAL", 325, 335], ["5\u2032-[\u03b3-32P", "SIMPLE_CHEMICAL", 340, 349], ["32P-labeled 100 nt RNA transcript", "RNA", 8, 41], ["rABC domains", "DNA", 58, 70], ["3\u2032UTR", "DNA", 78, 83], ["the rABC domains", "TEST", 54, 70], ["methodsATPase", "TREATMENT", 233, 246], ["RTPase activities", "TEST", 251, 268], ["TLC", "TEST", 288, 291], ["ATP", "TEST", 332, 335], ["\u2032", "TEST", 341, 342], ["crosslinking assay", "OBSERVATION", 127, 145]]], ["ATPase activity was also determined by an enzyme-coupled assay in which ATP hydrolysis was linked to NADH oxidation through the activities of pyruvate kinase and lactate dehydrogenase (Han et al., 2007).", [["ATP", "CHEMICAL", 72, 75], ["NADH", "CHEMICAL", 101, 105], ["pyruvate", "CHEMICAL", 142, 150], ["lactate", "CHEMICAL", 162, 169], ["ATP", "CHEMICAL", 72, 75], ["NADH", "CHEMICAL", 101, 105], ["pyruvate", "CHEMICAL", 142, 150], ["lactate", "CHEMICAL", 162, 169], ["ATPase", "GENE_OR_GENE_PRODUCT", 0, 6], ["ATP", "SIMPLE_CHEMICAL", 72, 75], ["NADH", "SIMPLE_CHEMICAL", 101, 105], ["pyruvate kinase", "GENE_OR_GENE_PRODUCT", 142, 157], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 162, 183], ["ATPase", "PROTEIN", 0, 6], ["pyruvate kinase", "PROTEIN", 142, 157], ["lactate dehydrogenase", "PROTEIN", 162, 183], ["ATPase activity", "PROBLEM", 0, 15], ["an enzyme", "TEST", 39, 48], ["ATP hydrolysis", "PROBLEM", 72, 86], ["NADH oxidation", "PROBLEM", 101, 115], ["pyruvate kinase", "TEST", 142, 157], ["lactate dehydrogenase", "TEST", 162, 183]]], ["Kinetic constants of ATP hydrolysis were calculated by Grafit software using data generated from the enzyme-coupled assays.Reversible formaldehyde crosslinking of protein and biotinylated RNA ::: Materials and methodsThe procedure for crosslinking the helicase-like domain to biotinylated RNA by formaldehyde was based on a previously-published method (Kim et al., 2005).", [["ATP", "CHEMICAL", 21, 24], ["formaldehyde", "CHEMICAL", 134, 146], ["formaldehyde", "CHEMICAL", 296, 308], ["ATP", "CHEMICAL", 21, 24], ["formaldehyde", "CHEMICAL", 134, 146], ["formaldehyde", "CHEMICAL", 296, 308], ["ATP", "SIMPLE_CHEMICAL", 21, 24], ["formaldehyde", "SIMPLE_CHEMICAL", 134, 146], ["formaldehyde", "SIMPLE_CHEMICAL", 296, 308], ["enzyme", "PROTEIN", 101, 107], ["helicase-like domain", "PROTEIN", 252, 272], ["biotinylated RNA", "RNA", 276, 292], ["ATP hydrolysis", "PROBLEM", 21, 35], ["the enzyme", "TEST", 97, 107], ["Reversible formaldehyde crosslinking of protein", "PROBLEM", 123, 170], ["The procedure", "TREATMENT", 217, 230], ["crosslinking the helicase", "TREATMENT", 235, 260], ["ATP hydrolysis", "OBSERVATION", 21, 35], ["formaldehyde crosslinking", "OBSERVATION", 134, 159]]], ["Briefly, 2 \u03bcM biotinylated RNA and 1 \u03bcM protein were incubated together in 10 mM Hepes [pH 7.5], 75 mM KCl, and 0.2% (v/v) formaldehyde at room temperature for 10 min.", [["KCl", "CHEMICAL", 103, 106], ["formaldehyde", "CHEMICAL", 123, 135], ["KCl", "CHEMICAL", 103, 106], ["formaldehyde", "CHEMICAL", 123, 135], ["formaldehyde", "SIMPLE_CHEMICAL", 123, 135], ["1 \u03bcM protein", "TEST", 35, 47], ["Hepes", "TEST", 81, 86], ["pH", "TEST", 88, 90], ["mM KCl", "TEST", 100, 106]]], ["The reaction was quenched by adding glycine to a final concentration of 0.2 M. The crosslinked complex was precipitated by mixing with an equal volume of acetone at \u2212 20 \u00b0C for 60 min and subjected to centrifugation at 15,000 rpm for 60 min at 4 \u00b0C. The dried pellet was then dissolved in 50 \u03bcl 100 mM ammonium bicarbonate [pH 8.0].", [["glycine", "CHEMICAL", 36, 43], ["acetone", "CHEMICAL", 154, 161], ["ammonium bicarbonate", "CHEMICAL", 302, 322], ["glycine", "CHEMICAL", 36, 43], ["acetone", "CHEMICAL", 154, 161], ["ammonium bicarbonate", "CHEMICAL", 302, 322], ["glycine", "SIMPLE_CHEMICAL", 36, 43], ["acetone", "SIMPLE_CHEMICAL", 154, 161], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 302, 322], ["The reaction", "PROBLEM", 0, 12], ["glycine", "TREATMENT", 36, 43], ["an equal volume of acetone", "TREATMENT", 135, 161], ["The dried pellet", "TREATMENT", 250, 266], ["mM ammonium bicarbonate", "TREATMENT", 299, 322], ["pH", "TEST", 324, 326]]], ["Sequencing grade trypsin (Trypsin Gold, Promega) was added in a ratio of protease:substrate of 1:10 (w/w), and the digestion was performed at 37 \u00b0C overnight.", [["trypsin", "GENE_OR_GENE_PRODUCT", 17, 24], ["Trypsin Gold", "SIMPLE_CHEMICAL", 26, 38], ["trypsin", "PROTEIN", 17, 24], ["protease", "PROTEIN", 73, 81], ["Sequencing grade trypsin (Trypsin Gold, Promega)", "TREATMENT", 0, 48], ["the digestion", "PROBLEM", 111, 124]]], ["TetraLink tetrameric avidin resin (Promega), equilibrated with 25 mM ammonium bicarbonate [pH 7.8], was used to capture the biotinylated RNA\u2013peptides complex.", [["ammonium bicarbonate", "CHEMICAL", 69, 89], ["ammonium bicarbonate", "CHEMICAL", 69, 89], ["TetraLink", "SIMPLE_CHEMICAL", 0, 9], ["avidin resin", "SIMPLE_CHEMICAL", 21, 33], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 69, 89], ["RNA\u2013peptides", "GENE_OR_GENE_PRODUCT", 137, 149], ["biotinylated RNA\u2013peptides complex", "PROTEIN", 124, 157], ["TetraLink tetrameric avidin resin (Promega)", "TREATMENT", 0, 43], ["25 mM ammonium bicarbonate", "TREATMENT", 63, 89], ["pH", "TEST", 91, 93]]], ["After extensive washing, at least six times, with the same buffer, 50 \u03bcl of 0.5% (v/v) trifluoroacetic acid was added, and the mixture was incubated at 70 \u00b0C for 60 min to reverse the crosslink between the RNA and peptides.", [["trifluoroacetic acid", "CHEMICAL", 87, 107], ["trifluoroacetic acid", "CHEMICAL", 87, 107], ["v/v) trifluoroacetic acid", "SIMPLE_CHEMICAL", 82, 107], ["extensive washing", "TREATMENT", 6, 23], ["v/v) trifluoroacetic acid", "TREATMENT", 82, 107], ["extensive", "OBSERVATION_MODIFIER", 6, 15], ["washing", "OBSERVATION", 16, 23]]], ["The released peptide in the supernatant was recovered after a 5 min centrifugation at 10,000 rpm and dried in a speed vacuum.", [["supernatant", "ANATOMY", 28, 39], ["The released peptide", "TREATMENT", 0, 20], ["a 5 min centrifugation", "TREATMENT", 60, 82], ["a speed vacuum", "TREATMENT", 110, 124]]], ["After being dissolved in 0.1% formic acid, the sample was purified with Ziptip (Millipore).", [["sample", "ANATOMY", 47, 53], ["formic acid", "CHEMICAL", 30, 41], ["formic acid", "CHEMICAL", 30, 41], ["formic acid", "SIMPLE_CHEMICAL", 30, 41], ["Ziptip (Millipore", "TREATMENT", 72, 89]]], ["A parallel treatment without the addition of formaldehyde was carried out as a background control.", [["formaldehyde", "CHEMICAL", 45, 57], ["formaldehyde", "CHEMICAL", 45, 57], ["formaldehyde", "SIMPLE_CHEMICAL", 45, 57], ["A parallel treatment", "TREATMENT", 0, 20], ["formaldehyde", "TREATMENT", 45, 57], ["a background control", "TREATMENT", 77, 97]]], ["The peptide identification was performed using an Applied Biosystems QStar LC-MS/MS spectrometer equipped with LC system.", [["The peptide identification", "TEST", 0, 26], ["an Applied Biosystems QStar LC", "TREATMENT", 47, 77], ["MS spectrometer", "TEST", 81, 96], ["LC system", "TREATMENT", 111, 120]]], ["The obtained mass spectrometry information was analyzed with Mascot software (Matrix Science).RNA-binding assay ::: Materials and methodsThe Northwestern experiment was modified from Robbins et al. (1986).", [["The obtained mass spectrometry", "TEST", 0, 30]]], ["Briefly, proteins resolved on a polyacrylamide gel were first transferred to a nitrocellulose paper (0.45 \u03bcm, MILLIPORE), and the membrane was then incubated in 10 mM Tris [pH 7.0], 50 mM NaCl, 1 mM EDTA, 0.02% bovine serum albumin, 0.02% Ficoll, and 0.02% polyvinyl pyrrolidone for three times of 90 min each, and probed with approximately 1 \u00d7 106 cpm of 32P-labeled RNA for 60 min.", [["membrane", "ANATOMY", 130, 138], ["serum", "ANATOMY", 218, 223], ["NaCl", "CHEMICAL", 188, 192], ["Ficoll", "CHEMICAL", 239, 245], ["polyvinyl pyrrolidone", "CHEMICAL", 257, 278], ["polyacrylamide", "CHEMICAL", 32, 46], ["nitrocellulose", "CHEMICAL", 79, 93], ["Tris", "CHEMICAL", 167, 171], ["NaCl", "CHEMICAL", 188, 192], ["EDTA", "CHEMICAL", 199, 203], ["polyvinyl pyrrolidone", "CHEMICAL", 257, 278], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["EDTA", "SIMPLE_CHEMICAL", 199, 203], ["bovine", "ORGANISM", 211, 217], ["serum", "ORGANISM_SUBSTANCE", 218, 223], ["albumin", "SIMPLE_CHEMICAL", 224, 231], ["Ficoll", "SIMPLE_CHEMICAL", 239, 245], ["polyvinyl pyrrolidone", "SIMPLE_CHEMICAL", 257, 278], ["32P", "SIMPLE_CHEMICAL", 356, 359], ["bovine", "SPECIES", 211, 217], ["bovine", "SPECIES", 211, 217], ["a polyacrylamide gel", "TREATMENT", 30, 50], ["a nitrocellulose paper", "TREATMENT", 77, 99], ["pH", "TEST", 173, 175], ["NaCl", "TEST", 188, 192], ["EDTA", "TEST", 199, 203], ["0.02% bovine serum albumin", "TREATMENT", 205, 231], ["0.02% Ficoll", "TREATMENT", 233, 245], ["0.02% polyvinyl pyrrolidone", "TREATMENT", 251, 278], ["resolved", "OBSERVATION_MODIFIER", 18, 26]]], ["Finally, the membrane was washed and dried.", [["membrane", "ANATOMY", 13, 21], ["membrane", "CELLULAR_COMPONENT", 13, 21]]], ["The bound RNA on the membrane was visualized with a phosphorimager (Fujifilm BAS 2500).RNA-binding assay ::: Materials and methodsThe gel mobility shift assay was carried out by incubating different amounts of the helicase-like domain (50, 130, or 260 ng) with 50 ng of 32P-labeled RNA probe, the first 50 nt of genomic RNA, in buffer that contained 50 mM Tris [pH 7.5], 100 mM KCl, 10% glycerol, 0.1% Brij-35, and 1 U RNase inhibitor at 20 \u00b0C for 1 h.", [["membrane", "ANATOMY", 21, 29], ["KCl", "CHEMICAL", 378, 381], ["glycerol", "CHEMICAL", 387, 395], ["Brij-35", "CHEMICAL", 402, 409], ["Tris", "CHEMICAL", 356, 360], ["KCl", "CHEMICAL", 378, 381], ["glycerol", "CHEMICAL", 387, 395], ["Brij-35", "CHEMICAL", 402, 409], ["membrane", "CELLULAR_COMPONENT", 21, 29], ["32P", "SIMPLE_CHEMICAL", 270, 273], ["KCl", "SIMPLE_CHEMICAL", 378, 381], ["glycerol", "SIMPLE_CHEMICAL", 387, 395], ["Brij-35", "SIMPLE_CHEMICAL", 402, 409], ["U RNase", "GENE_OR_GENE_PRODUCT", 417, 424], ["helicase-like domain", "PROTEIN", 214, 234], ["32P-labeled RNA probe", "RNA", 270, 291], ["genomic RNA", "RNA", 312, 323], ["a phosphorimager (Fujifilm BAS", "TREATMENT", 50, 80], ["The gel mobility shift assay", "TEST", 130, 158], ["RNA probe", "TREATMENT", 282, 291], ["pH", "TEST", 362, 364], ["KCl", "TEST", 378, 381], ["glycerol", "TREATMENT", 387, 395], ["1 U RNase inhibitor", "TREATMENT", 415, 434], ["bound RNA", "OBSERVATION", 4, 13]]], ["The mixture was then separated on 8% PAGE and visualized with a phosphorimager.RNA-binding assay ::: Materials and methodsThe UV-induced crosslinking assay was performed by incubating indicated protein (140 ng each) with 5 pmol 32P-labeled RNA probe in a 10-\u03bcl buffer that also contained 10 mM Hepes [pH 7.4] and 10% (v/v) glycerol for 10 min at room temperature.", [["glycerol", "CHEMICAL", 323, 331], ["32P", "CHEMICAL", 228, 231], ["glycerol", "CHEMICAL", 323, 331], ["32P", "SIMPLE_CHEMICAL", 228, 231], ["glycerol", "SIMPLE_CHEMICAL", 323, 331], ["a phosphorimager", "TREATMENT", 62, 78], ["The UV-induced crosslinking assay", "TEST", 122, 155], ["protein", "TEST", 194, 201], ["RNA probe", "TREATMENT", 240, 249], ["a 10-\u03bcl buffer", "TREATMENT", 253, 267], ["Hepes", "TEST", 294, 299], ["pH", "TEST", 301, 303], ["glycerol", "TREATMENT", 323, 331]]], ["The mixture was then irradiated on ice under 302 nm with energy of 120 mJ/sec/cm2 (Ultraviolet crosslinker, UVP) at a distance of 10 cm for 1 min.", [["Ultraviolet crosslinker", "TREATMENT", 83, 106]]], ["The irradiated products, after being digested with 1 \u03bcg RNase A at 37 \u00b0C for 2 h, were resolved on a 12% SDS-polyacrylamide gel and visualized with a phosphorimager.Viral replication assay in protoplasts ::: Materials and methodsProtoplast preparation from young leaves of N. benthamiana and the subsequent transfection were performed as the previous description (Tsai et al., 1999).", [["protoplasts", "ANATOMY", 192, 203], ["leaves", "ANATOMY", 263, 269], ["SDS", "CHEMICAL", 105, 108], ["polyacrylamide", "CHEMICAL", 109, 123], ["leaves", "ORGANISM_SUBDIVISION", 263, 269], ["N. benthamiana", "ORGANISM", 273, 287], ["N. benthamiana", "SPECIES", 273, 287], ["N. benthamiana", "SPECIES", 273, 287], ["The irradiated products", "TREATMENT", 0, 23], ["1 \u03bcg RNase A", "TREATMENT", 51, 63], ["a 12% SDS", "TREATMENT", 99, 108], ["polyacrylamide gel", "TREATMENT", 109, 127], ["a phosphorimager", "TREATMENT", 148, 164], ["Materials", "TREATMENT", 208, 217], ["methodsProtoplast preparation", "TREATMENT", 222, 251], ["the subsequent transfection", "TEST", 292, 319], ["irradiated", "OBSERVATION_MODIFIER", 4, 14], ["products", "OBSERVATION_MODIFIER", 15, 23]]], ["In brief, each 3 \u00d7 105 protoplast was introduced with 2 \u03bcg pCBG (or its derivatives) and 6 \u03bcg carrier DNA, and the cells were then incubated at 25 \u00b0C for 48 h under constant illumination.", [["protoplast", "ANATOMY", 23, 33], ["cells", "ANATOMY", 115, 120], ["pCBG", "CHEMICAL", 59, 63], ["pCBG", "CHEMICAL", 59, 63], ["protoplast", "CELL", 23, 33], ["pCBG", "SIMPLE_CHEMICAL", 59, 63], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["cells", "CELL", 115, 120], ["2 \u03bcg pCBG", "TREATMENT", 54, 63], ["its derivatives", "TREATMENT", 68, 83], ["6 \u03bcg carrier DNA", "TREATMENT", 89, 105]]], ["The accumulation of coat protein in protoplasts was assayed by Western blotting analysis using the coat protein specific antibodies and chemiluminescence reagent (PerkinElmer).", [["protoplasts", "ANATOMY", 36, 47], ["protoplasts", "CELL", 36, 47], ["coat protein", "PROTEIN", 20, 32], ["coat protein specific antibodies", "PROTEIN", 99, 131], ["The accumulation of coat protein in protoplasts", "PROBLEM", 0, 47], ["blotting analysis", "TEST", 71, 88], ["the coat protein specific antibodies", "TREATMENT", 95, 131], ["chemiluminescence reagent", "TEST", 136, 161], ["accumulation", "OBSERVATION_MODIFIER", 4, 16], ["coat protein", "OBSERVATION", 20, 32]]], ["For viral RNA analysis, total RNA from protoplasts was extracted, glyoxalated, electrophoresed through 1% agarose gel, transferred to nylon membranes, and hybridized with a 32P-labeled RNA probe complementary to 3\u2032UTR of BaMV as described earlier.Viral infectivity assay in plants ::: Materials and methodsEach of the selected leaves of 3-week-old N. benthamiana or C. quinoa (3\u20134 per plant) was inoculated with 2 \u03bcg pCBG (or its derivatives) in 10 \u03bcl aqueous solution by gently rubbing over the surface under the aid of sterile carborundum according to the method described previously (Lin and Hsu, 1994).", [["protoplasts", "ANATOMY", 39, 50], ["nylon membranes", "ANATOMY", 134, 149], ["leaves", "ANATOMY", 327, 333], ["surface", "ANATOMY", 496, 503], ["pCBG", "CHEMICAL", 417, 421], ["pCBG", "CHEMICAL", 417, 421], ["protoplasts", "CELL", 39, 50], ["agarose", "SIMPLE_CHEMICAL", 106, 113], ["membranes", "CELLULAR_COMPONENT", 140, 149], ["32P", "SIMPLE_CHEMICAL", 173, 176], ["BaMV", "GENE_OR_GENE_PRODUCT", 221, 225], ["Viral", "ORGANISM", 247, 252], ["N. benthamiana", "ORGANISM", 348, 362], ["C. quinoa", "ORGANISM", 366, 375], ["pCBG", "SIMPLE_CHEMICAL", 417, 421], ["viral RNA", "RNA", 4, 13], ["3\u2032UTR", "DNA", 212, 217], ["BaMV", "DNA", 221, 225], ["N. benthamiana", "SPECIES", 348, 362], ["C. quinoa", "SPECIES", 366, 375], ["N. benthamiana", "SPECIES", 348, 362], ["C. quinoa", "SPECIES", 366, 375], ["viral RNA analysis", "TEST", 4, 22], ["total RNA from protoplasts", "PROBLEM", 24, 50], ["1% agarose gel", "TREATMENT", 103, 117], ["a 32P-labeled RNA probe complementary", "TREATMENT", 171, 208], ["UTR of BaMV", "TREATMENT", 214, 225], ["Viral infectivity assay", "PROBLEM", 247, 270], ["2 \u03bcg pCBG", "TREATMENT", 412, 421], ["its derivatives)", "TREATMENT", 426, 442], ["sterile carborundum", "TREATMENT", 521, 540], ["infectivity", "OBSERVATION", 253, 264], ["benthamiana", "ANATOMY", 351, 362]]], ["Each plasmid DNA was applied to total six plantlets.", [["plasmid", "ANATOMY", 5, 12], ["plantlets", "ANATOMY", 42, 51], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["plasmid DNA", "DNA", 5, 16], ["Each plasmid DNA", "TREATMENT", 0, 16], ["plasmid DNA", "OBSERVATION", 5, 16]]], ["Fluorescent images of the inoculated leaves and upper leaves were obtained at 20 dpi with a fluorimager using an excitation filter of 465 nm and an emission filter of 535 nm.", [["leaves", "ANATOMY", 37, 43], ["leaves", "ANATOMY", 54, 60], ["leaves", "ORGANISM_SUBDIVISION", 37, 43], ["upper leaves", "ORGAN", 48, 60], ["Fluorescent images", "TEST", 0, 18], ["a fluorimager", "TREATMENT", 90, 103], ["an excitation filter", "TREATMENT", 110, 130], ["an emission filter", "TREATMENT", 145, 163], ["upper leaves", "ANATOMY", 48, 60], ["535 nm", "OBSERVATION_MODIFIER", 167, 173]]]], "PMC7256339": [["IntroductionAmong the photothermal techniques that are used to determine the thermal conductivity, effusivity or diffusivity of different solid, liquid and gaseous materials, thermal lens spectroscopy (TLS) is a versatile, sensitive and nondestructive tool employed for semitransparent samples.", [["samples", "ANATOMY", 286, 293], ["the photothermal techniques", "TREATMENT", 18, 45], ["the thermal conductivity", "PROBLEM", 73, 97], ["effusivity", "PROBLEM", 99, 109], ["diffusivity of different solid, liquid and gaseous materials", "PROBLEM", 113, 173], ["thermal lens spectroscopy", "TEST", 175, 200], ["semitransparent samples", "TEST", 270, 293], ["gaseous materials", "OBSERVATION", 156, 173]]], ["This technique is based on the use of two lasers: a pumping laser that excites the sample and causes a variation in the temperature and refractive index of the material, and a second probe laser, which is guided at this point, inducing a deviation of the laser in a convergent or divergent way depending on the type of sample to be studied.", [["sample", "ANATOMY", 83, 89], ["a pumping laser", "TREATMENT", 50, 65], ["a variation in the temperature", "PROBLEM", 101, 131], ["a second probe laser", "TREATMENT", 174, 194], ["the laser", "TREATMENT", 251, 260], ["variation", "OBSERVATION_MODIFIER", 103, 112], ["refractive index", "OBSERVATION", 136, 152]]], ["The thermal lens technique has been successfully applied for the measurement of samples with low optical absorption and thermal diffusivity, and for different organic solvents, edible oils, biodiesels and various complex materials [1].IntroductionThe investigation of the properties of Moringa oleifera extract is of special importance because it has many beneficial properties for health, nutrition and cosmetics, among others.", [["samples", "ANATOMY", 80, 87], ["oils", "ANATOMY", 184, 188], ["Moringa oleifera extract", "CHEMICAL", 286, 310], ["biodiesels", "SIMPLE_CHEMICAL", 190, 200], ["Moringa oleifera", "ORGANISM", 286, 302], ["Moringa oleifera", "SPECIES", 286, 302], ["Moringa oleifera", "SPECIES", 286, 302], ["The thermal lens technique", "TREATMENT", 0, 26], ["the measurement of samples", "TEST", 61, 87], ["low optical absorption and thermal diffusivity", "PROBLEM", 93, 139], ["different organic solvents", "TREATMENT", 149, 175], ["edible oils", "TREATMENT", 177, 188], ["Moringa oleifera extract", "TREATMENT", 286, 310]]], ["Moringa oleifera extract is a complex mixture of chemical compounds that provide its characteristic taste and color.", [["Moringa oleifera extract", "CHEMICAL", 0, 24], ["Moringa oleifera", "ORGANISM", 0, 16], ["Moringa oleifera", "SPECIES", 0, 16], ["Moringa oleifera", "SPECIES", 0, 16], ["chemical compounds", "OBSERVATION", 49, 67]]], ["These chemical compounds mainly include three groups: methylene, hydroxyl (\u2013OH) and amino (\u2013NH3+).", [["methylene", "CHEMICAL", 54, 63], ["hydroxyl", "CHEMICAL", 65, 73], ["\u2013OH", "CHEMICAL", 75, 78], ["amino", "CHEMICAL", 84, 89], ["NH3", "CHEMICAL", 92, 95], ["methylene", "CHEMICAL", 54, 63], ["hydroxyl", "CHEMICAL", 65, 73], ["\u2013OH", "CHEMICAL", 75, 78], ["amino (\u2013NH3+)", "CHEMICAL", 84, 97], ["methylene, hydroxyl (\u2013OH)", "SIMPLE_CHEMICAL", 54, 79], ["amino (\u2013NH3+", "SIMPLE_CHEMICAL", 84, 96], ["methylene, hydroxyl (\u2013OH)", "TREATMENT", 54, 79], ["amino (\u2013NH3", "TREATMENT", 84, 95]]], ["However, the chemical composition depends on the cultivation climate, the time of harvest, the biotype of the plant, and finally, the extraction process [2\u20139].IntroductionThere are many properties of the Moringa oleifera which can be supplied in different forms, extract of whole or ground leaves, or from the stem.", [["leaves", "ANATOMY", 290, 296], ["stem", "ANATOMY", 310, 314], ["Moringa oleifera", "ORGANISM", 204, 220], ["stem", "TISSUE", 310, 314], ["Moringa oleifera", "SPECIES", 204, 220], ["Moringa oleifera", "SPECIES", 204, 220], ["harvest", "TREATMENT", 82, 89], ["the Moringa oleifera", "TREATMENT", 200, 220], ["stem", "ANATOMY", 310, 314]]], ["This extract can be consumed as tea and in the form of commercial drinks.", [["extract", "ANATOMY", 5, 12], ["tea", "ANATOMY", 32, 35], ["tea", "ORGANISM_SUBDIVISION", 32, 35]]], ["Its consumption has great health benefits to fight against different diseases, such as fatigue, cholesterol, diabetes.", [["fatigue", "DISEASE", 87, 94], ["cholesterol", "CHEMICAL", 96, 107], ["diabetes", "DISEASE", 109, 117], ["cholesterol", "CHEMICAL", 96, 107], ["cholesterol", "SIMPLE_CHEMICAL", 96, 107], ["different diseases", "PROBLEM", 59, 77], ["fatigue", "PROBLEM", 87, 94], ["diabetes", "PROBLEM", 109, 117], ["diabetes", "OBSERVATION", 109, 117]]], ["It has been shown to be effective in reducing blood sugar levels within 3 h of ingestion; although it is less effective than the standard of hypoglycemic drugs such as glibenclamide.", [["blood", "ANATOMY", 46, 51], ["glibenclamide", "CHEMICAL", 168, 181], ["sugar", "CHEMICAL", 52, 57], ["glibenclamide", "CHEMICAL", 168, 181], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["sugar", "SIMPLE_CHEMICAL", 52, 57], ["glibenclamide", "SIMPLE_CHEMICAL", 168, 181], ["blood sugar levels", "TEST", 46, 64], ["hypoglycemic drugs", "TREATMENT", 141, 159], ["glibenclamide", "TREATMENT", 168, 181], ["shown to be", "UNCERTAINTY", 12, 23], ["effective", "OBSERVATION_MODIFIER", 24, 33], ["less effective", "OBSERVATION_MODIFIER", 105, 119]]], ["It is also useful for arthritis and prevents cancer because it contains a large amount of antioxidants (polyphenols) that destroy free radicals of organisms [2\u20135].", [["cancer", "ANATOMY", 45, 51], ["arthritis", "DISEASE", 22, 31], ["cancer", "DISEASE", 45, 51], ["polyphenols", "CHEMICAL", 104, 115], ["cancer", "CANCER", 45, 51], ["polyphenols", "SIMPLE_CHEMICAL", 104, 115], ["free radicals", "SIMPLE_CHEMICAL", 130, 143], ["arthritis", "PROBLEM", 22, 31], ["cancer", "PROBLEM", 45, 51], ["antioxidants (polyphenols", "TREATMENT", 90, 115], ["arthritis", "OBSERVATION", 22, 31], ["cancer", "OBSERVATION", 45, 51], ["large", "OBSERVATION_MODIFIER", 74, 79], ["amount", "OBSERVATION_MODIFIER", 80, 86]]], ["Different nutrients and minerals have been found in Moringa oleifera, i.e., 30 % high-quality proteins in vitamins A and C. Moringa has four times more calcium than cow\u2019s milk, four times more iron than spinach, three times more potassium than bananas and contains 25 % of fiber.", [["milk", "ANATOMY", 171, 175], ["vitamins A", "CHEMICAL", 106, 116], ["Moringa", "CHEMICAL", 124, 131], ["calcium", "CHEMICAL", 152, 159], ["iron", "CHEMICAL", 193, 197], ["potassium", "CHEMICAL", 229, 238], ["calcium", "CHEMICAL", 152, 159], ["iron", "CHEMICAL", 193, 197], ["potassium", "CHEMICAL", 229, 238], ["minerals", "SIMPLE_CHEMICAL", 24, 32], ["Moringa oleifera", "ORGANISM", 52, 68], ["vitamins A", "SIMPLE_CHEMICAL", 106, 116], ["calcium", "SIMPLE_CHEMICAL", 152, 159], ["cow", "ORGANISM", 165, 168], ["milk", "ORGANISM_SUBSTANCE", 171, 175], ["iron", "SIMPLE_CHEMICAL", 193, 197], ["spinach", "ORGANISM_SUBDIVISION", 203, 210], ["potassium", "SIMPLE_CHEMICAL", 229, 238], ["bananas", "ORGANISM_SUBDIVISION", 244, 251], ["Moringa oleifera", "SPECIES", 52, 68], ["cow", "SPECIES", 165, 168], ["Moringa oleifera", "SPECIES", 52, 68], ["cow", "SPECIES", 165, 168], ["Different nutrients and minerals", "TREATMENT", 0, 32], ["vitamins A and C. Moringa", "TREATMENT", 106, 131], ["calcium", "TEST", 152, 159], ["iron than spinach", "TREATMENT", 193, 210], ["potassium than bananas", "TREATMENT", 229, 251]]], ["Moringa could also be used in food condiments [2\u20136].", [["Moringa", "CHEMICAL", 0, 7], ["Moringa", "SIMPLE_CHEMICAL", 0, 7], ["Moringa", "TREATMENT", 0, 7]]], ["For example, in cosmetics, Moringa oleifera oil has many benefits when used rubbed in the body.", [["body", "ANATOMY", 90, 94], ["Moringa oleifera", "CHEMICAL", 27, 43], ["Moringa oleifera", "ORGANISM", 27, 43], ["oil", "ORGANISM_SUBSTANCE", 44, 47], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["Moringa oleifera", "SPECIES", 27, 43], ["Moringa oleifera", "SPECIES", 27, 43], ["Moringa oleifera oil", "TREATMENT", 27, 47], ["body", "ANATOMY", 90, 94]]], ["In the skin of the face it acts as anti-inflammatory; it is useful for acne\u2019s treatment, for the prevention of wrinkles and preventing premature aging.", [["skin", "ANATOMY", 7, 11], ["acne", "DISEASE", 71, 75], ["wrinkles", "DISEASE", 111, 119], ["premature aging", "DISEASE", 135, 150], ["skin", "ORGAN", 7, 11], ["acne\u2019s treatment", "TREATMENT", 71, 87], ["wrinkles", "PROBLEM", 111, 119], ["premature aging", "PROBLEM", 135, 150], ["skin", "ANATOMY", 7, 11], ["wrinkles", "OBSERVATION", 111, 119]]], ["Hair benefits include dandruff reduction, hair strengthening and shine promotion.", [["Hair", "ANATOMY", 0, 4], ["dandruff", "ANATOMY", 22, 30], ["hair", "ANATOMY", 42, 46], ["dandruff reduction", "DISEASE", 22, 40], ["hair", "MULTI-TISSUE_STRUCTURE", 42, 46], ["dandruff reduction", "TREATMENT", 22, 40], ["dandruff", "OBSERVATION", 22, 30]]], ["It is also ideal as an active carrier used in the production of perfumes and bar soaps [2\u20137].", [["bar soaps", "SIMPLE_CHEMICAL", 77, 86], ["an active carrier", "TREATMENT", 20, 37], ["active", "OBSERVATION_MODIFIER", 23, 29]]], ["Therefore, the importance of Moringa chemical composition, the variety of methods of preparation and purification, and the use of analytical techniques make necessary to determine their composition.", [["Moringa chemical composition", "TREATMENT", 29, 57], ["preparation and purification", "TREATMENT", 85, 113], ["analytical techniques", "TREATMENT", 130, 151]]], ["In this work, the thermal diffusivity of Moringa oleifera extracts with different concentration was studied using thermal lens spectroscopy (TLS).", [["extracts", "ANATOMY", 58, 66], ["Moringa oleifera", "CHEMICAL", 41, 57], ["Moringa oleifera", "ORGANISM", 41, 57], ["extracts", "ORGANISM_SUBSTANCE", 58, 66], ["Moringa oleifera", "SPECIES", 41, 57], ["Moringa oleifera", "SPECIES", 41, 57], ["the thermal diffusivity of Moringa oleifera extracts", "TREATMENT", 14, 66], ["thermal lens spectroscopy", "TEST", 114, 139]]], ["This study could be important in the food and pharmaceutical industries.", [["This study", "TEST", 0, 10]]], ["For example, it would be useful for drug release rate determination due to diffusion coefficient of the drug through the encapsulating agent [10].", [["drug release rate determination", "TEST", 36, 67], ["the encapsulating agent", "TREATMENT", 117, 140]]], ["The results of this work are reported for the first time for Moringa, including its thermo-optical characterization and its physico-chemical properties.Thermal Lens Spectroscopy (TLS) ::: Materials and MethodsThe Moringa extracts were thermally characterized using the thermal lens (TL) technique to obtain the thermal diffusivity.", [["extracts", "ANATOMY", 221, 229], ["Moringa", "CHEMICAL", 61, 68], ["its thermo-optical characterization", "TEST", 80, 115], ["Thermal Lens Spectroscopy (TLS)", "TEST", 152, 183], ["The Moringa extracts", "TREATMENT", 209, 229], ["the thermal lens (TL) technique", "TREATMENT", 265, 296], ["the thermal diffusivity", "TEST", 307, 330]]], ["This technique consists on the incidence of two collinear lasers in a sample.", [["two collinear lasers", "TREATMENT", 44, 64], ["collinear lasers", "OBSERVATION", 48, 64]]], ["One of these lasers heats the molecules of the medium by absorbing the optical power and is excited.", [["lasers", "OBSERVATION_MODIFIER", 13, 19], ["heats", "OBSERVATION", 20, 25]]], ["The non-radiative excitation of these molecules results in a release of energy in the form of heat producing a local variation of the refractive index.", [["non-radiative excitation", "OBSERVATION", 4, 28], ["local variation", "OBSERVATION", 111, 126], ["refractive index", "OBSERVATION", 134, 150]]], ["This region acts as a converging or divergent lens of a second laser passing through this region, reducing the intensity which is directed to the sensor to obtain a signal corresponding to the thermal lens.Thermal Lens Spectroscopy (TLS) ::: Materials and MethodsThe experimental setup of TL is shown in Fig. 2.", [["Thermal Lens Spectroscopy", "TEST", 206, 231], ["The experimental setup of TL", "TREATMENT", 263, 291], ["divergent", "OBSERVATION_MODIFIER", 36, 45], ["lens", "OBSERVATION_MODIFIER", 46, 50], ["second", "OBSERVATION_MODIFIER", 56, 62], ["laser", "OBSERVATION_MODIFIER", 63, 68], ["intensity", "OBSERVATION_MODIFIER", 111, 120], ["thermal lens", "OBSERVATION", 193, 205]]], ["The measurement of the TL signal was carried out using a 40-mW Ar+Xe laser (Spectra) emitting at \u03bb = 442 nm as excitation laser and a second laser of He\u2013Ne, \u03bb = 632.5 nm as a probe laser.", [["Xe", "CHEMICAL", 66, 68], ["the TL signal", "TEST", 19, 32], ["a 40-mW Ar+Xe laser (Spectra) emitting", "TREATMENT", 55, 93], ["excitation laser", "TREATMENT", 111, 127], ["a second laser of He\u2013Ne", "TREATMENT", 132, 155], ["a probe laser", "TREATMENT", 173, 186]]], ["A mechanical shutter was used to limit the excitation light beam to the sample.", [["sample", "ANATOMY", 72, 78], ["A mechanical shutter", "TREATMENT", 0, 20], ["the excitation light beam", "TREATMENT", 39, 64], ["mechanical shutter", "OBSERVATION", 2, 20]]], ["This was focalized by a lens focal length in a liquid sample contained in a 1-cm long quartz cuvette, positioned in the focal plane.", [["lens focal", "ANATOMY", 24, 34], ["sample", "ANATOMY", 54, 60], ["focal plane", "ANATOMY", 120, 131], ["quartz", "CHEMICAL", 86, 92], ["a lens focal length", "PROBLEM", 22, 41], ["a liquid sample", "TREATMENT", 45, 60], ["a 1-cm long quartz cuvette", "TREATMENT", 74, 100], ["lens", "OBSERVATION_MODIFIER", 24, 28], ["focal", "OBSERVATION_MODIFIER", 29, 34], ["length", "OBSERVATION_MODIFIER", 35, 41], ["liquid sample", "OBSERVATION", 47, 60], ["1-cm", "OBSERVATION_MODIFIER", 76, 80], ["long", "OBSERVATION_MODIFIER", 81, 85], ["quartz cuvette", "OBSERVATION", 86, 100], ["focal", "OBSERVATION_MODIFIER", 120, 125], ["plane", "OBSERVATION_MODIFIER", 126, 131]]], ["A second aligned probe laser, to a small angle, was focused by a lens focal length, oppositely directed to the excitation laser.Thermal Lens Spectroscopy (TLS) ::: Materials and MethodsThe light from the transmitted probe beam was recorded by a photodiode.", [["A second aligned probe laser", "TREATMENT", 0, 28], ["the excitation laser", "TREATMENT", 107, 127], ["Thermal Lens Spectroscopy", "TEST", 128, 153], ["the transmitted probe beam", "TREATMENT", 200, 226], ["a photodiode", "TREATMENT", 243, 255], ["second", "OBSERVATION_MODIFIER", 2, 8], ["aligned", "OBSERVATION_MODIFIER", 9, 16], ["probe", "OBSERVATION_MODIFIER", 17, 22], ["laser", "OBSERVATION_MODIFIER", 23, 28], ["small", "OBSERVATION_MODIFIER", 35, 40], ["angle", "OBSERVATION_MODIFIER", 41, 46], ["focal", "OBSERVATION_MODIFIER", 70, 75], ["length", "OBSERVATION_MODIFIER", 76, 82], ["excitation", "OBSERVATION_MODIFIER", 111, 121], ["laser", "OBSERVATION_MODIFIER", 122, 127]]], ["The sensor was coupled to a National Instrument card to record the time evolution of the thermal lens signal as showed in Fig. 2.", [["the thermal lens signal", "TEST", 85, 108]]], ["Labview software was used to control and capture TL data and normalizes this signal with respect to the initial time signal.", [["Labview software", "TEST", 0, 16], ["capture TL data", "TEST", 41, 56]]], ["5) as adjustment parameters.", [["adjustment parameters", "TEST", 6, 27]]], ["Hence, the thermal diffusivity of the sample was calculated from Eq.", [["sample", "ANATOMY", 38, 44], ["the thermal diffusivity of the sample", "PROBLEM", 7, 44]]], ["This process was used for all the experimental data to obtain the thermal diffusivity of the samples.Theory ::: Materials and MethodsShen et al. [11] derived from a theoretical expression a theory relation for the signal I(t) of the intensity of the excitation probe beam with a diffraction approximation for the Gaussian beam in the following way:1", [["samples", "ANATOMY", 93, 100], ["I(t)", "PROTEIN", 221, 225], ["the excitation probe beam", "TREATMENT", 246, 271], ["a diffraction approximation", "TREATMENT", 277, 304], ["the Gaussian beam", "TREATMENT", 309, 326]]]], "59c725e7aa0e91f3d055521d1786091179015003": [["cervical cancer cells, and is vital to maintain the malignant phenotype of these cells (10) .", [["cervical cancer cells", "ANATOMY", 0, 21], ["cells", "ANATOMY", 81, 86], ["cervical cancer", "DISEASE", 0, 15], ["cervical cancer cells", "CELL", 0, 21], ["cells", "CELL", 81, 86], ["cervical cancer cells", "CELL_TYPE", 0, 21], ["cervical cancer cells", "PROBLEM", 0, 21], ["cancer", "OBSERVATION", 9, 15]]], ["Moreover, HPV16 E7 can transform a variety of cell lines, including NIH/3T3 mouse fibroblasts (27) .", [["cell lines", "ANATOMY", 46, 56], ["NIH/3T3 mouse fibroblasts", "ANATOMY", 68, 93], ["HPV16 E7", "ORGANISM", 10, 18], ["cell lines", "CELL", 46, 56], ["NIH/3T3 mouse fibroblasts", "CELL", 68, 93], ["HPV16 E7", "PROTEIN", 10, 18], ["cell lines", "CELL_LINE", 46, 56], ["NIH/3T3 mouse fibroblasts", "CELL_LINE", 68, 93], ["mouse", "SPECIES", 76, 81], ["HPV16", "SPECIES", 10, 15], ["mouse", "SPECIES", 76, 81], ["cell lines", "TREATMENT", 46, 56], ["NIH/3T3 mouse fibroblasts", "TREATMENT", 68, 93], ["cell lines", "OBSERVATION", 46, 56], ["3T3 mouse fibroblasts", "OBSERVATION", 72, 93]]], ["The most well-characterized biochemical property of HPV16 E7 is its ability to bind to the unphosphorylated retinoblastoma tumor suppressor protein (Rb) and disrupt Rb-E2F complexes, resulting in a loss of the G1/S checkpoint (1, 7, 35, 38) .", [["tumor", "DISEASE", 123, 128], ["HPV16 E7", "ORGANISM", 52, 60], ["retinoblastoma tumor suppressor protein", "GENE_OR_GENE_PRODUCT", 108, 147], ["Rb", "GENE_OR_GENE_PRODUCT", 149, 151], ["Rb", "GENE_OR_GENE_PRODUCT", 165, 167], ["E2F", "GENE_OR_GENE_PRODUCT", 168, 171], ["HPV16 E7", "PROTEIN", 52, 60], ["unphosphorylated retinoblastoma tumor suppressor protein", "PROTEIN", 91, 147], ["Rb", "PROTEIN", 149, 151], ["Rb", "PROTEIN", 165, 167], ["E2F complexes", "PROTEIN", 168, 181], ["HPV16", "SPECIES", 52, 57], ["the unphosphorylated retinoblastoma tumor suppressor protein", "PROBLEM", 87, 147], ["a loss of the G1/S checkpoint", "PROBLEM", 196, 225], ["retinoblastoma tumor", "OBSERVATION", 108, 128], ["E2F complexes", "OBSERVATION", 168, 181], ["loss", "OBSERVATION_MODIFIER", 198, 202]]], ["The HPV16 E7 protein is a 98-amino-acid nuclear phosphoprotein and can be divided into three main domains -CR1, aa 1-15; CR2, aa 16-37; and CR3, aa 38-98.", [["98-amino-acid", "CHEMICAL", 26, 39], ["98-amino-acid", "CHEMICAL", 26, 39], ["HPV16", "ORGANISM", 4, 9], ["E7", "GENE_OR_GENE_PRODUCT", 10, 12], ["CR1", "GENE_OR_GENE_PRODUCT", 107, 110], ["CR2", "GENE_OR_GENE_PRODUCT", 121, 124], ["CR3", "GENE_OR_GENE_PRODUCT", 140, 143], ["HPV16 E7 protein", "PROTEIN", 4, 20], ["98-amino-acid nuclear phosphoprotein", "PROTEIN", 26, 62], ["CR1", "PROTEIN", 107, 110], ["CR2", "PROTEIN", 121, 124], ["CR3", "PROTEIN", 140, 143], ["HPV16", "SPECIES", 4, 9], ["The HPV16 E7 protein", "TEST", 0, 20], ["amino-acid nuclear phosphoprotein", "TEST", 29, 62], ["CR1", "TEST", 107, 110], ["aa", "TEST", 112, 114], ["CR2", "TEST", 121, 124], ["aa", "TEST", 126, 128], ["CR3", "TEST", 140, 143], ["aa", "TEST", 145, 147]]], ["All 3 domains are essential for the manifestation of the biological properties of E7 (33) .", [["E7", "ORGANISM", 82, 84]]], ["CR1 and CR2 mediate binding of the viral oncoproteins to an overlapping set of cellular proteins, including the product of the retinoblastoma gene (pRB), cyclin A and cyclin E (18, 24, 36) .", [["cellular", "ANATOMY", 79, 87], ["CR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["CR2", "GENE_OR_GENE_PRODUCT", 8, 11], ["cellular", "CELL", 79, 87], ["retinoblastoma gene", "GENE_OR_GENE_PRODUCT", 127, 146], ["pRB", "GENE_OR_GENE_PRODUCT", 148, 151], ["cyclin A", "GENE_OR_GENE_PRODUCT", 154, 162], ["cyclin E", "GENE_OR_GENE_PRODUCT", 167, 175], ["CR1", "PROTEIN", 0, 3], ["CR2", "PROTEIN", 8, 11], ["viral oncoproteins", "PROTEIN", 35, 53], ["cellular proteins", "PROTEIN", 79, 96], ["retinoblastoma gene", "DNA", 127, 146], ["pRB", "DNA", 148, 151], ["cyclin A", "DNA", 154, 162], ["cyclin E", "DNA", 167, 175], ["CR1", "TEST", 0, 3], ["the viral oncoproteins", "PROBLEM", 31, 53], ["cellular proteins", "PROBLEM", 79, 96], ["the retinoblastoma gene (pRB", "TREATMENT", 123, 151], ["cyclin A and cyclin E", "TREATMENT", 154, 175], ["viral oncoproteins", "OBSERVATION", 35, 53], ["cellular proteins", "OBSERVATION", 79, 96], ["retinoblastoma", "OBSERVATION", 127, 141]]], ["The CR3 domain contains two \"CXXC\" sequences participating in Zn binding (9, 23) .", [["Zn", "CHEMICAL", 62, 64], ["Zn", "CHEMICAL", 62, 64], ["CR3", "GENE_OR_GENE_PRODUCT", 4, 7], ["Zn", "SIMPLE_CHEMICAL", 62, 64], ["CR3 domain", "PROTEIN", 4, 14], ["CXXC", "PROTEIN", 29, 33], ["Zn", "PROTEIN", 62, 64], ["Zn binding", "OBSERVATION", 62, 72]]], ["It was reported that zinc finger structure at the C-terminal was essential for HPV16 E7 to stabilize its structure and biological function (30) .", [["zinc", "CHEMICAL", 21, 25], ["zinc", "CHEMICAL", 21, 25], ["C", "CHEMICAL", 50, 51], ["HPV16 E7", "GENE_OR_GENE_PRODUCT", 79, 87], ["zinc finger structure", "PROTEIN", 21, 42], ["C-terminal", "PROTEIN", 50, 60], ["HPV16 E7", "PROTEIN", 79, 87], ["HPV16", "SPECIES", 79, 84], ["zinc finger structure", "PROBLEM", 21, 42], ["HPV16 E7", "TREATMENT", 79, 87]]]], "1c914d9d3e8011efd09ffdfa00850b70328effcf": [["Overview of SARS-CoV-2In December 2019, pneumonia of an unknown etiology was confirmed in China [1] .", [["pneumonia", "DISEASE", 40, 49], ["SARS-CoV-2In December 2019", "SPECIES", 12, 38], ["pneumonia", "PROBLEM", 40, 49], ["pneumonia", "OBSERVATION", 40, 49]]], ["The Chinese Center for Disease Control and Prevention (CCDC) identified a novel coronavirus infection as the cause of this pneumonia [2] .", [["coronavirus infection", "DISEASE", 80, 101], ["pneumonia", "DISEASE", 123, 132], ["coronavirus", "ORGANISM", 80, 91], ["Disease Control", "TREATMENT", 23, 38], ["a novel coronavirus infection", "PROBLEM", 72, 101], ["this pneumonia", "PROBLEM", 118, 132], ["coronavirus", "OBSERVATION_MODIFIER", 80, 91], ["infection", "OBSERVATION", 92, 101], ["pneumonia", "OBSERVATION", 123, 132]]], ["The World Health Organization (WHO) named the disease \"2019-new coronavirus disease\" (or i and the International Committee on Taxonomy of Viruses (ICTV) named the virus \"severe acute respiratory syndrome coronavirus 2\" (or SARS-CoV-2) ii .", [["coronavirus disease", "DISEASE", 64, 83], ["acute respiratory syndrome coronavirus", "DISEASE", 177, 215], ["ICTV", "SPECIES", 147, 151], ["virus \"severe acute respiratory syndrome coronavirus", "SPECIES", 163, 215], ["SARS-CoV-2", "SPECIES", 223, 233], ["the disease \"", "PROBLEM", 42, 55], ["new coronavirus disease\"", "PROBLEM", 60, 84], ["the virus \"severe acute respiratory syndrome coronavirus", "PROBLEM", 159, 215], ["SARS", "PROBLEM", 223, 227], ["coronavirus disease", "OBSERVATION", 64, 83], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["respiratory syndrome", "OBSERVATION", 183, 203]]], ["The WHO soon declared that COVID-19 was a fast-evolving pandemic iii .", [["COVID-19", "CHEMICAL", 27, 35], ["COVID", "TEST", 27, 32]]], ["As of May, 26, 2020 , it is estimated that 5,406,282 people have been infected with COVID-19 and 343,562 people have died globally iii .", [["people", "ORGANISM", 53, 59], ["people", "ORGANISM", 105, 111], ["people", "SPECIES", 53, 59], ["people", "SPECIES", 105, 111], ["COVID", "TEST", 84, 89], ["infected", "OBSERVATION", 70, 78]]], ["Multiple clinical trials are currently underway for prevention or intervention in the disease progression [3] .", [["Multiple clinical trials", "TREATMENT", 0, 24], ["intervention", "TREATMENT", 66, 78], ["the disease progression", "PROBLEM", 82, 105]]], ["In parallel, it is also equally essential to carry out basic research on SARS-CoV-2 to support the efficient development of therapeutic agents.", [["CoV-2", "ORGANISM", 78, 83], ["therapeutic agents", "TREATMENT", 124, 142]]], ["For this, models that can faithfully reproduce the behavior of the virus and reproduce the pathology of COVID-19 are required.", [["the virus", "PROBLEM", 63, 72], ["COVID", "TEST", 104, 109]]], ["Here, we briefly review relevant cell lines, organoids, and animal model animals.Cell lines and organoids for SARS-CoV-2 researchAn in vitro cell model for SARS-CoV-2 research is essential for understanding the viral life cycle, for amplifying and isolating the virus for further research and for preclinical evaluation of therapeutic molecules.", [["cell lines", "ANATOMY", 33, 43], ["organoids", "ANATOMY", 45, 54], ["Cell lines", "ANATOMY", 81, 91], ["organoids", "ANATOMY", 96, 105], ["cell", "ANATOMY", 141, 145], ["cell lines", "CELL", 33, 43], ["organoids", "CELL", 45, 54], ["Cell lines", "CELL", 81, 91], ["organoids", "CELL", 96, 105], ["cell", "CELL", 141, 145], ["cell lines", "CELL_LINE", 33, 43], ["organoids", "TEST", 45, 54], ["Cell lines", "TREATMENT", 81, 91], ["organoids", "TEST", 96, 105], ["SARS", "PROBLEM", 110, 114], ["CoV", "TEST", 115, 118], ["vitro cell model", "TREATMENT", 135, 151], ["SARS", "PROBLEM", 156, 160], ["CoV", "TEST", 161, 164], ["preclinical evaluation", "TEST", 297, 319], ["therapeutic molecules", "PROBLEM", 323, 344], ["cell lines", "OBSERVATION", 33, 43]]], ["This section lays out the cell lines used to replicate and isolate SARS-CoV-2, as well as organoids that can be used to examine the effects of SARS-CoV-2 infection on specific human tissues (Table 1A, Figure 1 ).Cell linesIn humans, airway epithelial cells highly express the putative SARS-CoV-2 entry receptor, angiotensin-converting enzyme 2 (ACE2) and transmembrane serine [12] .", [["cell lines", "ANATOMY", 26, 36], ["organoids", "ANATOMY", 90, 99], ["tissues", "ANATOMY", 182, 189], ["Cell lines", "ANATOMY", 212, 222], ["airway epithelial cells", "ANATOMY", 233, 256], ["infection", "DISEASE", 154, 163], ["angiotensin", "CHEMICAL", 312, 323], ["serine", "CHEMICAL", 369, 375], ["cell lines", "CELL", 26, 36], ["SARS-CoV-2", "ORGANISM", 67, 77], ["organoids", "CELL", 90, 99], ["SARS-CoV-2", "ORGANISM", 143, 153], ["human", "ORGANISM", 176, 181], ["tissues", "TISSUE", 182, 189], ["Cell lines", "CELL", 212, 222], ["humans", "ORGANISM", 225, 231], ["airway epithelial cells", "CELL", 233, 256], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 285, 295], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 312, 343], ["ACE2", "GENE_OR_GENE_PRODUCT", 345, 349], ["cell lines", "CELL_LINE", 26, 36], ["Cell lines", "CELL_LINE", 212, 222], ["airway epithelial cells", "CELL_TYPE", 233, 256], ["SARS-CoV-2 entry receptor", "PROTEIN", 285, 310], ["angiotensin-converting enzyme 2", "PROTEIN", 312, 343], ["ACE2", "PROTEIN", 345, 349], ["human", "SPECIES", 176, 181], ["humans", "SPECIES", 225, 231], ["SARS-CoV", "SPECIES", 67, 75], ["SARS-CoV", "SPECIES", 143, 151], ["human", "SPECIES", 176, 181], ["humans", "SPECIES", 225, 231], ["This section", "TREATMENT", 0, 12], ["the cell lines", "TREATMENT", 22, 36], ["organoids", "TREATMENT", 90, 99], ["SARS", "PROBLEM", 143, 147], ["CoV-2 infection", "PROBLEM", 148, 163], ["Cell lines", "TREATMENT", 212, 222], ["airway epithelial cells", "TEST", 233, 256], ["the putative SARS", "TEST", 272, 289], ["CoV", "TEST", 290, 293], ["angiotensin", "TEST", 312, 323], ["converting enzyme", "TEST", 324, 341], ["transmembrane serine", "TEST", 355, 375], ["cell lines", "OBSERVATION", 26, 36], ["infection", "OBSERVATION", 154, 163], ["Cell lines", "OBSERVATION", 212, 222], ["airway", "ANATOMY", 233, 239], ["epithelial cells", "OBSERVATION", 240, 256]]], ["They reported that the viral RNA copies in the culture supernatants of these cells were >100 times higher than those of Vero E6 cells, suggesting that it would possible to isolate higher titer virus using TMPRSS2-overexpressing Vero E6 cells.OrganoidsOrganoids are composed of multiple cell types and model the physiological conditions of human organs.", [["supernatants", "ANATOMY", 55, 67], ["cells", "ANATOMY", 77, 82], ["Vero E6 cells", "ANATOMY", 120, 133], ["Vero E6 cells", "ANATOMY", 228, 241], ["cell", "ANATOMY", 286, 290], ["organs", "ANATOMY", 345, 351], ["cells", "CELL", 77, 82], ["Vero E6 cells", "CELL", 120, 133], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 205, 212], ["Vero E6 cells", "CELL", 228, 241], ["cell", "CELL", 286, 290], ["human", "ORGANISM", 339, 344], ["organs", "ORGAN", 345, 351], ["viral RNA copies", "RNA", 23, 39], ["Vero E6 cells", "CELL_LINE", 120, 133], ["TMPRSS2-overexpressing Vero E6 cells", "CELL_LINE", 205, 241], ["human", "SPECIES", 339, 344], ["Vero E6", "SPECIES", 120, 127], ["Vero E6", "SPECIES", 228, 235], ["human", "SPECIES", 339, 344], ["the viral RNA copies", "PROBLEM", 19, 39], ["the culture supernatants", "TEST", 43, 67], ["these cells", "TEST", 71, 82], ["Vero E6 cells", "PROBLEM", 120, 133], ["higher titer virus", "PROBLEM", 180, 198], ["TMPRSS2", "TEST", 205, 212], ["overexpressing Vero E6 cells", "PROBLEM", 213, 241], ["multiple cell types", "PROBLEM", 277, 296], ["E6 cells", "OBSERVATION", 125, 133], ["Vero E6 cells", "OBSERVATION", 228, 241], ["multiple cell types", "OBSERVATION", 277, 296]]], ["Because organoids have the ability to self-replicate, they are also suitable models for large-scale screening in drug discovery and disease research [13] .", [["organoids", "ANATOMY", 8, 17], ["organoids", "CELL", 8, 17], ["large-scale screening", "TREATMENT", 88, 109]]], ["Besides the lung damage caused by pneumonia, SARS-CoV-2 affects several organs like the kidney [14] , liver [15] , and the cardiovascular system [16] .", [["lung", "ANATOMY", 12, 16], ["organs", "ANATOMY", 72, 78], ["kidney", "ANATOMY", 88, 94], ["liver", "ANATOMY", 102, 107], ["cardiovascular", "ANATOMY", 123, 137], ["lung damage", "DISEASE", 12, 23], ["pneumonia", "DISEASE", 34, 43], ["SARS", "DISEASE", 45, 49], ["lung", "ORGAN", 12, 16], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["organs", "ORGAN", 72, 78], ["kidney", "ORGAN", 88, 94], ["liver", "ORGAN", 102, 107], ["cardiovascular", "ANATOMICAL_SYSTEM", 123, 137], ["SARS-CoV", "SPECIES", 45, 53], ["the lung damage", "PROBLEM", 8, 23], ["pneumonia", "PROBLEM", 34, 43], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["lung", "ANATOMY", 12, 16], ["damage", "OBSERVATION", 17, 23], ["pneumonia", "OBSERVATION", 34, 43], ["kidney", "ANATOMY", 88, 94], ["liver", "ANATOMY", 102, 107], ["cardiovascular system", "ANATOMY", 123, 144]]], ["Suzuki et al.Organoidsand Han et al. generated human bronchial organoids [17] or human lung organoids [18] , respectively, for SARS-CoV-2 research.", [["bronchial organoids", "ANATOMY", 53, 72], ["lung organoids", "ANATOMY", 87, 101], ["SARS", "DISEASE", 127, 131], ["human", "ORGANISM", 47, 52], ["bronchial organoids", "CELL", 53, 72], ["human", "ORGANISM", 81, 86], ["lung organoids", "CELL", 87, 101], ["human bronchial organoids", "CELL_TYPE", 47, 72], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 81, 86], ["generated human bronchial organoids", "PROBLEM", 37, 72], ["human lung organoids", "TEST", 81, 101], ["SARS", "PROBLEM", 127, 131], ["bronchial", "ANATOMY", 53, 62], ["lung", "ANATOMY", 87, 91]]], ["They showed that their organoids were permissive to the SARS-CoV-2 infection and could evaluate anti-viral effects of COVID-19 candidate therapeutic compounds including camostat [17] .", [["organoids", "ANATOMY", 23, 32], ["SARS", "DISEASE", 56, 60], ["infection", "DISEASE", 67, 76], ["COVID", "CHEMICAL", 118, 123], ["camostat", "CHEMICAL", 169, 177], ["camostat", "CHEMICAL", 169, 177], ["organoids", "CELL", 23, 32], ["SARS-CoV-2", "ORGANISM", 56, 66], ["COVID-19", "SIMPLE_CHEMICAL", 118, 126], ["SARS-CoV-2", "SPECIES", 56, 66], ["the SARS", "PROBLEM", 52, 60], ["CoV-2 infection", "PROBLEM", 61, 76], ["COVID", "TEST", 118, 123], ["camostat", "TREATMENT", 169, 177]]], ["Besides the lung damage caused by pneumonia, SARS-CoV-2 affects several organs like the kidney [14] , liver [15] , and the cardiovascular system [16] .", [["lung", "ANATOMY", 12, 16], ["organs", "ANATOMY", 72, 78], ["kidney", "ANATOMY", 88, 94], ["liver", "ANATOMY", 102, 107], ["cardiovascular", "ANATOMY", 123, 137], ["lung damage", "DISEASE", 12, 23], ["pneumonia", "DISEASE", 34, 43], ["SARS", "DISEASE", 45, 49], ["lung", "ORGAN", 12, 16], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["organs", "ORGAN", 72, 78], ["kidney", "ORGAN", 88, 94], ["liver", "ORGAN", 102, 107], ["cardiovascular", "ANATOMICAL_SYSTEM", 123, 137], ["SARS-CoV", "SPECIES", 45, 53], ["the lung damage", "PROBLEM", 8, 23], ["pneumonia", "PROBLEM", 34, 43], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["lung", "ANATOMY", 12, 16], ["damage", "OBSERVATION", 17, 23], ["pneumonia", "OBSERVATION", 34, 43], ["kidney", "ANATOMY", 88, 94], ["liver", "ANATOMY", 102, 107], ["cardiovascular system", "ANATOMY", 123, 144]]], ["Monteil infection and support replication [20] .", [["infection", "DISEASE", 8, 17], ["Monteil infection", "PROBLEM", 0, 17], ["support replication", "TREATMENT", 22, 41], ["infection", "OBSERVATION", 8, 17]]], ["Interestingly, virus infection impaired the bile acid transporting functions of cholangiocytes [20] .", [["bile", "ANATOMY", 44, 48], ["cholangiocytes", "ANATOMY", 80, 94], ["infection", "DISEASE", 21, 30], ["bile acid", "CHEMICAL", 44, 53], ["bile acid", "CHEMICAL", 44, 53], ["bile acid", "SIMPLE_CHEMICAL", 44, 53], ["cholangiocytes", "CELL", 80, 94], ["virus infection", "PROBLEM", 15, 30], ["virus", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["bile", "ANATOMY", 44, 48]]], ["This effect might be the reason for Furthermore, it is expected that the intestine is another viral target organ [21] .", [["intestine", "ANATOMY", 73, 82], ["organ", "ANATOMY", 107, 112], ["intestine", "ORGAN", 73, 82], ["organ", "ORGAN", 107, 112], ["intestine", "ANATOMY", 73, 82]]], ["LamersAnimal models for SARS-CoV-2 researchThe complex pathophysiology of the disease will only be understood by Figure 1 ).Small animalsOne of the works that set the pace for discovery of animal models was by Zhou et al. who conducted SARS-CoV-2 infection experiments using HeLa cells that expressed ACE2 proteins taken from multiple animal species from mice to humans [11] .Small animalsInterestingly, SARS-CoV-2 could use all ACE2 proteins, except for mouse ACE2.Small animalsTherefore, Bao et al. used transgenic mice that express human ACE2 [25] .", [["HeLa cells", "ANATOMY", 275, 285], ["SARS", "DISEASE", 24, 28], ["infection", "DISEASE", 247, 256], ["SARS", "DISEASE", 404, 408], ["HeLa cells", "CELL", 275, 285], ["ACE2", "GENE_OR_GENE_PRODUCT", 301, 305], ["mice", "ORGANISM", 355, 359], ["humans", "ORGANISM", 363, 369], ["ACE2", "GENE_OR_GENE_PRODUCT", 429, 433], ["mouse", "ORGANISM", 455, 460], ["ACE2", "GENE_OR_GENE_PRODUCT", 461, 465], ["mice", "ORGANISM", 517, 521], ["human", "ORGANISM", 535, 540], ["ACE2", "GENE_OR_GENE_PRODUCT", 541, 545], ["HeLa cells", "CELL_LINE", 275, 285], ["ACE2 proteins", "PROTEIN", 301, 314], ["ACE2 proteins", "PROTEIN", 429, 442], ["mouse ACE2", "PROTEIN", 455, 465], ["ACE2", "PROTEIN", 541, 545], ["mice", "SPECIES", 355, 359], ["humans", "SPECIES", 363, 369], ["mouse", "SPECIES", 455, 460], ["mice", "SPECIES", 517, 521], ["human", "SPECIES", 535, 540], ["SARS-CoV", "SPECIES", 24, 32], ["mice", "SPECIES", 355, 359], ["humans", "SPECIES", 363, 369], ["SARS-CoV", "SPECIES", 404, 412], ["mouse", "SPECIES", 455, 460], ["mice", "SPECIES", 517, 521], ["human", "SPECIES", 535, 540], ["LamersAnimal models", "TEST", 0, 19], ["SARS", "PROBLEM", 24, 28], ["CoV", "TEST", 29, 32], ["the disease", "PROBLEM", 74, 85], ["Small animals", "PROBLEM", 124, 137], ["SARS", "PROBLEM", 236, 240], ["CoV", "PROBLEM", 241, 244], ["2 infection experiments", "PROBLEM", 245, 268], ["HeLa cells", "TREATMENT", 275, 285], ["ACE2 proteins", "TEST", 301, 314], ["Small animals", "PROBLEM", 376, 389], ["SARS", "TEST", 404, 408], ["all ACE2 proteins", "TREATMENT", 425, 442], ["mouse ACE2", "PROBLEM", 455, 465], ["Small animals", "PROBLEM", 466, 479], ["transgenic mice", "TREATMENT", 506, 521], ["complex", "OBSERVATION_MODIFIER", 47, 54], ["disease", "OBSERVATION", 78, 85], ["animals", "OBSERVATION", 130, 137], ["animals", "OBSERVATION", 382, 389], ["animals", "OBSERVATION", 472, 479]]], ["The team found that such mice after SARS-CoV-2 infection, showed weight loss, virus replication in the lungs, and interstitial pneumonia [25] .", [["lungs", "ANATOMY", 103, 108], ["interstitial", "ANATOMY", 114, 126], ["infection", "DISEASE", 47, 56], ["weight loss", "DISEASE", 65, 76], ["interstitial pneumonia", "DISEASE", 114, 136], ["mice", "ORGANISM", 25, 29], ["SARS-CoV-2", "ORGANISM", 36, 46], ["lungs", "ORGAN", 103, 108], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["CoV-2 infection", "PROBLEM", 41, 56], ["weight loss", "PROBLEM", 65, 76], ["virus replication in the lungs", "PROBLEM", 78, 108], ["interstitial pneumonia", "PROBLEM", 114, 136], ["weight loss", "OBSERVATION", 65, 76], ["virus replication", "OBSERVATION", 78, 95], ["lungs", "ANATOMY", 103, 108], ["interstitial", "ANATOMY_MODIFIER", 114, 126], ["pneumonia", "OBSERVATION", 127, 136]]], ["In the search of alternative small animal models, molecular docking studies were performed on the binding between ACE2 of various mammals and the S protein of SARS-CoV-2, with the finding that the Syrian hamster might be suitable [26] .", [["hamster", "ANATOMY", 204, 211], ["ACE2", "GENE_OR_GENE_PRODUCT", 114, 118], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 159, 169], ["Syrian hamster", "ORGANISM", 197, 211], ["ACE2", "PROTEIN", 114, 118], ["S protein", "PROTEIN", 146, 155], ["Syrian hamster", "SPECIES", 197, 211], ["SARS-CoV", "SPECIES", 159, 167], ["Syrian hamster", "SPECIES", 197, 211], ["molecular docking studies", "TEST", 50, 75], ["the S protein", "TEST", 142, 155], ["SARS", "TEST", 159, 163], ["CoV", "TEST", 164, 167], ["small", "OBSERVATION_MODIFIER", 29, 34]]], ["After infection, these hamsters show rapid breathing, weight loss, and alveolar damage with extensive apoptosis [26] .Small animalsJ o u r n a l P r e -p r o o f Figure 1 ) and help assess the advantages and disadvantages of each towards discovery of better models.Small animalsJ o u r n a l P r e -p r o o f manuscript.", [["alveolar", "ANATOMY", 71, 79], ["infection", "DISEASE", 6, 15], ["weight loss", "DISEASE", 54, 65], ["alveolar damage", "DISEASE", 71, 86], ["hamsters", "ORGANISM", 23, 31], ["alveolar", "TISSUE", 71, 79], ["hamsters", "SPECIES", 23, 31], ["infection", "PROBLEM", 6, 15], ["rapid breathing", "PROBLEM", 37, 52], ["weight loss", "PROBLEM", 54, 65], ["alveolar damage", "PROBLEM", 71, 86], ["extensive apoptosis", "PROBLEM", 92, 111], ["a l P r e -p r o o f Figure", "TEST", 141, 168], ["infection", "OBSERVATION", 6, 15], ["rapid", "OBSERVATION_MODIFIER", 37, 42], ["breathing", "OBSERVATION", 43, 52], ["alveolar damage", "OBSERVATION", 71, 86], ["extensive", "OBSERVATION_MODIFIER", 92, 101], ["apoptosis", "OBSERVATION_MODIFIER", 102, 111]]], ["Human ACE2 transgenic mice After SARS-CoV-2 infection, the mice show weight loss, virus replication in the lungs, and interstitial pneumonia.Resources[25]ResourcesSyrian hamster After SARS-CoV-2 infection, the hamsters show rapid breathing, weight loss, and diffuse alveolar damage with extensive apoptosis.Resources[26]ResourcesFerrets After SARS-CoV-2 infection, acute bronchiolitis was observed in the lungs.Resources[27]ResourcesCats After SARS-CoV-2 infection, intra-alveolar edema and congestion in the interalveolar septa were observed.ResourcesAbnormal arrangement of the epithelium with loss of cilia and lymphocytic infiltration into the lamina propria were also observed.", [["lungs", "ANATOMY", 107, 112], ["interstitial", "ANATOMY", 118, 130], ["alveolar", "ANATOMY", 266, 274], ["lungs", "ANATOMY", 405, 410], ["intra-alveolar edema", "ANATOMY", 466, 486], ["interalveolar septa", "ANATOMY", 509, 528], ["epithelium", "ANATOMY", 580, 590], ["cilia", "ANATOMY", 604, 609], ["lymphocytic", "ANATOMY", 614, 625], ["lamina propria", "ANATOMY", 648, 662], ["infection", "DISEASE", 44, 53], ["weight loss", "DISEASE", 69, 80], ["interstitial pneumonia", "DISEASE", 118, 140], ["SARS-CoV-2 infection", "DISEASE", 184, 204], ["weight loss", "DISEASE", 241, 252], ["alveolar damage", "DISEASE", 266, 281], ["SARS-CoV-2 infection", "DISEASE", 343, 363], ["bronchiolitis", "DISEASE", 371, 384], ["infection", "DISEASE", 455, 464], ["intra-alveolar edema", "DISEASE", 466, 486], ["congestion", "DISEASE", 491, 501], ["Human", "ORGANISM", 0, 5], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["mice", "ORGANISM", 22, 26], ["SARS-CoV-2", "ORGANISM", 33, 43], ["mice", "ORGANISM", 59, 63], ["lungs", "ORGAN", 107, 112], ["ResourcesSyrian hamster", "ORGANISM", 154, 177], ["SARS-CoV-2", "ORGANISM", 184, 194], ["hamsters", "ORGANISM", 210, 218], ["alveolar", "TISSUE", 266, 274], ["CoV-2", "ORGANISM", 348, 353], ["lungs", "ORGAN", 405, 410], ["intra-alveolar edema", "PATHOLOGICAL_FORMATION", 466, 486], ["interalveolar septa", "MULTI-TISSUE_STRUCTURE", 509, 528], ["epithelium", "TISSUE", 580, 590], ["cilia", "CELLULAR_COMPONENT", 604, 609], ["lamina propria", "TISSUE", 648, 662], ["ACE2", "PROTEIN", 6, 10], ["Human", "SPECIES", 0, 5], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 59, 63], ["hamster", "SPECIES", 170, 177], ["hamsters", "SPECIES", 210, 218], ["Human", "SPECIES", 0, 5], ["mice", "SPECIES", 22, 26], ["SARS-CoV-2", "SPECIES", 33, 43], ["mice", "SPECIES", 59, 63], ["SARS-CoV-2", "SPECIES", 184, 194], ["hamsters", "SPECIES", 210, 218], ["SARS-CoV", "SPECIES", 343, 351], ["Human ACE2 transgenic mice", "TREATMENT", 0, 26], ["SARS", "PROBLEM", 33, 37], ["2 infection", "PROBLEM", 42, 53], ["weight loss", "PROBLEM", 69, 80], ["virus replication in the lungs", "PROBLEM", 82, 112], ["interstitial pneumonia", "PROBLEM", 118, 140], ["SARS", "PROBLEM", 184, 188], ["CoV-2 infection", "PROBLEM", 189, 204], ["rapid breathing", "PROBLEM", 224, 239], ["weight loss", "PROBLEM", 241, 252], ["diffuse alveolar damage", "PROBLEM", 258, 281], ["extensive apoptosis", "PROBLEM", 287, 306], ["SARS", "PROBLEM", 343, 347], ["CoV-2 infection", "PROBLEM", 348, 363], ["acute bronchiolitis", "PROBLEM", 365, 384], ["SARS", "PROBLEM", 444, 448], ["CoV-2 infection", "PROBLEM", 449, 464], ["intra-alveolar edema", "PROBLEM", 466, 486], ["congestion in the interalveolar septa", "PROBLEM", 491, 528], ["loss of cilia and lymphocytic infiltration into the lamina propria", "PROBLEM", 596, 662], ["infection", "OBSERVATION", 44, 53], ["weight loss", "OBSERVATION", 69, 80], ["virus replication", "OBSERVATION", 82, 99], ["lungs", "ANATOMY", 107, 112], ["interstitial", "ANATOMY_MODIFIER", 118, 130], ["pneumonia", "OBSERVATION", 131, 140], ["rapid", "OBSERVATION_MODIFIER", 224, 229], ["breathing", "OBSERVATION", 230, 239], ["diffuse", "OBSERVATION_MODIFIER", 258, 265], ["alveolar damage", "OBSERVATION", 266, 281], ["extensive", "OBSERVATION_MODIFIER", 287, 296], ["apoptosis", "OBSERVATION", 297, 306], ["infection", "OBSERVATION", 354, 363], ["acute", "OBSERVATION_MODIFIER", 365, 370], ["bronchiolitis", "OBSERVATION", 371, 384], ["lungs", "ANATOMY", 405, 410], ["infection", "OBSERVATION", 455, 464], ["intra-alveolar", "ANATOMY_MODIFIER", 466, 480], ["edema", "OBSERVATION", 481, 486], ["congestion", "OBSERVATION", 491, 501], ["interalveolar septa", "ANATOMY", 509, 528], ["epithelium", "ANATOMY_MODIFIER", 580, 590], ["loss", "OBSERVATION_MODIFIER", 596, 600], ["cilia", "ANATOMY", 604, 609], ["lymphocytic infiltration", "OBSERVATION", 614, 638], ["lamina propria", "ANATOMY", 648, 662]]]], "9105906307caf556a6be11a00d2cc3d76b6cafe3": [["INTRODUCTIONAt a time of the very visible effects of the climate impact on our urban lives, some cities have become unbreathable, and greenhouse gas emissions are produced by buildings heating and cooling networks and all-round petrol transport.", [["cooling networks", "TREATMENT", 197, 213], ["all-round petrol transport", "TREATMENT", 218, 244]]], ["At a time when transport has become the first emitter of CO 2 , we need to imagine, propose, other ways of occupying urban space.", [["CO 2", "CHEMICAL", 57, 61]]], ["The information age and the online mapping revolution allow us to globally study the interactions of humans with their built and natural environment (8) (9) (10) (11) (12) (13) .", [["humans", "ORGANISM", 101, 107], ["humans", "SPECIES", 101, 107], ["humans", "SPECIES", 101, 107]]], ["Pioneering work in multicity studies has uncovered scaling laws relating population to distribution of facilities and socioeconomic activities at macroscopic scale (3, 6, (14) (15) (16) .", [["multicity studies", "TEST", 19, 36], ["macroscopic scale", "TEST", 146, 163]]], ["However, a systematic understanding of the interplay of the urban form, their facilities distribution, and their accessibility at multiple scales remains an elusive task.INTRODUCTIONAt the country scale, when maximizing for the accessibility of population to a fixed number of facilities, Gastner and Newman (17) demonstrated a simple two-thirds power law between the optimal density of facilities d and their population density \uf072.", [["optimal density", "OBSERVATION_MODIFIER", 368, 383], ["population", "OBSERVATION_MODIFIER", 410, 420], ["density", "OBSERVATION", 421, 428]]], ["The power law was fitted by allocating 5000 facilities in the continental United States using population data within more than 8 million census blocks.", [["population data", "TEST", 94, 109]]], ["In this case, each facility covers an area about the size of a county (\u223c1000 km 2 ).", [["size", "OBSERVATION_MODIFIER", 53, 57]]], ["In a follow up study, Um et al. (18) proposed distinct optimization goals to differentiate public services, such as fire stations and public schools, from commercial facilities, such as banks and restaurants.", [["a follow up study", "TEST", 3, 20]]], ["Public service facilities aim to minimize the overall distance between people and the facilities and follow d \u221d \uf072 2/3 .", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77]]], ["The simple power law at city scale reveals the equilibrium of empirical allocation of resources across cities with different population.", [["simple", "OBSERVATION_MODIFIER", 4, 10], ["power", "OBSERVATION_MODIFIER", 11, 16], ["law", "OBSERVATION_MODIFIER", 17, 20]]], ["However, distributing facilities at fine scale within cities, where the coverage area per facility is of few blocks (\u223c10 km 2 ), results in more heterogeneous settlements of population with different socioeconomic characteristics.", [["few blocks", "PROBLEM", 105, 115], ["heterogeneous", "OBSERVATION_MODIFIER", 145, 158], ["settlements", "OBSERVATION", 159, 170]]], ["Studies of accessibility within cities merit attention for science-informed land use planning and the redistribution of public services after disasters and evacuations (19) (20) (21) (22) (23) .", [["evacuations", "TEST", 156, 167]]], ["Zhou et al. (24) introduced a location-based social network dataset to derive the demand for different types of cultural resources and identified the urban regions with lack of venues.", [["cultural resources", "TREATMENT", 112, 130]]], ["While efforts have been devoted to address the optimal allocation problem in specific cities (24) (25) (26) (27) , systematic understanding of the optimal distribution of facilities is still lacking from the urban science perspective.INTRODUCTIONTo contribute in this direction, we propose a multicity study that measures the accessibility of city blocks to different types of facilities through their road networks and investigate the role of population distributions.", [["road networks", "MULTI-TISSUE_STRUCTURE", 402, 415], ["a multicity study", "TEST", 290, 307]]], ["While at large scale, travel cost can be substituted by the Euclidean distance from residents to the facilities, road networks and geographic constraints play important roles for human mobility within cities (28) (29) (30) (31) .", [["human", "ORGANISM", 179, 184], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 179, 184]]], ["It has been well established that road network properties affect the daily journeys of residents (32) (33) (34) , their urban form (35, 36) , and their accessibility (29, 37) .", [["road network", "MULTI-TISSUE_STRUCTURE", 34, 46]]], ["As a complement to most studies devoted to travel costs of commuters, we analyze in this work the road network distance of individuals to the nearest amenity of various types, dividing the space in high-resolution blocks of constant area of 1 km 2 .", [["road network", "MULTI-TISSUE_STRUCTURE", 98, 110], ["high-resolution blocks", "TREATMENT", 198, 220], ["high", "OBSERVATION_MODIFIER", 198, 202]]], ["We observe that, in the redistribution, some blocks increase their accessibility and others decrease it.", [["some blocks", "PROBLEM", 40, 51], ["redistribution", "OBSERVATION_MODIFIER", 24, 38], ["some", "OBSERVATION_MODIFIER", 40, 44], ["blocks", "OBSERVATION_MODIFIER", 45, 51], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["decrease", "OBSERVATION_MODIFIER", 92, 100]]], ["We also revisit the power law between facility and population densities and observe that the two-thirds power law is not followed by the empirical cases, and it is observed in the optimal scenario only when the number of facilities is small compared to the total number of blocks in the city.INTRODUCTIONWe further investigate optimal distributions of facilities by modeling its average travel distance in different cities as a function of the number of facilities to assign.", [["small", "OBSERVATION_MODIFIER", 235, 240]]], ["For each city, we collect the population in blocks with a spatial resolution of 30 arc sec (1 km 2 near the equator) from LandScan (38) , road networks with the OpenStreetMap (39), and facilities from the Foursquare (40) service application.", [["the OpenStreetMap", "TEST", 157, 174]]], ["These novel, rich, and publicly available datasets have proven value in transportation planning (34, 41, 42) , land use studies (43, 44) , and human activity modeling (45) (46) (47) .", [["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["land use studies", "TEST", 111, 127], ["human activity modeling", "TEST", 143, 166]]], ["The boundary of each city is drawn along with the Metroplex, encompassing both urban and rural regions.", [["the Metroplex", "TREATMENT", 46, 59], ["rural", "ANATOMY_MODIFIER", 89, 94]]], ["Figure 1 depicts the road network, population density, and 10 selected types of facilities (e.g., hospitals and schools) in NYC and Doha.", [["road network", "MULTI-TISSUE_STRUCTURE", 21, 33]]], ["For clarity, all variables and notations introduced in this work are summarized in note S1.", [["S1", "PROTEIN", 88, 90]]], ["The distribution of all available facilities in Foursquare data for the six cities is presented in fig. S1 .", [["S1", "GENE_OR_GENE_PRODUCT", 104, 106], ["S1", "PROTEIN", 104, 106], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["Figure S2 presents the distribution of population and different facility categories as a function of the distance from the central business district, indicating the diversity of the selected cities.", [["distribution", "OBSERVATION_MODIFIER", 23, 35], ["central", "ANATOMY_MODIFIER", 123, 130]]], ["Specifically, it can be observed that Doha and Dubai have more facilities that are located in the highly populated areas, whereas Boston has the majority of facilities located near the city center where fewer people reside.", [["people", "ORGANISM", 209, 215], ["people", "SPECIES", 209, 215], ["highly", "OBSERVATION_MODIFIER", 98, 104], ["populated", "OBSERVATION", 105, 114]]], ["Discrepancy in the distributions between population and facilities can also be observed in LA, NYC, and Riyadh.", [["LA", "CHEMICAL", 91, 93], ["distributions", "OBSERVATION_MODIFIER", 19, 32]]], ["In these three cities, the population density peaks near the city center, but the facilities are distributed more uniformly across the city.Empirical distribution of facilitiesIt is noteworthy that, for calculating facility density and total number of facilities, we first merge the same type of facilities (e.g., hospitals) located in the same block as one facility.", [["the population density peaks", "PROBLEM", 23, 51], ["three", "OBSERVATION_MODIFIER", 9, 14], ["cities", "OBSERVATION_MODIFIER", 15, 21], ["population", "OBSERVATION_MODIFIER", 27, 37], ["density", "OBSERVATION", 38, 45], ["peaks", "OBSERVATION_MODIFIER", 46, 51], ["city", "OBSERVATION_MODIFIER", 61, 65], ["center", "OBSERVATION_MODIFIER", 66, 72], ["distributed", "OBSERVATION_MODIFIER", 97, 108], ["more", "OBSERVATION_MODIFIER", 109, 113], ["uniformly", "OBSERVATION_MODIFIER", 114, 123]]], ["Furthermore, as nearly unpopulated blocks do not weigh in the calculations of accessibility, we define N occ as the number of occupied blocks given by the blocks with population over a threshold.", [["N occ", "PROTEIN", 103, 108]]], ["We set the threshold as 500 in real-world cities, which is commonly used to distinguish between urban and rural regions.", [["rural", "ANATOMY_MODIFIER", 106, 111]]], ["The ratio between the number of blocks occupied by facilities N and populated blocks N occ is denoted by D occ .", [["N", "CHEMICAL", 62, 63], ["D occ", "PROTEIN", 105, 110], ["The ratio", "TEST", 0, 9]]], ["To quantify the accessibility of the population to facilities, previous work used the Voronoi cell around each facility as a proxy of the tendency of individuals to select the closest facility in a Euclidean distance (17, 18) .", [["cell", "ANATOMY", 94, 98], ["Voronoi cell", "CELL", 86, 98]]], ["However, within cities, the distance that people travel in the road networks is constrained by the infrastructure and the landscape.", [["people", "ORGANISM", 42, 48], ["road networks", "MULTI-TISSUE_STRUCTURE", 63, 76], ["people", "SPECIES", 42, 48], ["infrastructure", "OBSERVATION", 99, 113]]], ["Figure S2C compares the distributions of routing distance of the actual and optimal locations of facilities versus the Euclidean distances, respectively.", [["distributions", "OBSERVATION_MODIFIER", 24, 37]]], ["Our findings confirm that the optimal strategy based on the Euclidean distance achieves similar costs to the actual distribution of facilities, which is much less effective than the strategy that optimizes for routing distance.Empirical distribution of facilitiesOptimal distribution of facilities to maximize overall accessibility Accessibility indicates the level of service of facilities to the residents.", [["less effective", "OBSERVATION_MODIFIER", 158, 172]]], ["In network science, accessibility is defined as the ease of reaching points of interest within a given cost budget (48) (49) (50) .", [["cost budget", "TEST", 103, 114]]], ["The shortest distance between any pair of two blocks is calculated using the Dijkstra's algorithm in the road network.", [["road network", "MULTI-TISSUE_STRUCTURE", 105, 117], ["the Dijkstra's algorithm", "TREATMENT", 73, 97]]], ["The idea is to find a new set of N blocks and label them as facility-tagged such as it minimizes the total population-weighted travel distance from all N max blocks to the newly selected N blocks.", [["N blocks", "TREATMENT", 33, 41], ["all N max blocks", "TREATMENT", 148, 164]]], ["This optimal allocation problem in networks is known as the p-median problem and, here, it is solved with an efficient algorithm proposed by Resende and Werneck (51) (Materials and Methods).Empirical distribution of facilitiesThe difference of the travel distance between the actual and the optimal scenarios assesses the quality of the distribution and therefore, of the accessibility in different cities.", [["difference", "OBSERVATION_MODIFIER", 230, 240]]], ["It is important to note that we do not consider in the present study the capacity of facilities as a constraint, i.e., the number of people using the same facility is not limited.", [["people", "ORGANISM", 133, 139], ["people", "SPECIES", 133, 139]]], ["The communities in optimal scenario are more uniform in both size and population compared to those in the actual scenario.", [["communities", "OBSERVATION_MODIFIER", 4, 15], ["optimal scenario", "OBSERVATION", 19, 35], ["more", "OBSERVATION_MODIFIER", 40, 44], ["uniform", "OBSERVATION_MODIFIER", 45, 52], ["both", "OBSERVATION_MODIFIER", 56, 60], ["size", "OBSERVATION_MODIFIER", 61, 65], ["population", "OBSERVATION_MODIFIER", 70, 80]]], ["Particularly in the actual scenario, the communities have small area in downtown Boston but large in the rural area, revealing the uneven distribution of hospitals.Empirical distribution of facilitiesTo quantify the disparities between blocks in the level of service for a given type of facility, we compare the actual and optimal travel distances to facilities.", [["small area", "PROBLEM", 58, 68], ["small", "OBSERVATION_MODIFIER", 58, 63], ["area", "OBSERVATION_MODIFIER", 64, 68], ["downtown Boston", "OBSERVATION", 72, 87], ["large", "OBSERVATION_MODIFIER", 92, 97], ["rural", "ANATOMY_MODIFIER", 105, 110], ["area", "ANATOMY", 111, 115], ["uneven", "OBSERVATION_MODIFIER", 131, 137], ["distribution", "OBSERVATION_MODIFIER", 138, 150]]], ["An r i >1 identifies that the block is better served by the facility in the actual than the optimal scenario.", [["the block", "PROBLEM", 26, 35]]], ["In Fig. 2C , we illustrate in Boston the r i of each block to hospitals in a logarithmic scale.", [["a logarithmic scale", "TREATMENT", 75, 94]]], ["The blocks in green, near to hospitals, are located in the central, southern, and northeastern areas, while the blocks in red have lower accessibility to hospitals when compared with the optimal scenario and are located in the northern, southwestern, and southeastern areas.", [["The blocks in green", "PROBLEM", 0, 19], ["blocks", "OBSERVATION_MODIFIER", 4, 10], ["green", "OBSERVATION_MODIFIER", 14, 19], ["central", "ANATOMY_MODIFIER", 59, 66], ["southern", "OBSERVATION_MODIFIER", 68, 76], ["northeastern", "OBSERVATION_MODIFIER", 82, 94], ["areas", "OBSERVATION_MODIFIER", 95, 100], ["lower", "OBSERVATION_MODIFIER", 131, 136], ["accessibility", "OBSERVATION_MODIFIER", 137, 150], ["southwestern", "OBSERVATION_MODIFIER", 237, 249], ["southeastern", "OBSERVATION_MODIFIER", 255, 267]]], ["This has some resemblance with the spatial distribution of wealth in Boston metropolitan area (52) .", [["spatial", "OBSERVATION_MODIFIER", 35, 42], ["distribution", "OBSERVATION_MODIFIER", 43, 55], ["wealth", "OBSERVATION_MODIFIER", 59, 65], ["Boston", "OBSERVATION_MODIFIER", 69, 75]]], ["The actual travel distance \u02c6 l i and the gain index r i in the ith block to hospitals for six cities are presented in fig. S3 .Empirical distribution of facilitiesAlthough the inequality of the distribution of facilities can be visually observed from Fig. 2C , for comparing the inequality across facility types and between cities, we compute the Gini coefficient of r i of all blocks per facility type per city, as illustrated in fig. S4A .", [["S3", "GENE_OR_GENE_PRODUCT", 123, 125], ["S4A", "GENE_OR_GENE_PRODUCT", 436, 439], ["S4A", "PROTEIN", 436, 439]]], ["NYC has the most discrepancies in the Gini coefficients over the 10 facility types, where the distributions of schools, parks, pharmacies, banks, and bars are more equitable than others due to their high densities (see Table 1 ).", [["their high densities", "PROBLEM", 193, 213], ["most discrepancies", "OBSERVATION_MODIFIER", 12, 30]]], ["The Lorenz curves and the values of the Gini coefficients per facility type are presented in fig. S4B .", [["S4B", "GENE_OR_GENE_PRODUCT", 98, 101], ["S4B", "PROTEIN", 98, 101], ["The Lorenz curves", "TREATMENT", 0, 17]]], ["The first row displays the facilities with higher densities in the United States cities: banks, pharmacies, schools, parks, and bars.", [["higher", "OBSERVATION_MODIFIER", 43, 49], ["densities", "OBSERVATION", 50, 59]]], ["Next come hospitals and supermarkets, followed by concert halls, soccer fields, and fire stations, which have the lowest densities.", [["lowest", "OBSERVATION_MODIFIER", 114, 120], ["densities", "OBSERVATION", 121, 130]]], ["As expected, the lower the density, the longer the travel distance there is to them.", [["lower", "OBSERVATION_MODIFIER", 17, 22], ["density", "OBSERVATION", 27, 34]]], ["Note that the accessibilities to parks, fire stations, and bars have the largest differences between the United States and GCC cities mainly due to lower availability in the latter.", [["largest", "OBSERVATION_MODIFIER", 73, 80]]], ["To compare the travel distance in different cities in the same order, we exhibit the scatterplots of \u02c6 L and L versus D occ , the ratio between N and N occ , in Fig. 3 (B and C) .", [["N", "CHEMICAL", 144, 145], ["N", "CHEMICAL", 150, 151], ["the ratio", "TEST", 126, 135]]], ["The discrepancy of actual travel distance \u02c6 L among the six cities is mainly caused by the difference in facility planning strategy and urban form.", [["discrepancy", "OBSERVATION_MODIFIER", 4, 15]]], ["As expected, the optimal travel distance L displays a more uniform tendency than \u02c6 L , revealing the potential of modeling L with the number of facilities N.Empirical distribution of facilitiesAn interesting measure is the improvement of overall accessibility if the locations of facilities are optimally redistributed at a city scale.", [["more", "OBSERVATION_MODIFIER", 54, 58], ["uniform", "OBSERVATION_MODIFIER", 59, 66], ["tendency", "OBSERVATION", 67, 75], ["improvement", "OBSERVATION_MODIFIER", 223, 234], ["overall", "OBSERVATION_MODIFIER", 238, 245], ["accessibility", "OBSERVATION_MODIFIER", 246, 259], ["redistributed", "OBSERVATION_MODIFIER", 305, 318]]], ["To that end, we define the optimality index R for a given type of facility at city level as the ratio between the average travel distance to the nearest facilities in the optimal and actual scenariosEmpirical distribution of facilitieswhere p i is the population in the ith block.", [["the ith block", "TREATMENT", 266, 279]]], ["R ranges from 0 to 1, with 1 indicating that the facilities are optimally distributed in reality.", [["ranges", "OBSERVATION_MODIFIER", 2, 8]]], ["In note S3 and fig. S4C , we discuss the change of R with N/N max by introducing two extreme planning strategies, random and populationweighted assignments, described in note S3.", [["S4C", "GENE_OR_GENE_PRODUCT", 20, 23], ["S4C", "PROTEIN", 20, 23], ["S3", "PROTEIN", 175, 177], ["N/N max", "TREATMENT", 58, 65], ["two extreme planning strategies", "TREATMENT", 81, 112], ["random and populationweighted assignments", "TEST", 114, 155]]], ["This suggests the imbalance between facility locations and service delivery in Riyadh (53) .", [["imbalance", "OBSERVATION", 18, 27]]], ["Besides, we observe that the R score of actual planning is the highest when N/N max is the smallest for cities, except LA and NYC.", [["LA", "CHEMICAL", 119, 121]]], ["For the two extreme strategies, we observe R is ushaped as a function of N, except for LA.", [["LA", "CHEMICAL", 87, 89], ["LA", "SIMPLE_CHEMICAL", 87, 89]]], ["This suggests a higher R for both small and large N values.", [["both small and large N values", "PROBLEM", 29, 58], ["higher", "OBSERVATION_MODIFIER", 16, 22], ["small", "OBSERVATION_MODIFIER", 34, 39], ["large", "OBSERVATION_MODIFIER", 44, 49], ["N values", "OBSERVATION", 50, 58]]], ["This is because, for a small N, simply allocating the facilities in the most crowded blocks would shorten the total travel cost to a great extent, while for a large N, most blocks are occupied by facilities.", [["great extent", "OBSERVATION_MODIFIER", 133, 145]]], ["The R score of LA keeps flat compared to other cities mainly due to the polycentric distribution of population, indicating that a small number of facilities cannot efficiently serve most of the population.", [["LA", "CHEMICAL", 15, 17], ["LA", "OBSERVATION", 15, 17], ["flat", "OBSERVATION", 24, 28], ["population", "OBSERVATION", 100, 110], ["small", "OBSERVATION_MODIFIER", 130, 135]]], ["R is generally lower with larger facility density, suggesting that the gaps between actual and optimal distribution are larger.", [["R", "GENE_OR_GENE_PRODUCT", 0, 1], ["generally", "OBSERVATION_MODIFIER", 5, 14], ["lower", "OBSERVATION", 15, 20], ["larger", "OBSERVATION_MODIFIER", 26, 32], ["facility density", "OBSERVATION", 33, 49], ["optimal", "OBSERVATION_MODIFIER", 95, 102], ["distribution", "OBSERVATION_MODIFIER", 103, 115], ["larger", "OBSERVATION_MODIFIER", 120, 126]]], ["For example, hospitals and fire stations have much lower density than bars, but their R scores are larger.", [["lower density", "OBSERVATION_MODIFIER", 51, 64], ["larger", "OBSERVATION_MODIFIER", 99, 105]]], ["The more available facilities are banks, pharmacies, schools, parks, and bars, with an R between 0.4 and 0.5 on average, revealing that the average travel distance could be reduced by 50% if all facilities are planned in the optimal locations.Revisiting scaling law between facility and population densitiesPrevious work has related the facility density to population density as a power function both in the actual and optimal scenarios at the national scale (18) .", [["population", "OBSERVATION_MODIFIER", 287, 297], ["densities", "OBSERVATION", 298, 307], ["population", "OBSERVATION_MODIFIER", 357, 367], ["density", "OBSERVATION", 368, 375]]], ["Here, through introducing the road networks, we dissect these power laws in the two scenarios in diverse cities.", [["road networks", "MULTI-TISSUE_STRUCTURE", 30, 43], ["two", "OBSERVATION_MODIFIER", 80, 83], ["scenarios", "OBSERVATION", 84, 93], ["diverse", "OBSERVATION_MODIFIER", 97, 104], ["cities", "OBSERVATION_MODIFIER", 105, 111]]], ["We calculate both facility and population densities in the service communities, as shown in Fig. 2 (A and B) .", [["population", "OBSERVATION_MODIFIER", 31, 41], ["densities", "OBSERVATION", 42, 51]]], ["Specifically, d j S = 1 / a j S and \uf072 j S = p j S / a j S , where a j S is approximated by the product of the number of blocks n j S and the average block area in the city, that is, a j S = n j S a \u0304 .", [["d j S", "TEST", 14, 19], ["a j S", "TEST", 26, 31], ["j S", "TEST", 38, 41], ["j S", "TEST", 46, 49], ["a j S", "TEST", 52, 57], ["a j S", "TEST", 66, 71], ["j S", "TEST", 129, 132], ["a j S", "TEST", 182, 187]]], ["Taking hospitals as an example, their densities versus the population The blocks in red indicate that their actual travel distance to the hospital is larger than the optimal distance and they are underserved, such as in the northern and southeastern areas.Revisiting scaling law between facility and population densitiesdensities of the service communities in the actual scenario over the six cities are illustrated in Fig. 4A .", [["larger", "OBSERVATION_MODIFIER", 150, 156]]], ["The full lines represent the fitted power law functions with least squares method and with communities with more than 500 residents.", [["The full lines", "TREATMENT", 0, 14], ["full lines", "OBSERVATION", 4, 14]]], ["Cities have different exponents and the r 2 scores of the fitting are less than 0.5 in most cases.", [["different exponents", "PROBLEM", 12, 31], ["different", "OBSERVATION_MODIFIER", 12, 21], ["exponents", "OBSERVATION_MODIFIER", 22, 31]]], ["These results show that, although the two-thirds power law was found for public facilities at county resolution (18), we do not find a uniform law between facility and population densities at finer resolutions, i.e., intra-city community level.Revisiting scaling law between facility and population densitiesOnce facilities are optimally redistributed in the city, the service communities are reorganized accordingly.", [["population densities", "PROBLEM", 168, 188], ["population", "OBSERVATION_MODIFIER", 168, 178], ["densities", "OBSERVATION", 179, 188], ["population", "OBSERVATION_MODIFIER", 288, 298], ["densities", "OBSERVATION", 299, 308], ["redistributed", "OBSERVATION_MODIFIER", 338, 351]]], ["The fitted power laws between the distribution of hospitals and population in optimal scenario of the six cities are shown in Fig. 4B .", [["4B", "GENE_OR_GENE_PRODUCT", 131, 133], ["distribution", "OBSERVATION_MODIFIER", 34, 46]]], ["The fitted exponents are closer to 2/3 and have a larger r 2 , and the 95% confidence intervals are narrower than those in Fig. 4A , depicting the actual scenario.", [["exponents", "OBSERVATION_MODIFIER", 11, 20], ["larger", "OBSERVATION_MODIFIER", 50, 56], ["narrower", "OBSERVATION_MODIFIER", 100, 108]]], ["The exponents for the 10 selected types of facilities in the actual and optimal scenarios are reported in table S1.", [["exponents", "OBSERVATION_MODIFIER", 4, 13]]], ["As expected, cities have different exponents for both actual and optimal scenarios.", [["different exponents", "PROBLEM", 25, 44], ["different", "OBSERVATION_MODIFIER", 25, 34], ["exponents", "OBSERVATION_MODIFIER", 35, 44]]], ["In all cases, we observe that the optimal exponents deviate from the analytical 2/3 previously reported when the facilities are optimally distributed by a Euclidean distance at national case (17) .", [["the optimal exponents", "PROBLEM", 30, 51]]], ["Sources of difference are both the constraints introduced by the road networks and the higher density of facilities to be distributed.Revisiting scaling law between facility and population densitiesFor a comprehensive understanding of the existence of the power laws, we optimally allocate varying number of facilities N in our six cities of study and in synthetic cities.", [["road networks", "MULTI-TISSUE_STRUCTURE", 65, 78], ["difference", "OBSERVATION_MODIFIER", 11, 21], ["higher", "OBSERVATION_MODIFIER", 87, 93], ["density", "OBSERVATION", 94, 101], ["population", "OBSERVATION_MODIFIER", 178, 188], ["densities", "OBSERVATION", 189, 198]]], ["In Fig. 4 (C and D) , we relate the \uf062 to D occ , the ratio of N to N occ , and observe 2/3 when D occ < 0.2(0.1) for the real-world (synthetic) cities.", [["N", "CHEMICAL", 67, 68], ["the ratio", "TEST", 49, 58], ["D occ", "TEST", 96, 101]]], ["We simulate controlled scenarios via four synthetic or toy cities of size 100 \u00d7100, with population distributions depicted in Fig. 5A .", [["size", "OBSERVATION_MODIFIER", 69, 73], ["Fig", "OBSERVATION_MODIFIER", 126, 129]]], ["Note that the population threshold is set as 50 in toy cities to count N occ , and the total population is fixed as half million, which is about 1 / 10 of the studied cities.Revisiting scaling law between facility and population densitiesWe find that the curves of diverse cities collapse into a single one, indicating that the difference in the change of \uf062 across cities is mainly caused by different N occ .", [["N occ", "PROTEIN", 402, 407], ["N occ", "SPECIES", 402, 407], ["population", "OBSERVATION_MODIFIER", 218, 228], ["densities", "OBSERVATION", 229, 238], ["diverse", "OBSERVATION_MODIFIER", 265, 272], ["cities", "OBSERVATION_MODIFIER", 273, 279], ["collapse", "OBSERVATION", 280, 288]]], ["In the toy cities, we notice that the change of \uf062 is not monotonous.", [["not", "UNCERTAINTY", 53, 56], ["monotonous", "OBSERVATION_MODIFIER", 57, 67]]], ["Subsequently, \uf062 decreases with D occ as more facilities are assigned to the low-density regions and then increases as facilities start to refill the high-density regions.", [["decreases", "OBSERVATION_MODIFIER", 16, 25], ["density", "OBSERVATION", 80, 87], ["high-density", "OBSERVATION_MODIFIER", 149, 161]]], ["After all high-density blocks are assigned with facilities, \uf062 starts to drop to zero, implying that all blocks are filled with facilities.", [["all high-density blocks", "TREATMENT", 6, 29], ["density blocks", "OBSERVATION", 15, 29]]], ["The same fluctuation of \uf062 is not observed in real-world cities because the large and low-density regions are not segregated like in the synthetic cities.", [["the large and low-density regions", "PROBLEM", 71, 104], ["fluctuation", "OBSERVATION_MODIFIER", 9, 20], ["not observed", "UNCERTAINTY", 29, 41], ["large", "OBSERVATION_MODIFIER", 75, 80], ["low-density", "OBSERVATION_MODIFIER", 85, 96], ["not", "UNCERTAINTY", 109, 112], ["segregated", "OBSERVATION_MODIFIER", 113, 123]]], ["In summary, in the optimal scenario, the two-thirds power law can be found for a limited number of facilities but tends to disappear for larger values of N.Modeling accessibility to optimally distributed facilitiesIn Fig. 3B , we see that D occ is the most determinant factor to decrease the average distance \u02c6 L to a facility independent of its type and city.", [["D occ", "SIMPLE_CHEMICAL", 239, 244], ["Fig", "OBSERVATION", 217, 220]]], ["In Fig. 3C , we observe that these decreasing functions L(D occ ) collapse for the optimal distributions in each city.", [["these decreasing functions L(D occ ) collapse", "PROBLEM", 29, 74], ["decreasing", "OBSERVATION_MODIFIER", 35, 45], ["collapse", "OBSERVATION", 66, 74]]], ["Following up on this observation, we explore further the relation between travel distance in optimal scenario L and the number of facilities N for diverse cities with various geographic constraints and population distributions.", [["this observation", "TEST", 16, 32]]], ["The toy cities have the same population of half million and are equal sized, consisting of 100 \u00d7 100 blocks.", [["equal", "OBSERVATION_MODIFIER", 64, 69], ["sized", "OBSERVATION_MODIFIER", 70, 75]]], ["The size of each block is set to 1 km 2 , and the travel cost between two blocks is calculated with the Euclidean distance between their centroids.", [["size", "OBSERVATION_MODIFIER", 4, 8]]], ["We measure the centrality of a city by computing the urban centrality index (UCI), proposed by Pereira et al. (54) , of the population distribution (Materials and Methods).", [["centrality", "OBSERVATION_MODIFIER", 15, 25], ["population", "OBSERVATION_MODIFIER", 124, 134], ["distribution", "OBSERVATION_MODIFIER", 135, 147]]], ["UCI ranges from 0 to 1, with 0 indicating the totally polycentric-with the population of the city uniformly distributed-and 1 indicating totally monocentric-with all the population residing in one block.", [["UCI ranges", "TEST", 0, 10], ["population", "OBSERVATION_MODIFIER", 75, 85], ["one block", "OBSERVATION", 193, 202]]], ["In addition, we include 12 real-world cities for further exploration, the six aforementioned to which we add: Paris, Barcelona, London, Dublin, Mexico City, and Melbourne.", [["further exploration", "TEST", 49, 68]]], ["Population distributions of four selected cities are illustrated in Fig. 5B .", [["5B", "GENE_OR_GENE_PRODUCT", 73, 75], ["four", "OBSERVATION_MODIFIER", 28, 32], ["Fig", "OBSERVATION_MODIFIER", 68, 71]]], ["Paris is the most monocentric, with a UCI of 0.50 and most residents residing in the urban region, while Melbourne is the most polycentric, with a UCI of 0.08 and residents dispersed over the city.", [["a UCI", "TEST", 36, 41], ["a UCI", "TEST", 145, 150], ["most monocentric", "OBSERVATION_MODIFIER", 13, 29]]], ["For an estimate of the optimal travel distance L in each city, we first assume that the in-block travel distance is constant l min = 0.5 km, and the average travel distance within a service community approximates to g j S \u221a _ a j,occ S , where g j S denotes the geometric factor in the community; a j,occ S denotes the area of the occupied blocks (17) .", [["g j S", "TEST", 216, 221], ["a j,occ S", "PROBLEM", 226, 235], ["g j S", "TEST", 244, 249], ["a j,occ S", "PROBLEM", 297, 306], ["occupied blocks", "OBSERVATION", 331, 346]]], ["Then, L is expressed as the sum of two terms, the first for the population in the N blocks with facilities and the second for the population in the N max -N blocks without facilitiesModeling accessibility to optimally distributed facilitieswhere P is the total population in the city, and ~ p j S denotes the population in the service community of the jth facility after removing the block where the jth facility is located, that is, ~ p j S = p j S \u2212 p j .", [["the N max -N blocks", "TREATMENT", 144, 163], ["the block", "TREATMENT", 380, 389]]], ["We find that a j,occ S follows power law relation to the total area in community a j S in most cities, that is, a j,occ S5A ).", [["j,occ S5A", "GENE_OR_GENE_PRODUCT", 114, 123], ["a j,occ S", "PROBLEM", 13, 22]]], ["We assume that g j S is constant in each city, written as g city , and a j S \u2248 \u00af a S = a \u0304 \u00b7 N max / N , with a \u0304 denoting the average block area in the city.", [["a j S", "TEST", 71, 76], ["a S", "TEST", 81, 84], ["g j S", "OBSERVATION_MODIFIER", 15, 20]]], ["3 asModeling accessibility to optimally distributed facilitieswhere p(N) denotes the share of population in blocks with facilities; A and \uf06c are both constant.", [["population", "OBSERVATION", 94, 104], ["constant", "OBSERVATION_MODIFIER", 149, 157]]], ["We further study how the share of population in blocks without facilities is related to the number of facilities N, and find that 1 \u2212 p(N) \u2248 e \u2212\uf061N when N \u226a N occ (see details in fig. S5B and notes S4.2 and S4.3).", [["N", "CHEMICAL", 136, 137], ["N", "CHEMICAL", 145, 146], ["N", "CHEMICAL", 152, 153], ["N", "CHEMICAL", 156, 157], ["S5B", "GENE_OR_GENE_PRODUCT", 183, 186], ["S5B", "PROTEIN", 183, 186], ["S4.3", "PROTEIN", 206, 210], ["further study", "TEST", 3, 16], ["S5B", "TEST", 183, 186]]], ["Thereby, we could model L as (5) where the number of facilities N is the main variable that determines L. While \uf061 controls the relation between p(N) and N, A and \uf06c are two free parameters to calibrate.", [["p(N)", "TREATMENT", 144, 148]]], ["The model of L(N) summarizes the fact that to model L, the only two essential ingredients are the number of facilities to allocate N and the distribution of population in space.", [["essential", "OBSERVATION_MODIFIER", 68, 77], ["ingredients", "OBSERVATION", 78, 89], ["distribution", "OBSERVATION_MODIFIER", 141, 153], ["population", "OBSERVATION", 157, 167]]], ["In Fig. 5C , we see that for the same N, the global travel costs in polycentric cities are larger than in the monocentric ones.", [["global", "OBSERVATION_MODIFIER", 45, 51], ["larger", "OBSERVATION_MODIFIER", 91, 97]]], ["The fitted L(N) values are shown with lines in Fig. 5 (C and D) .", [["The fitted L(N) values", "TREATMENT", 0, 22], ["lines in Fig.", "TREATMENT", 38, 51]]], ["Figure S7C confirms this, showing that A = 1.4443 \uf061 \u2212 \u00af \uf06c .", [["Figure S7C", "TEST", 0, 10], ["A", "TEST", 39, 40]]], ["5 as followsModeling accessibility to optimally distributed facilitiesThis function with only one free parameter \uf061 suggests that we are able to rescale N with \uf061 to collapse the curves of L in all cities into one, as shown in Fig. 5F that depicts Eq.", [["collapse", "OBSERVATION", 164, 172], ["L", "ANATOMY_MODIFIER", 187, 188]]], ["6 as solid line.", [["solid line", "ANATOMY", 5, 15], ["solid line", "CELL", 5, 15], ["solid line", "OBSERVATION", 5, 15]]], ["The same rescaling of N in toy cities is presented in Fig. 5E , where the collapse is not as good as in the real cities due to the divergent values of \uf06c of toy cities in table S2.", [["the collapse", "PROBLEM", 70, 82], ["collapse", "OBSERVATION", 74, 82], ["not as", "UNCERTAINTY", 86, 92], ["good", "OBSERVATION_MODIFIER", 93, 97], ["S2", "ANATOMY", 176, 178]]], ["Next, we go beyond the average distance L and plot the distribution of travel distances when keeping \uf061N fixed ( fig. S7, F and G) .", [["N", "CHEMICAL", 102, 103], ["S7", "PROTEIN", 117, 119], ["distribution", "OBSERVATION_MODIFIER", 55, 67]]], ["In all cases, the travel distance follows a gamma distribution.", [["gamma distribution", "OBSERVATION", 44, 62]]], ["This universality suggests that (i) given a certain \uf061N, all real-world cities can reach comparable accessibility; and (ii) the overall accessibility in the optimal scenario depends not only on the availability of the resources but also on the settlement of population, independently from the road network and total area of the city.Modeling accessibility to optimally distributed facilitiesEmpirically, the decay of population share in blocks without facilities \uf061 depends on the population distribution in space.", [["road network", "MULTI-TISSUE_STRUCTURE", 292, 304], ["total", "OBSERVATION_MODIFIER", 309, 314], ["area", "OBSERVATION_MODIFIER", 315, 319]]], ["Taking into account that unpopulated blocks are not ideal when optimizing accessibility, N occ is a better variable to express \uf061.", [["N occ", "PROTEIN", 89, 94], ["unpopulated blocks", "PROBLEM", 25, 43]]], ["Given that \uf061 = 1.833/N occ and the universal relation of L(\uf061N), we can explain the collapses found in Figs.", [["the collapses", "PROBLEM", 79, 92], ["collapses", "OBSERVATION", 83, 92]]], ["3C and 4 (C and D) .", [["3C", "TEST", 0, 2]]], ["As a concrete application of this universal model for optimal distance of facilities, in Eq.", [["this universal model", "TREATMENT", 29, 49]]], ["Figure 5H presents the estimated and simulated N versus L for two limiting cases, LA, in which the approximation agrees well with the simulation, and Barcelona, in which the approximation underestimates N. The results of other real-world cities are depicted in fig. S8 , showing in general a good agreement between the analytical approximation via the Lambert W function and the numerical simulations.DISCUSSIONAs cities differ in their form, economy, and population distribution, the interplay between population and facility distributions is challenging to plan.", [["LA", "CHEMICAL", 82, 84], ["the Lambert W function", "TREATMENT", 348, 370]]], ["The accessibility of facilities is constrained by their availability, the road network, and means of transportation.", [["road network", "MULTI-TISSUE_STRUCTURE", 74, 86]]], ["We present a framework that uses publicly available data to compare the optimal and the actual accessibility of various facility types at the resolution of urban blocks.", [["urban blocks", "TREATMENT", 156, 168]]], ["This allows us to efficiently pinpoint blocks that are underserved, i.e., those where people have to travel longer distances to reach the facilities they need compared to the social optimum.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["By relocating the facilities to optimize the global travel distance, we find that the relation between facility and population densities follows the scaling law, d \u221d \uf072 \uf062 only in the limit of few or limited number of facilities, regardless of the differences in road network structures.", [["road network structures", "MULTI-TISSUE_STRUCTURE", 261, 284]]], ["The observed exponent \uf062 is generally around 2/3 if the number of facilities is diluted or less than 10% of the occupied blocks, and it starts to decay for larger number of facilities.", [["exponent", "OBSERVATION_MODIFIER", 13, 21], ["\uf062", "OBSERVATION", 22, 23]]], ["We observe that the empirical conditions within cities do not follow the continuous approximation for the power law with population density because facilities are not equally planned, and the number of facilities is large in comparison with the number of populated blocks.DISCUSSIONTo gain further insights when the number of facilities is large, we analytically model the average travel distance L in the optimal scenario versus the number of facilities N and three parameters.", [["large", "OBSERVATION_MODIFIER", 216, 221], ["large", "OBSERVATION", 340, 345]]], ["This function can be applied to estimate the number of facilities needed to offer services to people within a given accessibility in average.", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100]]], ["When relating \uf061 to the urban form, we uncover that centralized cities require less facilities than polycentric cities to achieve the same levels of accessibility.", [["polycentric cities", "TREATMENT", 99, 117]]], ["Applications of this framework could be to optimally reallocate resources that provide emergency services, such as the placement of shelters, ambulances, or mobile petrol stations in the event of natural disasters.DISCUSSIONThe optimal planning of facilities in this work supposes that all residents equally need the resources, and the accessibility is measured from their places of residence.", [["emergency services", "TREATMENT", 87, 105], ["the placement of shelters", "TREATMENT", 115, 140]]], ["In reality, the socioeconomic segregation in cities results in heterogeneous needs for resources.", [["the socioeconomic segregation in cities", "PROBLEM", 12, 51], ["heterogeneous", "OBSERVATION_MODIFIER", 63, 76]]], ["On the other hand, people's needs are naturally dynamic and change in time and space owing to their time-varying mobility behavior.", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25]]], ["This became ever more evident when distributing the health care system resources during the outbreak of a pandemic, such as the COVID-19 in 2020.Population densityThe population with a spatial resolution of 30 arc sec (approximately 1 km 2 near the equator) of each city was obtained from the LandScan (38) in 2015.", [["Population density", "PROBLEM", 145, 163], ["density", "OBSERVATION", 156, 163], ["spatial", "OBSERVATION_MODIFIER", 185, 192], ["resolution", "OBSERVATION_MODIFIER", 193, 203]]], ["The average population density varies from 1431 per km 2 in Boston to 7175 per km 2 in NYC.Facility dataFacilities were crawled from Foursquare using their public application programming interfaces (APIs) in 2017 (40) .", [["average", "OBSERVATION_MODIFIER", 4, 11], ["population", "OBSERVATION_MODIFIER", 12, 22], ["density", "OBSERVATION", 23, 30], ["varies", "OBSERVATION_MODIFIER", 31, 37]]], ["The total number of facilities in the six cities is given in Table 1 .", [["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["The distributions of facility categories for each city are presented in fig. S1 .", [["S1", "GENE_OR_GENE_PRODUCT", 77, 79], ["S1", "PROTEIN", 77, 79]]], ["The United States cities generally have more dense facilities than the GCC cities.Road networksWe extract the road networks from OpenStreetMap (39) .", [["Road networks", "MULTI-TISSUE_STRUCTURE", 82, 95], ["road networks", "MULTI-TISSUE_STRUCTURE", 110, 123], ["OpenStreetMap", "TEST", 129, 142], ["more", "OBSERVATION_MODIFIER", 40, 44], ["dense", "OBSERVATION_MODIFIER", 45, 50]]], ["The road network is represented as a directed graph, in which edges indicate road segments and nodes indicate intersections.", [["road network", "MULTI-TISSUE_STRUCTURE", 4, 16], ["road segments", "OBSERVATION", 77, 90], ["nodes", "OBSERVATION", 95, 100]]], ["Each edge is associated with a weight representing its length.", [["edge", "OBSERVATION_MODIFIER", 5, 9], ["length", "OBSERVATION_MODIFIER", 55, 61]]], ["The travel distance between two blocks is computed by finding the shortest path between two randomly selected nodes in these blocks using the Dijkstra's algorithm (55) .Optimal distribution of facilities in spaceFinding the optimal locations of facilities to minimize the total travel cost is essentially an optimal placement problem in network theory, which is non-deterministic polynomial (NP) hard and known as p-median problem.", [["nodes", "ANATOMY", 110, 115], ["the Dijkstra's algorithm", "TEST", 138, 162], ["an optimal placement problem", "TREATMENT", 305, 333], ["nodes", "OBSERVATION", 110, 115], ["distribution", "OBSERVATION_MODIFIER", 177, 189], ["facilities", "OBSERVATION", 193, 203], ["space", "OBSERVATION", 207, 212]]], ["The problem in this work is formalized as follows: \"Given a set of blocks N max in a city, a set of residential blocks X \u2208 N max is with population, and each block in N max can only accommodate one facility.", [["residential blocks", "TREATMENT", 100, 118]]], ["The goal is to open N facilities in N max so as to minimize the sum of population-weighted travel distances from each residential block to its nearest open facility.\" (56) .Optimal distribution of facilities in spaceFor simplicity, the p-median problem is written as a linear programming problemOptimal distribution of facilities in spacewhere i and j are indices of the blocks; x i, j = 1 means that people living in block i are assigned to their nearest facility in block j, and i = j signifies that there is a facility located in residential block i; y j = 1 if there is a facility in block j, else y j = 0; N is the number of facilities to assign, and we assume that one block can only accommodate one facility of the same type; c i, j is the travel cost from block i to block j, which equals to the total routing distance of all population residing in block i.", [["people", "ORGANISM", 401, 407], ["people", "SPECIES", 401, 407], ["distribution", "OBSERVATION_MODIFIER", 181, 193], ["facilities", "OBSERVATION", 197, 207], ["space", "OBSERVATION", 211, 216]]], ["In this work, we solve the p-median problem with a fast algorithm based on swap-based local search procedure implemented by Resende and Werneck (51) .Urban centrality indexWe adopt the UCI proposed by Pereira et al. (54) to measure the centrality of the population distribution in cities.", [["a fast algorithm", "TEST", 49, 65], ["swap", "TEST", 75, 79], ["local search procedure", "TREATMENT", 86, 108], ["population", "OBSERVATION_MODIFIER", 254, 264], ["distribution", "OBSERVATION_MODIFIER", 265, 277]]], ["UCI is the product of two components, the location coefficient (LC) and the proximity index (PI).", [["UCI", "PROTEIN", 0, 3], ["two", "OBSERVATION_MODIFIER", 22, 25], ["components", "OBSERVATION_MODIFIER", 26, 36], ["coefficient", "OBSERVATION_MODIFIER", 51, 62]]], ["The former is introduced to measure the inhomogeneity of population distribution in space.", [["population", "OBSERVATION_MODIFIER", 57, 67], ["distribution", "OBSERVATION_MODIFIER", 68, 80]]], ["The calculation of LC and PI are as followsUrban centrality indexwhere V = \u2032 \u00d7 \u00d7 . is a vector of population fraction in block i, s i = p i /P, signifying the share of population in block i (p i ) of the total population of the city (P); is the distance matrix between blocks.", [["PI", "SIMPLE_CHEMICAL", 26, 28], ["matrix", "CELLULAR_COMPONENT", 254, 260], ["The calculation of LC and PI", "TEST", 0, 28], ["i /P", "TEST", 138, 142], ["LC", "ANATOMY", 19, 21], ["population", "OBSERVATION", 168, 178], ["total", "OBSERVATION_MODIFIER", 204, 209]]], ["V max is calculated by assuming that the total population are uniformly settling on the boundary of the city, which indicates an extreme sprawl.", [["the total population", "PROBLEM", 37, 57], ["an extreme sprawl", "PROBLEM", 126, 143], ["uniformly", "OBSERVATION_MODIFIER", 62, 71], ["settling", "OBSERVATION_MODIFIER", 72, 80], ["extreme", "OBSERVATION_MODIFIER", 129, 136], ["sprawl", "OBSERVATION", 137, 143]]], ["UCI ranges from 0 to 1.", [["UCI ranges", "TEST", 0, 10]]], ["Large UCI values indicate more centralized population distributions.", [["Large UCI values", "PROBLEM", 0, 16], ["UCI", "OBSERVATION", 6, 9], ["more", "OBSERVATION_MODIFIER", 26, 30], ["centralized", "OBSERVATION_MODIFIER", 31, 42], ["population distributions", "OBSERVATION", 43, 67]]]], "fcd581e05b5b194de8445db4773025877e06588d": [["50 % of the PM10 particulates in our inner cities.", [["PM10", "CHEMICAL", 12, 16], ["PM10", "CHEMICAL", 12, 16], ["inner", "ANATOMY_MODIFIER", 37, 42]]], ["This includes the dust stirred up by traffic and wear debris from tires and brakes.", [["debris", "PROBLEM", 54, 60], ["debris", "OBSERVATION", 54, 60]]], ["Because of the introduction of particulate filters for diesels and, since September 2017 (Euro 6d Temp), also for gasoline engines with direct injection, this source of emissions has been reduced once again by more than 90 %.", [["particulate filters", "TREATMENT", 31, 50], ["diesels", "PROBLEM", 55, 62], ["Temp", "TEST", 98, 102], ["gasoline engines", "TREATMENT", 114, 130], ["direct injection", "TREATMENT", 136, 152], ["reduced", "OBSERVATION_MODIFIER", 188, 195]]]], "72a45cd4a78dca24910667cf9fe00460ce8a2fa7": [["Introduction and Related Work5G networks are expected to bring a new disrupting ecosystem, prompting the creation of innovative next generation vertical applications.", [["innovative next generation vertical applications", "TREATMENT", 117, 165]]], ["To that end, one of the most awaited features is the provisioning and management of network slices tailored to the needs of each particular vertical industry and specific deployment.", [["network slices", "MULTI-TISSUE_STRUCTURE", 84, 98], ["management of network slices", "TREATMENT", 70, 98]]], ["In particular, Network Function Virtualization (NFV) is embraced as one of the key technologies that will allow the creation of customized network slices to meet different service requirements.Introduction and Related WorkThe public safety sector will be one of the major beneficiaries of this technological development.", [["network slices", "MULTI-TISSUE_STRUCTURE", 139, 153], ["customized network slices", "TREATMENT", 128, 153]]], ["Traditional mission critical applications expose tight QoS requirements, which find difficulties to be fulfilled by traditional network models.", [["Traditional mission critical applications", "TREATMENT", 0, 41]]], ["But now, network slicing through proper resource orchestration is making the network sharing model a reality.Introduction and Related WorkThe concept of network slicing was introduced by the Next Generation Mobile Network (NGMN) alliance within its whitepaper [8] .", [["network", "MULTI-TISSUE_STRUCTURE", 153, 160], ["network slicing", "TREATMENT", 153, 168], ["the Next Generation Mobile Network (NGMN)", "TREATMENT", 187, 228], ["network slicing", "OBSERVATION", 153, 168]]], ["Later, the 3GPP took the responsability of standardising this technology, defining the entities and the functionality required to manage network slicing [2] .", [["standardising this technology", "TREATMENT", 43, 72]]], ["Current NFV standards [5] define the interaction between the network slice management functions defined by the 3GPP and the NFV Management and Orchestration (MANO) module, establishing the required connection between the network controllers and the NFV orchestration unit in order to perform the dynamic assignment of network resources.Introduction and Related WorkHowever, the implementation of the concept of orchestrating a service slice within this standardized network architecture is still in a development phase.", [["NFV", "CHEMICAL", 8, 11], ["NFV", "CHEMICAL", 124, 127], ["network slice", "MULTI-TISSUE_STRUCTURE", 61, 74], ["network", "MULTI-TISSUE_STRUCTURE", 318, 325], ["network architecture", "MULTI-TISSUE_STRUCTURE", 466, 486], ["3GPP", "PROTEIN", 111, 115], ["Current NFV standards", "TREATMENT", 0, 21], ["the NFV Management", "TREATMENT", 120, 138], ["Orchestration (MANO) module", "TREATMENT", 143, 170], ["the network controllers", "TREATMENT", 217, 240], ["the NFV orchestration unit", "TREATMENT", 245, 271]]], ["In this sense, there are some independent initiatives as [3, 6, 7, 9] that are contributing to the creation of modules that complement the current MANO capabilities in order to orchestrate E2E slices.Introduction and Related WorkIn this paper, we present an NFV-based intelligent orchestration cycle with the capability of providing a set of shared resources to deal with the dynamic reconfiguration challenge.", [["E2E slices", "ANATOMY", 189, 199], ["NFV", "CHEMICAL", 258, 261], ["NFV", "SIMPLE_CHEMICAL", 258, 261], ["MANO", "PROTEIN", 147, 151], ["E2E", "PROTEIN", 189, 192]]], ["This feature is of utmost importance in mission critical applications where sudden events can instantly alter the network requirements and priorities.", [["sudden events", "PROBLEM", 76, 89]]], ["2 describes the orchestration cycle defined to dynamically adjust the end-to-end network slices in a NFV-based deployment.", [["NFV", "CHEMICAL", 101, 104], ["NFV", "CHEMICAL", 101, 104], ["network slices", "MULTI-TISSUE_STRUCTURE", 81, 95], ["NFV", "SIMPLE_CHEMICAL", 101, 104], ["a NFV-based deployment", "TREATMENT", 99, 121]]], ["4 summarizes the main contributions and poses new research challenges that will be addressed in the future.NFV-Based Intelligent Orchestration CycleNFV comes up driven by the telecommunications industry in order to enhance the deployment flexibility, foster the integration of new services within operators and also attain CAPEX/OPEX drawdowns.NFV-Based Intelligent Orchestration CycleHowever, the dynamic allocation of resources to separated and customised network slices still remains a challenge.", [["network slices", "ANATOMY", 458, 472], ["NFV", "CHEMICAL", 107, 110], ["NFV", "CHEMICAL", 344, 347], ["NFV", "CHEMICAL", 107, 110], ["NFV", "CHEMICAL", 344, 347], ["NFV", "SIMPLE_CHEMICAL", 107, 110], ["NFV", "SIMPLE_CHEMICAL", 344, 347], ["network slices", "MULTI-TISSUE_STRUCTURE", 458, 472], ["CAPEX", "PROTEIN", 323, 328], ["new research challenges", "TREATMENT", 46, 69], ["NFV", "TREATMENT", 107, 110], ["NFV", "TREATMENT", 344, 347], ["main", "OBSERVATION_MODIFIER", 17, 21]]], ["This section describes a novel orchestration cycle providing new tools for automated E2E network slicing.", [["E2E network", "MULTI-TISSUE_STRUCTURE", 85, 96], ["automated E2E network slicing", "TREATMENT", 75, 104]]], ["The proposed orchestration cycle involves the monitoring system, the alert mitigation module and the execution of the mitigation actions.Network ArchitectureThe 5G ESSENCE approach, depicted in Fig. 1 , takes the existing 5G architectures as a reference point, combining the 3GPP framework for network management in Radio Access Network (RAN) sharing scenarios and the ETSI NFV framework for managing virtualised network functions.", [["the monitoring system", "TEST", 42, 63], ["the mitigation actions", "TREATMENT", 114, 136], ["the existing 5G architectures", "TREATMENT", 209, 238], ["the 3GPP framework", "TREATMENT", 271, 289], ["network management", "TREATMENT", 294, 312], ["the ETSI NFV framework", "TREATMENT", 365, 387], ["orchestration cycle", "OBSERVATION", 13, 32]]], ["Our architecture allows multiple network operators (tenants) to provide services to their users through a set of Cloud-enabled Small Cells (CESCs) deployed, owned and managed by a third party (i.e., the CESC provider).", [["Cells", "ANATOMY", 133, 138], ["Small Cells", "CELL", 127, 138], ["Cloud-enabled Small Cells", "CELL_LINE", 113, 138], ["Cloud-enabled Small Cells (CESCs)", "TREATMENT", 113, 146], ["multiple", "OBSERVATION_MODIFIER", 24, 32], ["Small Cells", "OBSERVATION", 127, 138]]], ["The CESC offers virtualised environment with computing, storage and radio resources at the edge of the mobile network.", [["mobile network", "MULTI-TISSUE_STRUCTURE", 103, 117]]], ["This cloud can also be 'sliced' to enable multi-tenancy.Network ArchitectureBesides, the two-tier architecture of 5G ESSENCE is well aligned with the 5G architecture described by 5G-PPP, where the infrastructure programmability is identified as one key design paradigm for 5G.", [["5G ESSENCE", "DNA", 114, 124], ["PPP", "PROTEIN", 182, 185], ["Network ArchitectureBesides", "TEST", 56, 83]]], ["First, 5G ESSENCE achieves infrastructure programmability by leveraging the virtualised computation resources available in an Edge Datacenter (Edge DC).", [["DC", "ANATOMY", 148, 150], ["Edge DC", "CELL_LINE", 143, 150]]], ["These resources are used for hosting VNFs tailored according to the needs of each tenant, on a per-slice basis.", [["hosting VNFs", "TREATMENT", 29, 41]]], ["Second, the Main Datacenter (Main DC) allows centralising and softwarising the control plane of small cell functions to enable a more efficient utilisation of the radio resources coordinated among multiple CESCs.Network ArchitectureWe propose to enhance the orchestration functionalities adding more intelligence into the CESC Manager (CESCM) together with the NFV Orchestrator (NFVO).", [["cell", "ANATOMY", 102, 106], ["CESCs", "ANATOMY", 206, 211], ["NFV", "CHEMICAL", 361, 364], ["cell", "CELL", 102, 106], ["CESCs", "CANCER", 206, 211], ["Main Datacenter", "PROTEIN", 12, 27], ["Main DC", "CELL_LINE", 29, 36], ["CESCs", "CELL_TYPE", 206, 211], ["centralising", "TREATMENT", 45, 57], ["small cell functions", "PROBLEM", 96, 116], ["the radio resources", "TREATMENT", 159, 178], ["multiple CESCs", "TREATMENT", 197, 211], ["the NFV Orchestrator (NFVO", "TREATMENT", 357, 383], ["Main", "OBSERVATION_MODIFIER", 12, 16], ["small cell functions", "OBSERVATION", 96, 116]]], ["In particular, 5G ESSENCE provides a network monitoring and alert mitigation mechanism that supports and improves both the NFVO and RAN controlling functions.", [["RAN", "GENE_OR_GENE_PRODUCT", 132, 135], ["5G ESSENCE", "PROTEIN", 15, 25], ["a network monitoring", "TEST", 35, 55]]], ["The event flow for the management of end-to-end slicing for a Mission-critical Push-to-talk (MCPTT) service is depicted in Fig. 2 , and each component is further described in the following sections.System and Service Monitoring and Alert MitigationThe main objective of the Monitoring and Alert Mitigation system shown in Fig. 3 is to access the available information about the network elements and process it in order to conclude if and when a network reconfiguration is needed.", [["sections", "ANATOMY", 189, 197], ["network elements", "DNA", 378, 394], ["the Monitoring", "TEST", 270, 284], ["component", "OBSERVATION_MODIFIER", 141, 150], ["main", "OBSERVATION_MODIFIER", 252, 256]]], ["The orchestration cycle begins with the collection of the monitored data through the exporters in each monitoring-enabled building block.", [["The orchestration cycle", "TREATMENT", 0, 23]]], ["The monitored data is stored in Prometheus, which is on charge of triggering the alerts as defined according to the different services and their Service Level Agreement (SLA).", [["The monitored data", "TEST", 0, 18]]], ["These alerts are defined to notify about an unexpected behaviour in the system and SLA violations.System and Service Monitoring and Alert MitigationIt must be also noted that the monitoring of the Wi-Fi RAN controller relies on the federation of the Prometheus server installed in the component.", [["the monitoring", "TEST", 175, 189], ["the Prometheus server", "TREATMENT", 246, 267], ["component", "OBSERVATION_MODIFIER", 285, 294]]], ["The main idea for using Federation is to have a decentralised system in order to monitor the Wi-Fi RAN metrics through another Prometheus for other tasks.", [["a decentralised system", "TREATMENT", 46, 68]]], ["The alerts raised are picked by the Alert Mitigation Module (AMM), which is part of the Management Monitoring Gateway.", [["the Management", "TREATMENT", 84, 98]]], ["The purpose of AMM is to manage the configuration of the architectural components responsible of the behavior of the E2E slice.", [["E2E slice", "ANATOMY", 117, 126], ["architectural components", "OBSERVATION", 57, 81]]], ["To that aim, AMM contains the mitigation logic based on a ponderation of the rules defined in the Rulebook.", [["the mitigation logic", "TREATMENT", 26, 46]]], ["When an alert is triggered, AMM differences between different severity levels.", [["AMM differences between different severity levels", "PROBLEM", 28, 77]]], ["For warning severities, the Mitigation module saves the alert in a time window, which is configured by the Rulebook (Fig. 4) .", [["warning severities", "PROBLEM", 4, 22]]], ["If the sum of the ponderations in the mitigation queue exceeds the mitigation ponderation, configured in the Rulebook, a mitigation action composed with all the warning severity alerts is triggered, emptying the mitigation queue and silencing the alert.System and Service Monitoring and Alert MitigationFinally, within the scope of this paper, we have defined two endpoints to forward the mitigation actions and close the monitoring and mitigation loop: the NFVO orchestrator to manage the scaling options of the Network Service, and Wi-Fi RAN controller to manage the resources used by the Wi-Fi slice.", [["the mitigation actions", "TREATMENT", 385, 407], ["the monitoring", "TEST", 418, 432], ["the NFVO orchestrator", "TREATMENT", 454, 475]]], ["These two blocks are further described in the next sections.MCPTT Service ArchitectureMission Critical Push-To-Talk (MCPTT) is a mission critical communication standard that allows half duplex one-to-many and one-to-one voice services in order to coordinate emergency teams.", [["sections", "ANATOMY", 51, 59]]], ["As it appears, the management of this type of half-duplex communication is not trivial, since it requires an appropriate management of priorities and privileges to allow communication.", [["an appropriate management", "TREATMENT", 106, 131]]], ["This service is defined in multiple Virtual Deployment Units (VDU) to optimise the usage of the resources: a DNS server, an IMS (IP Multimedia Subsystem) service for session management, a CSC (Common Service Core) for service status information, and the MCPTT AS (Application Server) providing centralised support for MCPTT services and call control.", [["centralised support", "TREATMENT", 294, 313], ["MCPTT services", "TREATMENT", 318, 332]]], ["Figure 5 depicts the deployment of the described MCPTT network architecture.MCPTT Service ArchitectureIn order to integrate the described MCPTT network service within the orchestration cycle detailed above, we must include a tailored exporter to extract the required metrics for the monitoring tasks.", [["MCPTT network", "MULTI-TISSUE_STRUCTURE", 49, 62], ["MCPTT network", "MULTI-TISSUE_STRUCTURE", 138, 151], ["the monitoring tasks", "TEST", 279, 299]]], ["It appears as mcptt exporter in Fig. 5 .", [["mcptt", "GENE_OR_GENE_PRODUCT", 14, 19], ["mcptt exporter", "PROTEIN", 14, 28]]], ["This component is responsible for collecting the metrics from the MCPTT service to later expose them for the analysis in the monitoring system.", [["the analysis", "TEST", 105, 117]]], ["It is implemented as a REST API: when the mcptt exporter receives a status request from the Prometheus in the Monitoring module, it queries the involved components of the NS (mainly IMS and MCPTT AS ) to gather the metrics and format them properly.", [["mcptt", "GENE_OR_GENE_PRODUCT", 42, 47], ["mcptt exporter", "PROTEIN", 42, 56], ["the NS", "TREATMENT", 167, 173]]], ["The Controller Manager is the core of RACOON.", [["RACOON", "DNA", 38, 44]]], ["It is in charge of Open-DayLight SDN controller, Open vSwitch database server and the Netconf Manager by means of the different implemented clients (REST APIs) and controls the CESCs according to the deployed slices and services.", [["Open-DayLight SDN controller", "TREATMENT", 19, 47], ["REST APIs", "TREATMENT", 149, 158], ["the CESCs", "TREATMENT", 173, 182]]], ["It also gathers telemetry from the Wi-Fi RAN by means of its Prometheus server.", [["Wi-Fi RAN", "DNA", 35, 44], ["telemetry", "TEST", 16, 25]]], ["Moreover, through its REST API, the RAN Controller exposes the management of the infrastructure and the slices to the CESCM.RAN Controller ArchitectureThe Global Scheduler Controller manages the weights/quotas of the instantiated slices in the Wi-Fi RAN.", [["slices", "ANATOMY", 230, 236], ["the management", "TREATMENT", 59, 73], ["infrastructure", "OBSERVATION", 81, 95], ["Global", "OBSERVATION_MODIFIER", 155, 161]]], ["It allows enabling, modifying and disabling the local schedulers of the different Wi-Fi CESCs, which locally manage the percentage of airtime or channel time assigned to each slice.", [["Wi-Fi CESCs", "CELL_LINE", 82, 93], ["the different Wi-Fi CESCs", "TREATMENT", 68, 93]]], ["It implements a REST API to allow its control via the CESCM.RAN Controller ArchitectureFinally, the Wi-Fi CESC is composed by Single Board Computers (SBCs) with a Linux distribution.", [["CESCM", "DNA", 54, 59], ["Wi-Fi CESC", "DNA", 100, 110], ["a REST API", "TREATMENT", 14, 24]]], ["The main software used in order to deploy Wi-Fi connectivity is Hostapd, which has been modified in order to deploy, monitor and control multiple virtual Access Points (vAPs) on top of a single physical interface, according to the desired Wi-Fi slices.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["By means of these modifications, the Local Scheduler is able to manage the MAC-scheduler which controls the airtime or channel time assigned to each slice (which is then fairly distributed among all the user terminals of each slice).", [["the MAC-scheduler", "TREATMENT", 71, 88]]], ["Also, it hosts a Prometheus Exporter (Hostapd Exporter 1 ) in order to gather RAN telemetry.Orchestration Cycle for MCPTT DeploymentsThis section shows the results of the integration of the described enhanced orchestration tools developed within the 5G ESSENCE project to deploy a MCPTT service slice.", [["RAN", "GENE_OR_GENE_PRODUCT", 78, 81], ["a MCPTT service slice", "TREATMENT", 279, 300]]], ["Then, we describe the validation scenario and show the results of the complete deployment.Monitoring Metrics and Mitigation Action DefinitionThe monitoring system collects network status information from network elements at different levels: NFVI through node exporter, MCPTT service through a tailored exporter and RACOON cSD-RAN controller through Prometheus federation.", [["network elements", "MULTI-TISSUE_STRUCTURE", 204, 220], ["node", "MULTI-TISSUE_STRUCTURE", 255, 259], ["network elements", "DNA", 204, 220], ["cSD", "PROTEIN", 323, 326], ["The monitoring system", "TEST", 141, 162], ["RACOON cSD", "TREATMENT", 316, 326]]], ["The information collected from the NFVI that is involved in this experiment includes CPU, memory and disk usages, VM port throughput and availability of VMs (if they are up).", [["VM port", "TREATMENT", 114, 121], ["VMs", "PROBLEM", 153, 156]]], ["Finally, the system collects information from RACOON about the number of users per slice per cell, transmitted bit rate and quality of the signal.", [["cell", "ANATOMY", 93, 97], ["cell", "CELL", 93, 97], ["transmitted bit rate", "TEST", 99, 119]]], ["For each identified metric, the measurement framework and the alarms it can trigger is included.", [["the measurement framework", "TEST", 28, 53]]], ["Two alarm thresholds are defined.", [["Two alarm thresholds", "TEST", 0, 20], ["alarm thresholds", "OBSERVATION", 4, 20]]], ["The first alarm threshold provides a warning, whereas the second threshold is considered a critical situation.Scenario Definition and Deployment ResultsThe demonstration of the dynamically orchestrated MCPTT deployment cannot be based on a static scenario, since one of its objectives to be proven is the elastic allocation of resources attending to different levels of emergency conditions detected by the monitoring system.", [["the dynamically orchestrated MCPTT deployment", "TREATMENT", 173, 218], ["a static scenario", "TEST", 238, 255], ["emergency conditions", "TREATMENT", 370, 390], ["the monitoring system", "TEST", 403, 424], ["MCPTT deployment", "OBSERVATION", 202, 218]]], ["We propose a deployment topology in three main stages.", [["a deployment topology", "TREATMENT", 11, 32]]], ["Under normal circumstances, the system instantiates the network slices that correspond to a default service agreement.", [["network slices", "MULTI-TISSUE_STRUCTURE", 56, 70], ["normal circumstances", "OBSERVATION", 6, 26]]], ["Here, the first responder only needs a reduced amount of access capacity and communication features for its normal operations.", [["a reduced amount of access capacity", "PROBLEM", 37, 72]]], ["Then, triggered by an emergency incident that is detected through a private emergency call, the first responder requires increased capacity in terms of edge computing resources, in order to serve a higher number of incoming communications and/or public safety users.", [["increased capacity", "PROBLEM", 121, 139], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["capacity", "OBSERVATION_MODIFIER", 131, 139]]], ["This implies the scaling of the MCPTT VNF and it may involve a deterioration of the service for legacy users, since their network slice(s) must be reduced in order to appropriately allocate the higher priority MCPTT service.", [["network slice", "MULTI-TISSUE_STRUCTURE", 122, 135], ["the MCPTT VNF", "TREATMENT", 28, 41]]], ["Finally, in the third stage triggered by a group emergency call, the system responds with an expansion of the MCPTT radio slice up to the 75% of the available bandwidth in the cell where the emergency events are happening (detected by the increasing number of users in the cell).", [["cell", "ANATOMY", 176, 180], ["cell", "ANATOMY", 273, 277], ["cell", "CELL", 176, 180], ["cell", "CELL", 273, 277]]], ["Again, this situation may involve an impairment of the service provided to civilians in favor of the communications for first responders, which require higher priority.", [["impairment", "OBSERVATION", 37, 47]]], ["Figure 7 shows some screenshots that illustrate the operation of the orchestration process.", [["some screenshots", "PROBLEM", 15, 31], ["the operation", "TREATMENT", 48, 61], ["the orchestration process", "TREATMENT", 65, 90], ["orchestration process", "OBSERVATION", 69, 90]]], ["The upper screen shows the monitoring of MCPTT calls during the experiment.", [["The upper screen", "TEST", 0, 16], ["MCPTT calls", "TREATMENT", 41, 52], ["upper", "ANATOMY_MODIFIER", 4, 9]]], ["It can be observed how the different events are detected over time.Scenario Definition and Deployment ResultsThe screenshot in the middle shows the result of an alert mitigation action in the second stage that leads to the MCPTT VNF scale.", [["the MCPTT VNF scale", "TREATMENT", 219, 238], ["middle", "ANATOMY_MODIFIER", 131, 137]]], ["Finally, the lower screenshot shows the reconfiguration of the radio slice as a result of the mitigation action in the third stage.Conclusions and Future WorkThis paper has described the intelligent orchestration cycle that proves that the 5G ESSENCE context provides a solution for an efficient and elastic E2E network slicing and the efficient orchestration of the radio and cloud resources.", [["a solution", "TREATMENT", 268, 278], ["an efficient and elastic E2E network slicing", "TREATMENT", 283, 327], ["lower", "ANATOMY_MODIFIER", 13, 18]]], ["The elastic allocation of resources is performed automatically, leveraging the monitoring and alert mitigation functionalities that complement the orchestration processes in the CESCM.Conclusions and Future WorkOur research work will continue to further develop orchestration tools to enhance the E2E slicing capabilities of NFV environments.", [["NFV", "CHEMICAL", 325, 328], ["NFV", "CHEMICAL", 325, 328], ["NFV", "SIMPLE_CHEMICAL", 325, 328], ["the monitoring", "TEST", 75, 89], ["alert mitigation functionalities", "TREATMENT", 94, 126], ["elastic", "OBSERVATION_MODIFIER", 4, 11]]], ["New research trends include the use of machine learning techniques in the decision-making process, the migration and placement of VNFs and the analysis of the possibilities of multi-RAT access.", [["machine learning techniques", "TREATMENT", 39, 66], ["the migration", "TREATMENT", 99, 112], ["placement of VNFs", "TREATMENT", 117, 134], ["the analysis", "TEST", 139, 151], ["multi-RAT access", "TREATMENT", 176, 192]]]], "PMC7206352": [], "335b0a3f21f764adcbe20ff71e422d823c410098": [["IntroductionSeveral high-mortality disease outbreaks among carnivore populations have demonstrated the potential for pathogen-induced population declines [1] [2] [3] [4] [5] [6] and have emphasized the role of infectious disease in carnivore conservation [7, 8] .", [["infectious disease", "DISEASE", 210, 228], ["[1] [2] [3] [4] [5", "SIMPLE_CHEMICAL", 154, 172], ["IntroductionSeveral high-mortality disease outbreaks", "PROBLEM", 0, 52], ["pathogen", "PROBLEM", 117, 125], ["infectious disease", "PROBLEM", 210, 228], ["infectious", "OBSERVATION", 210, 220]]], ["These outbreaks have underscored both the need for better baseline data on disease prevalence, and a better understanding of the ecology of disease in wild populations [7, 9] .IntroductionYellowstone National Park (YNP) is home to one of the largest, protected, intact suites of carnivores in the contiguous United States.", [["disease", "PROBLEM", 140, 147], ["largest", "OBSERVATION_MODIFIER", 242, 249]]], ["Gray wolves (Canis lupus) were reintroduced into the Yellowstone Ecosystem after a .", [["lupus", "DISEASE", 19, 24], ["Gray wolves", "ORGANISM", 0, 11], ["Canis lupus", "ORGANISM", 13, 24], ["Canis lupus", "SPECIES", 13, 24], ["Canis lupus", "SPECIES", 13, 24], ["Gray wolves", "TEST", 0, 11], ["Canis lupus", "OBSERVATION", 13, 24], ["Yellowstone Ecosystem", "OBSERVATION", 53, 74]]], ["In 1999 and 2005, pup survival was significantly reduced, suggestive of a disease outbreak [12] .IntroductionThus we sought to use long-term serological data to identify temporal, spatial, and demographic patterns of pathogen exposure among wolves, coyotes (Canis latrans), and foxes (Vulpes vulpes) in YNP.", [["pup", "ANATOMY", 18, 21], ["pup", "ORGAN", 18, 21], ["Canis latrans", "ORGANISM", 258, 271], ["Vulpes vulpes", "ORGANISM", 285, 298], ["Canis latrans", "SPECIES", 258, 271], ["Vulpes vulpes", "SPECIES", 285, 298], ["Canis latrans", "SPECIES", 258, 271], ["Vulpes vulpes", "SPECIES", 285, 298], ["a disease outbreak", "PROBLEM", 72, 90], ["long-term serological data", "TEST", 131, 157], ["pathogen exposure", "PROBLEM", 217, 234], ["suggestive of", "UNCERTAINTY", 58, 71], ["disease", "OBSERVATION", 74, 81]]], ["We screened for exposure to canine parvovirus (CPV), canine adenovirus type-1 (CAV-1), canine distemper virus (CDV), and canine herpesvirus (CHV), all of which can inflict morbidity and mortality in canids (Table S1 ) [13] [14] [15] [16] [17] [18] [19] .", [["canine parvovirus", "DISEASE", 28, 45], ["canine distemper virus", "DISEASE", 87, 109], ["canine herpesvirus (CHV", "DISEASE", 121, 144], ["canine parvovirus", "ORGANISM", 28, 45], ["CPV", "ORGANISM", 47, 50], ["canine adenovirus type-1", "ORGANISM", 53, 77], ["CAV-1", "ORGANISM", 79, 84], ["canine distemper virus", "ORGANISM", 87, 109], ["CDV", "ORGANISM", 111, 114], ["canine herpesvirus", "ORGANISM", 121, 139], ["CHV", "CANCER", 141, 144], ["[13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 218, 252], ["canine parvovirus", "SPECIES", 28, 45], ["canine adenovirus type-1", "SPECIES", 53, 77], ["CAV-1", "SPECIES", 79, 84], ["canine distemper virus", "SPECIES", 87, 109], ["canine herpesvirus", "SPECIES", 121, 139], ["canine parvovirus", "SPECIES", 28, 45], ["CPV", "SPECIES", 47, 50], ["canine adenovirus type-1", "SPECIES", 53, 77], ["CAV-1", "SPECIES", 79, 84], ["canine distemper virus", "SPECIES", 87, 109], ["CDV", "SPECIES", 111, 114], ["canine herpesvirus", "SPECIES", 121, 139], ["CHV", "SPECIES", 141, 144], ["canine parvovirus", "PROBLEM", 28, 45], ["CPV", "TEST", 47, 50], ["canine adenovirus type", "TEST", 53, 75], ["CAV", "TEST", 79, 82], ["canine distemper virus", "PROBLEM", 87, 109], ["canine herpesvirus", "PROBLEM", 121, 139], ["distemper virus", "OBSERVATION", 94, 109], ["canine herpesvirus", "ANATOMY", 121, 139]]], ["In wolves, we also screened for exposure to Neospora caninum, a protozoan parasite whose life cycle includes canids, the definitive hosts where sexual reproduction takes place, and ungulates, the intermediate hosts [20, 21] .", [["Neospora caninum", "DISEASE", 44, 60], ["protozoan parasite", "DISEASE", 64, 82], ["Neospora caninum", "ORGANISM", 44, 60], ["Neospora caninum", "SPECIES", 44, 60], ["Neospora caninum", "SPECIES", 44, 60], ["Neospora caninum", "TREATMENT", 44, 60], ["a protozoan parasite", "TREATMENT", 62, 82]]], ["N. caninum is transmitted between canids and ungulates when a canid consumes infected ungulate tissue.", [["tissue", "ANATOMY", 95, 101], ["N. caninum", "ORGANISM", 0, 10], ["ungulate tissue", "TISSUE", 86, 101], ["N. caninum", "SPECIES", 0, 10], ["N. caninum", "SPECIES", 0, 10], ["infected ungulate tissue", "PROBLEM", 77, 101], ["caninum", "OBSERVATION", 3, 10], ["infected", "OBSERVATION", 77, 85], ["ungulate tissue", "OBSERVATION", 86, 101]]], ["N. caninum reproduces in the canid's intestines, and oocysts are shed in feces and then consumed by ungulates through contaminated forage and water.", [["canid", "ANATOMY", 29, 34], ["intestines", "ANATOMY", 37, 47], ["oocysts", "ANATOMY", 53, 60], ["feces", "ANATOMY", 73, 78], ["N. caninum", "ORGANISM", 0, 10], ["intestines", "ORGAN", 37, 47], ["oocysts", "ORGANISM_SUBSTANCE", 53, 60], ["feces", "ORGANISM_SUBSTANCE", 73, 78], ["N. caninum", "SPECIES", 0, 10], ["N. caninum", "SPECIES", 0, 10], ["oocysts", "PROBLEM", 53, 60], ["caninum", "OBSERVATION", 3, 10], ["intestines", "ANATOMY", 37, 47], ["oocysts", "OBSERVATION", 53, 60]]], ["N. caninum infection can cause high rates of abortion in cattle, and thus is a pathogen of special interest to the local ranching community.IntroductionWe assessed whether each of the pathogens of interest were enzootic or epizootic in the YNP canid community, and whether pathogen exposure varied by region of the park in relation to canid density.", [["N. caninum infection", "DISEASE", 0, 20], ["abortion", "DISEASE", 45, 53], ["N. caninum", "ORGANISM", 0, 10], ["cattle", "ORGANISM", 57, 63], ["N. caninum", "SPECIES", 0, 10], ["cattle", "SPECIES", 57, 63], ["N. caninum", "SPECIES", 0, 10], ["cattle", "SPECIES", 57, 63], ["N. caninum infection", "PROBLEM", 0, 20], ["IntroductionWe", "TREATMENT", 140, 154], ["enzootic", "PROBLEM", 211, 219], ["pathogen exposure", "PROBLEM", 273, 290], ["caninum infection", "OBSERVATION", 3, 20], ["canid", "ANATOMY", 335, 340], ["density", "OBSERVATION", 341, 348]]], ["We investigated if behavioral differences between resident and transient coyotes, the latter potentially interacting with many more individuals across many different packs, and thus potentially at greater risk for pathogen exposure, contributed to differences in exposure risk.", [["pathogen exposure", "PROBLEM", 214, 231]]], ["Host age was used primarily to examine temporal patterns of exposure, but it was also evaluated as a risk factor for recent or current infection with CHV and N. caninum.IntroductionSurvival data were not available for coyotes or foxes.", [["infection", "DISEASE", 135, 144], ["N. caninum", "DISEASE", 158, 168], ["N. caninum", "ORGANISM", 158, 168], ["N. caninum", "SPECIES", 158, 168], ["CHV", "SPECIES", 150, 153], ["N. caninum", "SPECIES", 158, 168], ["a risk factor", "PROBLEM", 99, 112], ["current infection", "PROBLEM", 127, 144], ["CHV", "TREATMENT", 150, 153], ["IntroductionSurvival data", "TEST", 169, 194], ["infection", "OBSERVATION", 135, 144], ["caninum", "OBSERVATION", 161, 168]]], ["However, we did examine the relationship between pathogen exposure and wolf-pup survival.", [["pup", "ORGANISM_SUBDIVISION", 76, 79]]], ["Furthermore, we used comparisons of exposure patterns among the canids to assess the likelihood of single versus multi-host pathogen transmission within YNP.Ethics statementAll wolves, coyotes, and foxes used in this study were handled in strict accordance with recommendations from the American Society of Mammalogists [22, 23] , and all animal work was approved by a National Park Service veterinarian, a YNP review committee, and by the YNP superintendent.Study areaYNP encompasses 8,991-km 2 of protected land in northwestern Wyoming and adjacent parts of Montana and Idaho in the western United States (44u339 N, 110u309 W).", [["YNP", "CANCER", 153, 156], ["exposure patterns", "TEST", 36, 53], ["this study", "TEST", 212, 222], ["host", "OBSERVATION_MODIFIER", 119, 123], ["pathogen", "OBSERVATION", 124, 132]]], ["YNP is surrounded by the Greater Yellowstone Ecosystem (GYE), a 60,000-km 2 area that includes Yellowstone and Grand Teton National Parks, national forests, wildlife refuges, and a mosaic of state and private lands.", [["Greater", "OBSERVATION_MODIFIER", 25, 32], ["Yellowstone Ecosystem", "OBSERVATION", 33, 54], ["Yellowstone", "OBSERVATION", 95, 106]]], ["YNP is mountainous (elevation range: 1,500 to 3,800 m), and its steep gradients in elevation, soil, and climate contribute to varied land cover, including riparian vegetation, shrubland, grassland, alpine meadows, and mixed coniferous forests.Study areaWe divided the park into two units, the Northern Range (NR) and the Interior, based on ecological and physiographical differences [24] .", [["YNP", "CHEMICAL", 0, 3], ["its steep gradients in elevation", "PROBLEM", 60, 92], ["varied land cover", "PROBLEM", 126, 143], ["riparian vegetation", "PROBLEM", 155, 174], ["alpine meadows", "TREATMENT", 198, 212], ["mixed coniferous forests", "TREATMENT", 218, 242], ["Study areaWe", "TEST", 243, 255], ["mountainous", "OBSERVATION_MODIFIER", 7, 18], ["steep", "OBSERVATION_MODIFIER", 64, 69], ["gradients", "OBSERVATION_MODIFIER", 70, 79], ["elevation", "OBSERVATION_MODIFIER", 83, 92], ["riparian vegetation", "OBSERVATION", 155, 174], ["alpine meadows", "OBSERVATION", 198, 212], ["coniferous forests", "OBSERVATION", 224, 242], ["Interior", "OBSERVATION_MODIFIER", 321, 329]]], ["The 1,000-km 2 area of the NR within YNP is characterized by lower elevations (1,500-2,200 m), serves as prime wintering habitat for the park's ungulates [25] , and supports a higher density of wolves than the Interior (20-99 wolves/1000 km 2 versus 2-11 wolves/1000 km 2 [26] ; minimum population count for entire YNP ranged between 118 and 172 wolves between 2000 and 2007 [27] ).", [["lower elevations", "PROBLEM", 61, 77], ["minimum population count", "TEST", 279, 303], ["entire YNP", "TEST", 308, 318], ["NR", "OBSERVATION", 27, 29], ["lower", "OBSERVATION_MODIFIER", 61, 66], ["elevations", "OBSERVATION_MODIFIER", 67, 77], ["higher density", "OBSERVATION_MODIFIER", 176, 190]]], ["The Interior of the park (7,991 km 2 ) is higher in elevation (.2,500 m), receives higher annual snowfall, and generally supports lower densities of wolves and ungulates, with the exception of a large migratory herd of bison (Bison bison).Study areaYNP has an intact suite of terrestrial carnivores, including gray wolves, grizzly (Ursus arctos) and black bears (Ursus americanus), cougars, coyotes, red foxes, badgers (Taxidea taxus), river otters (Lontra canadensis), American martens (Martes americana), short (Mustela erminea) and long-tailed weasels (Mustela frenata), striped skunks (Mephitis mephitis), and wolverines (Gulo gulo) [28] .", [["bison", "ORGANISM_SUBDIVISION", 219, 224], ["Ursus arctos", "ORGANISM", 332, 344], ["black bears", "ORGANISM", 350, 361], ["Ursus americanus", "ORGANISM", 363, 379], ["red foxes", "ORGANISM", 400, 409], ["badgers", "ORGANISM", 411, 418], ["Taxidea taxus", "ORGANISM", 420, 433], ["Lontra canadensis", "ORGANISM", 450, 467], ["Martes americana", "ORGANISM", 488, 504], ["Mustela erminea", "ORGANISM", 514, 529], ["Mustela frenata", "ORGANISM", 556, 571], ["skunks", "ORGANISM_SUBDIVISION", 582, 588], ["Mephitis mephitis", "ORGANISM", 590, 607], ["Ursus arctos", "SPECIES", 332, 344], ["Ursus americanus", "SPECIES", 363, 379], ["badgers", "SPECIES", 411, 418], ["Taxidea taxus", "SPECIES", 420, 433], ["Lontra canadensis", "SPECIES", 450, 467], ["martens", "SPECIES", 479, 486], ["Martes americana", "SPECIES", 488, 504], ["Mustela erminea", "SPECIES", 514, 529], ["Mustela frenata", "SPECIES", 556, 571], ["Mephitis mephitis", "SPECIES", 590, 607], ["bison", "SPECIES", 219, 224], ["Bison bison", "SPECIES", 226, 237], ["gray wolves", "SPECIES", 310, 321], ["Ursus arctos", "SPECIES", 332, 344], ["black bears", "SPECIES", 350, 361], ["Ursus americanus", "SPECIES", 363, 379], ["red foxes", "SPECIES", 400, 409], ["Taxidea taxus", "SPECIES", 420, 433], ["river otters", "SPECIES", 436, 448], ["Lontra canadensis", "SPECIES", 450, 467], ["American martens", "SPECIES", 470, 486], ["Martes americana", "SPECIES", 488, 504], ["Mustela erminea", "SPECIES", 514, 529], ["long-tailed weasels", "SPECIES", 535, 554], ["Mustela frenata", "SPECIES", 556, 571], ["striped skunks", "SPECIES", 574, 588], ["Mephitis mephitis", "SPECIES", 590, 607], ["lower densities of wolves and ungulates", "PROBLEM", 130, 169], ["gray wolves", "TEST", 310, 321], ["badgers (Taxidea taxus", "TREATMENT", 411, 433], ["American martens (Martes americana", "PROBLEM", 470, 504], ["short (Mustela erminea)", "PROBLEM", 507, 530], ["long-tailed weasels (Mustela frenata)", "TREATMENT", 535, 572], ["striped skunks (Mephitis mephitis", "PROBLEM", 574, 607], ["Interior", "ANATOMY_MODIFIER", 4, 12], ["higher", "OBSERVATION_MODIFIER", 42, 48], ["elevation", "OBSERVATION_MODIFIER", 52, 61], ["lower densities", "OBSERVATION_MODIFIER", 130, 145], ["wolves", "OBSERVATION", 149, 155], ["ungulates", "OBSERVATION_MODIFIER", 160, 169], ["large", "OBSERVATION_MODIFIER", 195, 200], ["migratory", "OBSERVATION_MODIFIER", 201, 210], ["intact", "OBSERVATION", 260, 266], ["terrestrial carnivores", "OBSERVATION", 276, 298]]], ["Although extremely rare inside YNP, raccoons (Procyon lotor) are present in the surrounding GYE.Sample collectionWolves.", [["GYE", "CANCER", 92, 95], ["raccoons (Procyon lotor", "TREATMENT", 36, 59], ["Sample collectionWolves", "TEST", 96, 119]]], ["We darted wolves from a helicopter during November-March and anesthetized them using a 10 mg/kg dose of TelazolH (tiletamine & zolazepam).", [["TelazolH", "CHEMICAL", 104, 112], ["tiletamine", "CHEMICAL", 114, 124], ["zolazepam", "CHEMICAL", 127, 136], ["TelazolH", "CHEMICAL", 104, 112], ["tiletamine", "CHEMICAL", 114, 124], ["zolazepam", "CHEMICAL", 127, 136], ["TelazolH", "SIMPLE_CHEMICAL", 104, 112], ["tiletamine", "SIMPLE_CHEMICAL", 114, 124], ["zolazepam", "SIMPLE_CHEMICAL", 127, 136], ["TelazolH", "TREATMENT", 104, 112], ["tiletamine", "TREATMENT", 114, 124], ["zolazepam", "TREATMENT", 127, 136]]], ["We fitted them with radio-collars (Telonics, Inc. Mesa, AZ), drew 6-8 ml of blood from the saphenous vein, and categorized the animals as pups (,12 months) or adults, with precise ages estimated from tooth wear [29] .", [["blood", "ANATOMY", 76, 81], ["saphenous vein", "ANATOMY", 91, 105], ["tooth", "ANATOMY", 200, 205], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["saphenous vein", "MULTI-TISSUE_STRUCTURE", 91, 105], ["tooth", "ORGAN", 200, 205], ["saphenous vein", "ANATOMY", 91, 105]]], ["We stored whole blood and serum (serum collected by centrifuging whole blood for 15 minutes after 30 minutes of rest) at 280 C until analysis.", [["whole blood", "ANATOMY", 10, 21], ["serum", "ANATOMY", 26, 31], ["serum", "ANATOMY", 33, 38], ["blood", "ANATOMY", 71, 76], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["whole blood", "TEST", 10, 21], ["serum (serum", "TEST", 26, 38], ["analysis", "TEST", 133, 141]]], ["Following capture, each wolf was identified as belonging to a particular pack.Sample collectionCoyotes and foxes.", [["Sample collectionCoyotes", "TEST", 78, 102], ["foxes", "OBSERVATION", 107, 112]]], ["Foxes were also captured on the NR of YNP, but trapping efforts were less intense and less frequent (1993, 1996, 2003, and 2005) .", [["Foxes", "GENE_OR_GENE_PRODUCT", 0, 5], ["less", "OBSERVATION_MODIFIER", 69, 73], ["intense", "OBSERVATION_MODIFIER", 74, 81]]], ["Coyotes and foxes were captured from three regions (Lamar Valley, Blacktail Plateau, and Gardiner River Basin) spanning east to west on the NR inside YNP from September through October.", [["foxes", "TREATMENT", 12, 17]]], ["Juvenile and adult coyotes and foxes were captured using padded, offset, centerswivel, foot-hold traps (Victor soft-catch, Woodstream Corp., Lititz, PA, USA) baited with species-specific urine lures.", [["urine", "ANATOMY", 187, 192], ["coyotes", "ORGANISM", 19, 26], ["foxes", "ORGANISM", 31, 36], ["urine", "ORGANISM_SUBSTANCE", 187, 192], ["adult coyotes", "TREATMENT", 13, 26], ["foxes", "TREATMENT", 31, 36], ["hold traps", "TREATMENT", 92, 102], ["urine lures", "TEST", 187, 198], ["foot", "ANATOMY", 87, 91]]], ["Sex, weight, condition, dentition, and body measurement data were collected for each animal.", [["body", "ANATOMY", 39, 43], ["body", "ORGANISM_SUBDIVISION", 39, 43], ["body measurement data", "TEST", 39, 60]]], ["Individuals were classified as juveniles (0.5-1.5 yrs), young adults (1.6-4.9 yrs), or old adults ($5 yrs) based on tooth wear [30] .", [["tooth", "ANATOMY", 116, 121], ["tooth", "ORGAN", 116, 121]]], ["Technicians drew blood and isolated serum as described for wolves and radio-collared (Advanced Telemetry Systems, Isanti, MN, USA; Telonics, Mesa, AZ, USA) the animals.Sample collectionMonitoring of radio-collared coyotes permitted classifying individuals as residents (i.e., member of a territorial pack) or transients (i.e., solitary individuals, typically inhabiting an area overlapping one or more pack territories).", [["blood", "ANATOMY", 17, 22], ["serum", "ANATOMY", 36, 41], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["collared coyotes", "SPECIES", 205, 221], ["blood", "TEST", 17, 22], ["isolated serum", "TEST", 27, 41], ["Sample collection", "TEST", 168, 185], ["transients (i.e., solitary individuals", "PROBLEM", 309, 347]]], ["Thus, exposure data from resident and transient individuals captured in the same region were assumed to be non-independent.", [["exposure data", "TEST", 6, 19], ["transient individuals", "PROBLEM", 38, 59]]], ["1991-1992, 1996-1999, and 2003-2005) , and foxes (n = 9 samples [3 females, 3 males, 3 unk.] during 1993, 1996, 2003, and 2005) were screened for antibodies to CPV, CAV-1, CDV, CHV, and N. caninum (wolf samples only due to insufficient quantities of coyote and fox sera) by the New York State Animal Health Diagnostic Center (Ithaca, NY, USA).", [["samples", "ANATOMY", 203, 210], ["sera", "ANATOMY", 265, 269], ["CPV", "ORGANISM", 160, 163], ["CAV-1", "ORGANISM", 165, 170], ["CDV", "ORGANISM", 172, 175], ["CHV", "ORGANISM", 177, 180], ["N. caninum", "ORGANISM", 186, 196], ["wolf", "ORGANISM", 198, 202], ["coyote", "ORGANISM", 250, 256], ["fox", "ORGANISM", 261, 264], ["sera", "ORGANISM_SUBSTANCE", 265, 269], ["antibodies", "PROTEIN", 146, 156], ["N. caninum", "SPECIES", 186, 196], ["CPV", "SPECIES", 160, 163], ["CAV-1", "SPECIES", 165, 170], ["CDV", "SPECIES", 172, 175], ["CHV", "SPECIES", 177, 180], ["N. caninum", "SPECIES", 186, 196], ["antibodies", "TEST", 146, 156], ["CPV", "TEST", 160, 163], ["CAV", "TEST", 165, 168], ["CDV", "PROBLEM", 172, 175], ["CHV", "PROBLEM", 177, 180]]], ["Serum neutralization tests [31] were used to detect CAV-1 (positive titer: $8), CHV (positive titer: $8), and CDV (positive titer: .12) antibodies (titer cutoff selected so as to minimize false positives; data not shown) [32] .", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["CAV-1", "GENE_OR_GENE_PRODUCT", 52, 57], ["CDV", "ORGANISM", 110, 113], ["antibodies", "PROTEIN", 136, 146], ["CAV-1", "SPECIES", 52, 57], ["CHV", "SPECIES", 80, 83], ["CDV", "SPECIES", 110, 113], ["Serum neutralization tests", "TEST", 0, 26], ["CAV", "TEST", 52, 55], ["CHV", "TEST", 80, 83], ["CDV", "TEST", 110, 113], ["titer", "TEST", 124, 129], ["antibodies", "TEST", 136, 146], ["titer cutoff", "TEST", 148, 160], ["false positives", "TEST", 188, 203], ["CAV", "ANATOMY", 52, 55]]], ["A hemagglutination inhibition test was used to detect CPV antibodies (positive titer: $20) [33] , and an indirect fluorescent antibody test was used to detect N. caninum antibodies (positive titer: $50) [34, 35] .Serological screeningData from wolf and coyote pups were used only for animals $5 months old to avoid the influence of maternal antibodies [36] [37] [38] .", [["CPV", "ORGANISM", 54, 57], ["N. caninum", "ORGANISM", 159, 169], ["coyote", "ORGANISM", 253, 259], ["pups", "ORGANISM_SUBDIVISION", 260, 264], ["CPV antibodies", "PROTEIN", 54, 68], ["N. caninum antibodies", "PROTEIN", 159, 180], ["N. caninum", "SPECIES", 159, 169], ["CPV", "SPECIES", 54, 57], ["N. caninum", "SPECIES", 159, 169], ["coyote", "SPECIES", 253, 259], ["A hemagglutination inhibition test", "TEST", 0, 34], ["CPV antibodies", "TEST", 54, 68], ["an indirect fluorescent antibody test", "TEST", 102, 139], ["N. caninum antibodies", "TEST", 159, 180], ["Serological screeningData", "TEST", 213, 238], ["coyote pups", "TREATMENT", 253, 264], ["maternal antibodies", "TEST", 332, 351]]], ["Repeat samples from the same individual were excluded from the statistical analysis unless they seroconverted or tested negative for two consecutive sampling periods for a given pathogen.Wolf-pup survivalWe identified wolf dens by tracking radio-collared adult females throughout April.", [["samples", "ANATOMY", 7, 14], ["samples", "CANCER", 7, 14], ["Repeat samples", "TEST", 0, 14], ["the statistical analysis", "TEST", 59, 83], ["pathogen", "PROBLEM", 178, 186], ["wolf dens", "PROBLEM", 218, 227]]], ["Dens were monitored and pups counted weekly in May and June.", [["Dens", "PROBLEM", 0, 4]]], ["Pup counts in the remote Interior were primarily conducted from airplanes.", [["Pup counts", "TEST", 0, 10]]], ["Aerial monitoring of NR dens was often supplemented with ground counts using spotting scopes.", [["Aerial monitoring", "TEST", 0, 17], ["spotting scopes", "TREATMENT", 77, 92], ["NR dens", "OBSERVATION", 21, 28]]], ["We estimated pups born per pack based on high counts observed between May-June.", [["pups", "ORGANISM_SUBDIVISION", 13, 17], ["high counts", "PROBLEM", 41, 52], ["high counts", "OBSERVATION_MODIFIER", 41, 52]]], ["We also estimated pup survival per pack between May and December by calculating the proportion of pups in a pack still alive at the end of December based on weekly (at minimum) aerial and ground counts.", [["pup", "ANATOMY", 18, 21], ["pup", "ORGANISM_SUBDIVISION", 18, 21], ["pups", "ORGANISM_SUBDIVISION", 98, 102], ["aerial and ground counts", "TEST", 177, 201], ["ground counts", "OBSERVATION", 188, 201]]], ["Survival data were not available for coyote-pups and fox-kits.Analytical and statistical methodsTo accommodate the available datasets and the biological differences between both the canid hosts and the pathogens, our analyses involved several different approaches outlined below.Analytical and statistical methodsAge effects.", [["pups", "ORGANISM_SUBDIVISION", 44, 48], ["Survival data", "TEST", 0, 13]]], ["The viral pathogens CPV, CDV, and CAV-1 generally produce long-lasting immunity in their hosts [14] [15] [16] [17] [18] , so we assumed that once a wolf, coyote, or fox was exposed to one of these pathogens they remained seropositive for life (although Mech and Goyal [unpublished] have found exceptions to this for CPV among wolves).", [["CPV", "ORGANISM", 20, 23], ["CDV", "ORGANISM", 25, 28], ["CAV-1", "ORGANISM", 34, 39], ["coyote", "ORGANISM", 154, 160], ["fox", "ORGANISM", 165, 168], ["CPV", "ORGANISM", 316, 319], ["CPV", "SPECIES", 20, 23], ["CDV", "SPECIES", 25, 28], ["CAV-1", "SPECIES", 34, 39], ["CPV", "SPECIES", 316, 319], ["The viral pathogens CPV", "PROBLEM", 0, 23], ["CDV", "PROBLEM", 25, 28], ["CAV", "TEST", 34, 37], ["these pathogens", "PROBLEM", 191, 206], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["pathogens CPV", "OBSERVATION", 10, 23], ["CAV", "ANATOMY", 34, 37]]], ["Under this assumption, the serological status of pups, as compared to adults, offers the most precise information about whether a pathogen is circulating in a given year or region.", [["pups", "ORGANISM_SUBDIVISION", 49, 53], ["a pathogen", "PROBLEM", 128, 138]]], ["Therefore, we examined wolf-pup and coyote-juvenile data separately from wolf adult ($1 yr) and coyote adult ($1.6 yrs) data in the analysis of CPV, CDV, and CAV-1 serological data.Analytical and statistical methodsBy contrast, CHV, a herpesvirus, produces life-long infections characterized by periods of latency where the virus is present but does not provoke a strong immune response [39] .", [["CHV", "CHEMICAL", 228, 231], ["herpesvirus", "DISEASE", 235, 246], ["infections", "DISEASE", 267, 277], ["pup", "ORGANISM_SUBDIVISION", 28, 31], ["CPV", "ORGANISM", 144, 147], ["CDV", "ORGANISM", 149, 152], ["herpesvirus", "ORGANISM", 235, 246], ["coyote", "SPECIES", 96, 102], ["CPV", "SPECIES", 144, 147], ["CDV", "SPECIES", 149, 152], ["CAV-1", "SPECIES", 158, 163], ["CHV", "SPECIES", 228, 231], ["the analysis", "TEST", 128, 140], ["CPV", "TEST", 144, 147], ["CDV", "TEST", 149, 152], ["CAV", "TEST", 158, 161], ["statistical methodsBy contrast", "TEST", 196, 226], ["CHV", "PROBLEM", 228, 231], ["a herpesvirus", "PROBLEM", 233, 246], ["long infections", "PROBLEM", 262, 277], ["latency", "PROBLEM", 306, 313], ["the virus", "PROBLEM", 320, 329], ["CAV", "ANATOMY", 158, 161], ["latency", "OBSERVATION", 306, 313]]], ["A negative CHV test result most likely reflects an uninfected individual, although a latent infection cannot be ruled out, whereas a positive result suggests exposure, a more recent infection, or recrudescence [19, 40] .Analytical and statistical methodsCanids acquire N. caninum infections by consuming ungulate tissue infected with the asexual stage of the parasite [41] , and a positive N. caninum test suggests an active or recent infection with the parasite [35] .", [["tissue", "ANATOMY", 313, 319], ["infection", "DISEASE", 92, 101], ["infection", "DISEASE", 182, 191], ["recrudescence", "DISEASE", 196, 209], ["N. caninum infections", "DISEASE", 269, 290], ["infection", "DISEASE", 435, 444], ["CHV", "CANCER", 11, 14], ["N. caninum", "ORGANISM", 269, 279], ["tissue", "TISSUE", 313, 319], ["N. caninum", "ORGANISM", 390, 400], ["N. caninum", "SPECIES", 269, 279], ["N. caninum", "SPECIES", 390, 400], ["N. caninum", "SPECIES", 269, 279], ["N. caninum", "SPECIES", 390, 400], ["A negative CHV test", "TEST", 0, 19], ["an uninfected individual", "PROBLEM", 48, 72], ["a latent infection", "PROBLEM", 83, 101], ["a more recent infection", "PROBLEM", 168, 191], ["caninum infections", "PROBLEM", 272, 290], ["ungulate tissue", "PROBLEM", 304, 319], ["a positive N. caninum test", "PROBLEM", 379, 405], ["recent infection", "PROBLEM", 428, 444], ["most likely reflects", "UNCERTAINTY", 27, 47], ["uninfected", "OBSERVATION", 51, 61], ["latent", "OBSERVATION_MODIFIER", 85, 91], ["infection", "OBSERVATION", 92, 101], ["infection", "OBSERVATION", 182, 191], ["caninum infections", "OBSERVATION", 272, 290], ["active", "OBSERVATION_MODIFIER", 418, 424], ["infection", "OBSERVATION", 435, 444]]], ["Because neither CHV nor N. caninum induce consistent, long-term immunity, and because positive results suggest a recent or active infection, we evaluated age class (juvenile (wolf: 0.5-1.9 yrs; coyote: 0.5-1.5 yrs), young adult (wolf: 2-4.9 yrs; coyote: 1.6-4.9 yrs), and old adult (wolf & coyote: $5 yrs)) for both wolves and coyotes as a risk factor for recent infection in our analyses of these two pathogens.Analytical and statistical methodsTemporal, spatial, and demographic patterns of pathogen exposure.", [["N. caninum", "DISEASE", 24, 34], ["infection", "DISEASE", 130, 139], ["infection", "DISEASE", 363, 372], ["CHV", "GENE_OR_GENE_PRODUCT", 16, 19], ["N. caninum", "ORGANISM", 24, 34], ["N. caninum", "SPECIES", 24, 34], ["CHV", "SPECIES", 16, 19], ["N. caninum", "SPECIES", 24, 34], ["active infection", "PROBLEM", 123, 139], ["a risk factor", "PROBLEM", 338, 351], ["recent infection", "PROBLEM", 356, 372], ["these two pathogens", "PROBLEM", 392, 411], ["pathogen exposure", "PROBLEM", 493, 510], ["active", "OBSERVATION_MODIFIER", 123, 129], ["infection", "OBSERVATION", 130, 139], ["infection", "OBSERVATION", 363, 372], ["pathogens", "OBSERVATION", 402, 411], ["spatial", "OBSERVATION_MODIFIER", 456, 463], ["pathogen exposure", "OBSERVATION", 493, 510]]], ["Positive and negative test results were analyzed using a logistic, generalized, linear, mixed model with random ''pack,'' or in the case of coyotes, ''region'' effects [42, 43] .", [["random ''pack", "TREATMENT", 105, 118]]], ["These random effects were considered important because they allowed for the nonindependence of individuals sampled from the same pack or trapping region.", [["trapping", "OBSERVATION", 137, 145]]], ["We developed sets of a priori candidate models including factors such as year, spatial location (wolves only; NR versus Interior), resident versus transient status (coyotes only), and age class (CHV and N. caninum analyses only), thought to potentially influence the probability of pathogen exposure ( Table 1, Table 2 ).Analytical and statistical methodsYear effects were evaluated to test the evidence for temporal variation in exposure, location effects to determine whether NR wolves, living at higher densities, exhibited a higher risk of exposure compared to Interior wolves, and a yearlocation interaction (Table 4 ).", [["N. caninum", "ORGANISM", 203, 213], ["N. caninum", "SPECIES", 203, 213], ["CHV", "SPECIES", 195, 198], ["N. caninum", "SPECIES", 203, 213], ["N. caninum analyses", "TEST", 203, 222], ["pathogen exposure", "PROBLEM", 282, 299], ["temporal variation in exposure", "PROBLEM", 408, 438], ["NR wolves", "PROBLEM", 478, 487]]], ["Pup survival was significantly lower on the NR than in the Interior (OR = 0.25, 95% CI: 0.12, 0.49) (Figure 3) .", [["Pup", "MULTI-TISSUE_STRUCTURE", 0, 3], ["Pup survival", "TEST", 0, 12], ["CI", "TEST", 84, 86], ["significantly", "OBSERVATION_MODIFIER", 17, 30], ["lower", "OBSERVATION_MODIFIER", 31, 36], ["Interior", "ANATOMY_MODIFIER", 59, 67]]], ["Although there was no significant year effect common to both NR and Interior wolves, the probability of survival was significantly lower among NR pups in 2005 (Pr[Survival] = 0.13, 95% CI: 0.04, 0.33) (survival = 13%) when compared to most years, and lower than average, but not significantly so, in 1999 (Pr[Survival] = 0.37, CI: 0.12, 0.71) (survival = 37%) (See Figure 3 for a comparison of 95% CIs).", [["Survival", "TEST", 163, 171], ["CI", "TEST", 185, 187], ["survival", "TEST", 202, 210], ["Survival", "TEST", 309, 317], ["CI", "TEST", 327, 329], ["survival", "TEST", 344, 352], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33]]], ["Although the 95% CIs on the NR survival estimates from 2005 overlap with those of 1995 and 1996, the latter's confidence intervals are almost certainly too large.", [["large", "OBSERVATION_MODIFIER", 156, 161]]], ["Survival estimates in these two years were derived from censuses of the small, closely monitored, reintroduced population, and thus were both accurate and precise.ResultsAnnual wolf-pup CDV seroprevalence coincided with significant variation in annual pup survival on the NR (r 2 = 0.69, t = 24.51, df = 10, P = 0.001), although this was not the case in the Interior (r 2 = 0.02, t = 0.48, df = 10, P = 0.65).", [["wolf-pup CDV", "ORGANISM", 177, 189], ["pup", "ORGANISM_SUBDIVISION", 252, 255], ["CDV", "SPECIES", 186, 189], ["significant variation", "PROBLEM", 220, 241], ["the NR", "TEST", 268, 274], ["t", "TEST", 288, 289], ["df", "TEST", 299, 301], ["P", "TEST", 308, 309], ["t", "TEST", 380, 381], ["df", "TEST", 390, 392], ["P", "TEST", 399, 400], ["small", "OBSERVATION_MODIFIER", 72, 77], ["significant", "OBSERVATION_MODIFIER", 220, 231], ["variation", "OBSERVATION_MODIFIER", 232, 241]]], ["None of the other viral pathogens (CPV, CAV-1, and CHV) exhibited significant temporal variation capable of explaining temporal patterns of pup survival.", [["pup", "ANATOMY", 140, 143], ["CPV", "ORGANISM", 35, 38], ["CAV-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["pup", "ORGANISM_SUBDIVISION", 140, 143], ["CPV", "SPECIES", 35, 38], ["CAV-1", "SPECIES", 40, 45], ["CHV", "SPECIES", 51, 54], ["the other viral pathogens", "PROBLEM", 8, 33], ["CPV", "TEST", 35, 38], ["CAV", "TEST", 40, 43], ["significant temporal variation", "PROBLEM", 66, 96], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["pathogens", "OBSERVATION", 24, 33], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["temporal variation", "OBSERVATION", 78, 96], ["pup survival", "OBSERVATION", 140, 152]]], ["Annual wolf-pup survival was independent of annual pup exposure to N. caninum (NR: r 2 = 0.18, t = 21.39, df = 10, P = 0.20; Interior: r 2 = 0.09, t = 20.91, df = 10, P = 0.38).DiscussionThe discussion that follows must be qualified by the fact that overall, our sample sizes were quite small.", [["N. caninum", "DISEASE", 67, 77], ["pup", "ORGAN", 12, 15], ["pup", "ORGANISM_SUBDIVISION", 51, 54], ["N. caninum", "ORGANISM", 67, 77], ["N. caninum", "SPECIES", 67, 77], ["N. caninum", "SPECIES", 67, 77], ["annual pup exposure", "PROBLEM", 44, 63], ["t", "TEST", 95, 96], ["df", "TEST", 106, 108], ["P", "TEST", 115, 116], ["t", "TEST", 147, 148], ["df", "TEST", 158, 160], ["P", "TEST", 167, 168], ["small", "OBSERVATION_MODIFIER", 287, 292]]], ["Small samples reduced our accuracy and precision in estimating exposure rates as well as our power to detect significant differences in exposure between groups, hence limiting the strength of our inferences based on our data.", [["samples", "ANATOMY", 6, 13], ["Small samples", "PROBLEM", 0, 13], ["our data", "TEST", 216, 224], ["reduced", "OBSERVATION_MODIFIER", 14, 21], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["differences", "OBSERVATION", 121, 132]]], ["This is particularly apparent in our analysis of CDV exposure, where our supported models included many estimable parameters.", [["CDV", "ORGANISM", 49, 52], ["CDV", "SPECIES", 49, 52], ["CDV exposure", "TREATMENT", 49, 61], ["CDV exposure", "OBSERVATION", 49, 61]]], ["However, in some cases, small samples were unavoidable.", [["samples", "ANATOMY", 30, 37], ["small samples", "PROBLEM", 24, 37], ["small", "OBSERVATION_MODIFIER", 24, 29]]], ["For example, in 1999 and 2005, pup survival was so poor that only 13 and 8 pups, respectively, were known to be alive on the NR, making it very difficult to capture pups in those years.", [["pup", "ORGANISM_SUBDIVISION", 31, 34], ["pups", "ORGANISM_SUBDIVISION", 165, 169]]], ["Our conclusions must further be qualified by the fact that our serological assays were not specifically validated or optimized for wolves, coyotes, or foxes.", [["our serological assays", "TEST", 59, 81]]], ["Without knowing the sensitivity and specificity of our tests for these species, we do not know the degree to which our positive and negative test results reflect true exposure status.", [["our tests", "TEST", 51, 60], ["these species", "PROBLEM", 65, 78], ["true exposure status", "PROBLEM", 162, 182]]], ["We cannot rule out, for example, false positive results caused by non-specific antibody binding or exposure to closely related or cross-reacting viruses.", [["false positive results", "PROBLEM", 33, 55], ["non-specific antibody binding", "PROBLEM", 66, 95], ["cross-reacting viruses", "PROBLEM", 130, 152], ["non-specific", "OBSERVATION_MODIFIER", 66, 78], ["antibody", "OBSERVATION", 79, 87], ["viruses", "OBSERVATION", 145, 152]]], ["However, there is good biological reason to believe that wolf and coyote immune systems would behave very similarly to those of closely related domestic dogs, for which the tests have been optimized.", [["coyote", "ORGANISM", 66, 72], ["dogs", "ORGANISM", 153, 157], ["dogs", "SPECIES", 153, 157], ["coyote", "SPECIES", 66, 72], ["wolf and coyote immune systems", "PROBLEM", 57, 87], ["the tests", "TEST", 169, 178]]], ["Previous serological work with foxes (including CDV assay validation via vaccination trials) suggests our titer cutoffs were appropriate for this species as well [32] .", [["CDV", "SPECIES", 48, 51], ["foxes", "TREATMENT", 31, 36], ["CDV assay validation", "TREATMENT", 48, 68], ["vaccination trials", "TREATMENT", 73, 91], ["our titer cutoffs", "PROBLEM", 102, 119]]], ["Furthermore, the fact that multiple species exhibited similar patterns of exposure suggests that we did detect 'real' signals of disease exposure.DiscussionOur findings suggest CPV, CAV-1, and CHV are enzootic, and that CDV is epizootic, within Yellowstone's canid community.", [["CPV", "ORGANISM", 177, 180], ["CAV-1", "GENE_OR_GENE_PRODUCT", 182, 187], ["CHV", "GENE_OR_GENE_PRODUCT", 193, 196], ["CDV", "ORGANISM", 220, 223], ["CPV", "SPECIES", 177, 180], ["CAV-1", "SPECIES", 182, 187], ["CHV", "SPECIES", 193, 196], ["CDV", "SPECIES", 220, 223], ["multiple species", "PROBLEM", 27, 43], ["disease exposure", "PROBLEM", 129, 145], ["CPV", "PROBLEM", 177, 180], ["CAV", "TEST", 182, 185], ["enzootic", "PROBLEM", 201, 209], ["CDV", "PROBLEM", 220, 223], ["epizootic", "PROBLEM", 227, 236], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["species", "OBSERVATION", 36, 43], ["CPV", "OBSERVATION", 177, 180], ["CAV", "ANATOMY", 182, 185], ["enzootic", "OBSERVATION", 201, 209], ["epizootic", "OBSERVATION_MODIFIER", 227, 236]]], ["Among wolves, N. caninum appears enzootic, although it does exhibit some temporal variation, possibly reflecting complex dynamics between the parasite, its intermediate hosts (domestic and wild ungulates), and definitive hosts (wild canids and domestic dogs).DiscussionResident status of coyotes was the one variable that consistently emerged as a possible risk factor, regardless of age group or pathogen.", [["N. caninum", "ORGANISM", 14, 24], ["dogs", "ORGANISM_SUBDIVISION", 253, 257], ["coyotes", "ORGANISM", 288, 295], ["N. caninum", "SPECIES", 14, 24], ["dogs", "SPECIES", 253, 257], ["N. caninum", "SPECIES", 14, 24], ["enzootic", "PROBLEM", 33, 41], ["some temporal variation", "PROBLEM", 68, 91], ["complex dynamics between the parasite", "PROBLEM", 113, 150], ["pathogen", "PROBLEM", 397, 405], ["caninum", "OBSERVATION", 17, 24], ["enzootic", "OBSERVATION_MODIFIER", 33, 41], ["temporal", "OBSERVATION_MODIFIER", 73, 81], ["variation", "OBSERVATION", 82, 91], ["possibly reflecting", "UNCERTAINTY", 93, 112], ["complex", "OBSERVATION_MODIFIER", 113, 120], ["dynamics", "OBSERVATION", 121, 129], ["parasite", "OBSERVATION_MODIFIER", 142, 150], ["intermediate hosts", "OBSERVATION_MODIFIER", 156, 174]]], ["Contrary to our original hypothesis, resident coyotes tended to have a greater probability of pathogen exposure than their transient counterparts.", [["coyotes", "ORGANISM", 46, 53], ["pathogen exposure", "PROBLEM", 94, 111]]], ["We had hypothesized that transient coyotes, whose home-ranges overlap multiple resident packs' territories, might contact a greater variety of individuals and be at greater risk for pathogen exposure.", [["pathogen exposure", "PROBLEM", 182, 199]]], ["From our study alone, it is not clear whether social status among coyotes has a true effect on the pathogen-exposure risk as hypothesized for other social-mammal systems [45, 46] .Canine parvovirusFollowing the emergence of CPV in the late 1970s, studies throughout North America have reported high seroprevalences for Table S3 for number of packs sampled and 95% CIs).", [["Canine parvovirus", "DISEASE", 180, 197], ["Canine parvovirus", "ORGANISM", 180, 197], ["CPV", "ORGANISM", 224, 227], ["Canine parvovirus", "SPECIES", 180, 197], ["Canine parvovirus", "SPECIES", 180, 197], ["CPV", "SPECIES", 224, 227], ["our study", "TEST", 5, 14], ["Canine parvovirus", "PROBLEM", 180, 197], ["parvovirus", "OBSERVATION", 187, 197]]], ["Where points overlap, the top number refers to NR, the bottom to Interior. doi:10.1371/journal.pone.0007042.g001Canine parvovirusCPV among wild canids [47] [48] [49] .", [["top", "OBSERVATION_MODIFIER", 26, 29], ["NR", "OBSERVATION", 47, 49], ["bottom", "ANATOMY_MODIFIER", 55, 61], ["Interior", "ANATOMY_MODIFIER", 65, 73]]], ["Nearly all wolves and coyotes that we tested in YNP were positive for CPV exposure by 0.5-0.75 yrs of age.", [["YNP", "CANCER", 48, 51], ["CPV", "ORGANISM", 70, 73], ["CPV", "SPECIES", 70, 73], ["CPV exposure", "PROBLEM", 70, 82], ["wolves", "OBSERVATION", 11, 17]]], ["This high seroprevalence suggests low levels of diseaseinduced host mortality [50, 51] and high rates of transmission, perhaps aided by the stability of CPV in the environment [52] .", [["CPV", "ORGANISM", 153, 156], ["CPV", "SPECIES", 153, 156], ["low levels", "OBSERVATION_MODIFIER", 34, 44]]], ["We did not detect evidence for CPV-induced wolf-pup mortality, contrary to reports of suspected or confirmed CPV-induced mortality in the 1980s and early 1990s [53] [54] [55] , including among coyote pups in YNP [47] .", [["CPV", "ORGANISM", 31, 34], ["pup", "ORGANISM_SUBDIVISION", 48, 51], ["coyote", "ORGANISM", 193, 199], ["pups", "ORGANISM_SUBDIVISION", 200, 204], ["CPV", "SPECIES", 31, 34], ["CPV", "SPECIES", 109, 112], ["CPV", "PROBLEM", 31, 34], ["CPV", "PROBLEM", 109, 112], ["not detect evidence for", "UNCERTAINTY", 7, 30]]], ["Furthermore, CPV seroprevalence offered no explanation for pup-survival patterns because there was no annual variation in exposure to CPV among wolves or coyotes.", [["CPV", "ORGANISM", 13, 16], ["pup", "ORGANISM_SUBDIVISION", 59, 62], ["CPV", "ORGANISM", 134, 137], ["CPV", "SPECIES", 13, 16], ["CPV", "SPECIES", 134, 137], ["CPV seroprevalence", "TREATMENT", 13, 31], ["pup", "PROBLEM", 59, 62], ["annual variation", "PROBLEM", 102, 118]]], ["However, it is possible that CPV either causes a constant, low level of mortality or periodic mortality when combined with other factors such as nutritional stress or co-infection with other pathogens, both scenarios of which our current methods would fail to detect.Canine adenovirus type-1Nearly all wolves also exhibited exposure to CAV-1, but there was no evidence for or against disease-induced mortality.", [["co-infection", "DISEASE", 167, 179], ["CPV", "ORGANISM", 29, 32], ["Canine adenovirus", "ORGANISM", 267, 284], ["Canine", "SPECIES", 267, 273], ["CPV", "SPECIES", 29, 32], ["Canine adenovirus type-1Nearly all wolves", "SPECIES", 267, 308], ["CAV-1", "SPECIES", 336, 341], ["CPV", "PROBLEM", 29, 32], ["a constant, low level of mortality", "PROBLEM", 47, 81], ["periodic mortality", "PROBLEM", 85, 103], ["other factors", "PROBLEM", 123, 136], ["nutritional stress", "PROBLEM", 145, 163], ["co-infection", "PROBLEM", 167, 179], ["other pathogens", "PROBLEM", 185, 200], ["Canine adenovirus type", "PROBLEM", 267, 289], ["disease", "PROBLEM", 384, 391], ["no evidence for", "UNCERTAINTY", 357, 372]]], ["CAV-1 seroprevalence has generally been high in other canid surveys [47, [56] [57] [58] , suggesting that transmission among wild canids is high.", [["CAV-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["canids", "ORGANISM", 130, 136], ["CAV", "TEST", 0, 3], ["high", "OBSERVATION_MODIFIER", 40, 44], ["high", "OBSERVATION_MODIFIER", 140, 144]]], ["Juvenile coyotes had much lower seroprevalences to CAV-1 than did wolf pups, but this may have been due, in part, to the slightly younger age at which coyotes were sampled.Canine herpesvirusNone of the studies that screened for CHV antibodies among wild canids found evidence for exposure ( [59] (Canis lupus); [56] (Canis latrans); [60] (Chrysocyon brachyurus)).", [["CAV-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["wolf", "ORGANISM", 66, 70], ["pups", "ORGANISM_SUBDIVISION", 71, 75], ["Canine herpesvirus", "ORGANISM", 172, 190], ["CHV antibodies", "GENE_OR_GENE_PRODUCT", 228, 242], ["Canis latrans", "ORGANISM", 317, 330], ["Chrysocyon brachyurus", "ORGANISM", 339, 360], ["CHV antibodies", "PROTEIN", 228, 242], ["Canine herpesvirus", "SPECIES", 172, 190], ["Canis", "SPECIES", 297, 302], ["Canis latrans", "SPECIES", 317, 330], ["Chrysocyon brachyurus", "SPECIES", 339, 360], ["CAV-1", "SPECIES", 51, 56], ["Canine herpesvirus", "SPECIES", 172, 190], ["CHV", "SPECIES", 228, 231], ["Canis latrans", "SPECIES", 317, 330], ["Chrysocyon brachyurus", "SPECIES", 339, 360], ["Juvenile coyotes", "PROBLEM", 0, 16], ["the studies", "TEST", 198, 209], ["CHV antibodies", "PROBLEM", 228, 242], ["exposure", "TEST", 280, 288], ["Canis lupus", "TEST", 297, 308], ["Canis latrans", "TEST", 317, 330], ["herpesvirus", "OBSERVATION", 179, 190]]], ["By contrast, CHV seroprevalence was high among YNP wolves, but somewhat lower and age-dependent in coyotes.", [["CHV", "SPECIES", 13, 16]]], ["Canine herpesvirus is primarily spread though direct contact, so wolves' higher seroprevalence may be attributed to higher contact rates or a greater variety of contacts compared to coyotes or foxes.", [["Canine herpesvirus", "ORGANISM", 0, 18], ["Canine", "SPECIES", 0, 6], ["Canine herpesvirus", "SPECIES", 0, 18], ["coyotes", "SPECIES", 182, 189], ["Canine herpesvirus", "PROBLEM", 0, 18]]], ["Similarly, relatively high intra-pack contact rates may help explain the trend towards a slightly higher risk of pathogen exposure among resident coyotes compared to their transient counterparts.", [["relatively high intra-pack contact rates", "PROBLEM", 11, 51], ["high", "OBSERVATION_MODIFIER", 22, 26]]], ["Furthermore, increasing risk of exposure with age, as observed among wolves and coyotes, is common for enzootic diseases.Canine herpesvirusNeospora caninum.", [["enzootic diseases", "DISEASE", 103, 120], ["Neospora caninum", "DISEASE", 139, 155], ["Canine herpesvirus", "ORGANISM", 121, 139], ["Neospora caninum", "ORGANISM", 139, 155], ["Canine herpesvirus", "SPECIES", 121, 139], ["Neospora caninum", "SPECIES", 139, 155], ["Canine herpesvirus", "SPECIES", 121, 139], ["Neospora caninum", "SPECIES", 139, 155], ["enzootic diseases", "PROBLEM", 103, 120], ["Neospora caninum", "PROBLEM", 139, 155], ["herpesvirus", "OBSERVATION", 128, 139]]], ["N. caninum exposure among wolves suggests that a sylvatic cycle of this protozoan parasite exists in YNP.", [["N. caninum", "ORGANISM", 0, 10], ["YNP", "CANCER", 101, 104], ["N. caninum", "SPECIES", 0, 10], ["N. caninum", "SPECIES", 0, 10], ["this protozoan parasite", "PROBLEM", 67, 90], ["caninum", "OBSERVATION", 3, 10]]], ["Domestic livestock, except horses, are prohibited in YNP.", [["YNP", "CANCER", 53, 56], ["livestock", "OBSERVATION", 9, 18]]], ["As hoofed-stock-to-canid transmission occurs through ingestion of infected tissue, livestock is likely not the source of canid exposure to N. caninum in YNP.", [["tissue", "ANATOMY", 75, 81], ["ingestion of infected", "DISEASE", 53, 74], ["tissue", "TISSUE", 75, 81], ["canid", "ORGANISM_SUBDIVISION", 121, 126], ["N. caninum", "ORGANISM", 139, 149], ["YNP", "CANCER", 153, 156], ["N. caninum", "SPECIES", 139, 149], ["N. caninum", "SPECIES", 139, 149], ["infected tissue", "PROBLEM", 66, 81], ["infected tissue", "OBSERVATION", 66, 81], ["caninum", "OBSERVATION", 142, 149]]], ["While there is no information on N. caninum [20, 64] , infected wolves probably shed them as well.", [["N. caninum", "ORGANISM", 33, 43], ["N. caninum", "SPECIES", 33, 43], ["N. caninum", "SPECIES", 33, 43], ["no", "UNCERTAINTY", 15, 17], ["infected", "OBSERVATION_MODIFIER", 55, 63], ["wolves", "OBSERVATION", 64, 70]]], ["Although we had insufficient quantities of coyote and fox sera to screen for N. caninum, we suspect that exposure levels in at least coyotes would be similar to that of YNP wolves.", [["sera", "ANATOMY", 58, 62], ["N. caninum", "DISEASE", 77, 87], ["coyote", "ORGANISM", 43, 49], ["fox", "ORGANISM", 54, 57], ["sera", "ORGANISM_SUBSTANCE", 58, 62], ["N. caninum", "ORGANISM", 77, 87], ["N. caninum", "SPECIES", 77, 87], ["N. caninum", "SPECIES", 77, 87], ["N. caninum", "PROBLEM", 77, 87], ["exposure levels", "PROBLEM", 105, 120]]], ["We did not sample wild canids outside of YNP, and thus future research could employ a combination of serologic and genetic tools to look at the relationships between N. caninum in wild and domestic canids and ungulates in regions where N. caninum is of concern to local livestock producers.", [["N. caninum", "DISEASE", 166, 176], ["N. caninum", "DISEASE", 236, 246], ["N. caninum", "ORGANISM", 166, 176], ["N. caninum", "ORGANISM", 236, 246], ["N. caninum", "SPECIES", 166, 176], ["N. caninum", "SPECIES", 236, 246], ["N. caninum", "SPECIES", 166, 176], ["N. caninum", "SPECIES", 236, 246], ["serologic and genetic tools", "PROBLEM", 101, 128], ["caninum", "OBSERVATION", 169, 176], ["caninum", "OBSERVATION", 239, 246]]], ["However, at this time, there is no evidence to suggest that N. caninum has been or will be significantly impacting either domestic or wild ungulates or canids in the GYE.Canine distemper virusThe dynamics of highly immunizing, fast acting, epidemic-type pathogens such as CDV are challenging to decipher within the usual 3-5-year time frame of most wildlife studies.", [["N. caninum", "DISEASE", 60, 70], ["Canine distemper virus", "DISEASE", 170, 192], ["N. caninum", "ORGANISM", 60, 70], ["Canine distemper virus", "ORGANISM", 170, 192], ["CDV", "ORGANISM", 272, 275], ["N. caninum", "SPECIES", 60, 70], ["Canine distemper virus", "SPECIES", 170, 192], ["N. caninum", "SPECIES", 60, 70], ["Canine distemper virus", "SPECIES", 170, 192], ["CDV", "SPECIES", 272, 275], ["N. caninum", "PROBLEM", 60, 70], ["Canine distemper virus", "PROBLEM", 170, 192], ["type pathogens", "PROBLEM", 249, 263], ["CDV", "PROBLEM", 272, 275], ["no evidence to suggest", "UNCERTAINTY", 32, 54], ["caninum", "OBSERVATION", 63, 70], ["distemper virus", "OBSERVATION", 177, 192]]], ["In these situations, reports of average seroprevalence, without regard to year or age of the sampled animal, can be misleading and of limited value for comparisons across different study sites and populations.", [["different study sites", "TEST", 171, 192]]], ["In many of the serosurveys among coyotes [47, [65] [66] [67] and wolves [55, 68] , dynamic temporal patterns may have been masked by examining CDV seroprevalence averaged across years or age classes at spatial scales likely too small for CDV to be enzootic [69] .Canine distemper virusThe supported CDV seroprevalence models suggested that (1) coyotes experienced CDV outbreaks in 1999 and 2005, (2) all wolves experienced CDV outbreaks in 1999, 2002, and 2005 (although 2000 and 2006 adult wolf seroprevalence was also high, these were likely individuals that were exposed in 1999 and 2005 and were thus positive upon capture the following year), and (3) NR wolves experienced a greater probability of CDV exposure than Interior wolves.", [["CDV", "DISEASE", 423, 426], ["CDV", "ORGANISM", 143, 146], ["CDV", "ORGANISM", 238, 241], ["Canine distemper virus", "ORGANISM", 263, 285], ["CDV", "ORGANISM", 299, 302], ["CDV", "ORGANISM", 364, 367], ["CDV", "ORGANISM", 703, 706], ["Canine distemper virus", "SPECIES", 263, 285], ["CDV", "SPECIES", 143, 146], ["CDV", "SPECIES", 238, 241], ["Canine distemper virus", "SPECIES", 263, 285], ["CDV", "SPECIES", 299, 302], ["CDV", "SPECIES", 364, 367], ["CDV", "SPECIES", 423, 426], ["CDV", "SPECIES", 703, 706], ["wolves", "TEST", 65, 71], ["dynamic temporal patterns", "TEST", 83, 108], ["age classes at spatial scales", "PROBLEM", 187, 216], ["CDV", "PROBLEM", 238, 241], ["enzootic", "PROBLEM", 248, 256], ["Canine distemper virus", "PROBLEM", 263, 285], ["CDV exposure", "PROBLEM", 703, 715], ["distemper virus", "OBSERVATION", 270, 285], ["CDV exposure", "OBSERVATION", 703, 715]]], ["This last finding was consistent our hypothesis that high wolf densities on the NR may result in higher inter-pack contact rates and thus higher levels of pathogen exposure compared to the less-dense Interior.", [["high wolf densities", "PROBLEM", 53, 72], ["higher inter-pack contact rates", "PROBLEM", 97, 128], ["pathogen exposure", "PROBLEM", 155, 172], ["high", "OBSERVATION_MODIFIER", 53, 57], ["wolf densities", "OBSERVATION_MODIFIER", 58, 72], ["pathogen exposure", "OBSERVATION", 155, 172], ["dense", "OBSERVATION_MODIFIER", 194, 199], ["Interior", "OBSERVATION_MODIFIER", 200, 208]]], ["Although we do not have Interior density estimates for the other canids, it is quite possible that coyote and fox densities are also higher on the NR than in the Interior, and thus higher canid densities in general may contribute to higher rates of wolf exposure observed on the NR.Canine distemper virusHowever, as the seroprevalence data suggested, these aforementioned generalities obscured some potentially important differences in spatial and temporal CDV dynamics.", [["Canine distemper", "DISEASE", 282, 298], ["Canine distemper virus", "ORGANISM", 282, 304], ["CDV", "ORGANISM", 457, 460], ["Canine distemper virus", "SPECIES", 282, 304], ["Canine distemper virus", "SPECIES", 282, 304], ["CDV", "SPECIES", 457, 460], ["coyote and fox densities", "PROBLEM", 99, 123], ["higher canid densities", "PROBLEM", 181, 203], ["wolf exposure", "PROBLEM", 249, 262], ["Canine distemper virus", "PROBLEM", 282, 304], ["the seroprevalence data", "TEST", 316, 339], ["Interior", "OBSERVATION_MODIFIER", 24, 32], ["density", "OBSERVATION", 33, 40], ["quite possible", "UNCERTAINTY", 79, 93], ["fox densities", "OBSERVATION", 110, 123], ["higher", "OBSERVATION_MODIFIER", 133, 139], ["Interior", "ANATOMY_MODIFIER", 162, 170], ["higher", "OBSERVATION_MODIFIER", 181, 187], ["canid", "OBSERVATION_MODIFIER", 188, 193], ["densities", "OBSERVATION", 194, 203], ["distemper virus", "OBSERVATION", 289, 304], ["temporal", "OBSERVATION_MODIFIER", 448, 456], ["CDV dynamics", "OBSERVATION", 457, 469]]], ["For example, none of the Interior wolf pups handled in 1999 and 2005 had been exposed to CDV in contrast to the high levels of exposure found among the limited samples of Interior adults and NR adults and pups.", [["samples", "ANATOMY", 160, 167], ["CDV", "ORGANISM", 89, 92], ["pups", "ORGANISM_SUBDIVISION", 205, 209], ["CDV", "SPECIES", 89, 92], ["CDV", "PROBLEM", 89, 92]]], ["These inconsistencies may be the result of small samples or differences in case-fatality rates across sampling locations.", [["small samples", "PROBLEM", 43, 56], ["small", "OBSERVATION_MODIFIER", 43, 48], ["samples", "OBSERVATION", 49, 56]]], ["If all infected pups in the Interior died due to disease, those available for sampling would all be negative.", [["pups", "ORGANISM", 16, 20], ["all infected pups", "PROBLEM", 3, 20], ["disease", "PROBLEM", 49, 56], ["sampling", "TEST", 78, 86], ["infected", "OBSERVATION", 7, 15], ["disease", "OBSERVATION", 49, 56]]], ["It is also possible that the timing and point of disease introduction into YNP could account for these differences.", [["disease introduction into YNP", "PROBLEM", 49, 78], ["is also possible", "UNCERTAINTY", 3, 19], ["disease", "OBSERVATION", 49, 56], ["could account for", "UNCERTAINTY", 79, 96]]], ["CDV is generally thought to move quickly through populations as it is highly contagious, infected individuals shed virus for a relatively short time (mean duration of infectiousness = 14 days, maximum 90 days), and the virus rapidly degrades in the environment (within hours at $20uC, and within several weeks at 0-4uC) [15, 16] .", [["CDV", "ORGANISM", 0, 3], ["CDV", "SPECIES", 0, 3], ["CDV", "PROBLEM", 0, 3], ["infected individuals shed virus", "PROBLEM", 89, 120], ["infectiousness", "PROBLEM", 167, 181], ["the virus", "PROBLEM", 215, 224], ["contagious", "OBSERVATION_MODIFIER", 77, 87]]], ["Thus, if CDV had entered from the south before pup birth or weaning, it could have swept through the Interior adults, sparing the young Interior pups protected by maternal antibodies but arriving on the NR when pups would be most vulnerable.Canine distemper virusFurthermore, if there was in fact a 2002 outbreak, it seems to have been confined to the Interior wolves; none of the NR pups and only a few of the NR adults were exposed that year.", [["distemper virusFurthermore", "DISEASE", 248, 274], ["CDV", "ORGANISM", 9, 12], ["pup", "ORGANISM_SUBDIVISION", 47, 50], ["pups", "ORGANISM_SUBDIVISION", 145, 149], ["pups", "ORGANISM", 211, 215], ["Canine distemper virusFurthermore", "ORGANISM", 241, 274], ["adults", "ORGANISM", 414, 420], ["maternal antibodies", "PROTEIN", 163, 182], ["Canine distemper", "SPECIES", 241, 257], ["CDV", "SPECIES", 9, 12], ["Canine distemper virusFurthermore", "SPECIES", 241, 274], ["CDV", "PROBLEM", 9, 12], ["weaning", "TREATMENT", 60, 67], ["maternal antibodies", "PROBLEM", 163, 182], ["distemper", "OBSERVATION", 248, 257]]], ["However, there may be reason to suspect false positives in this particular case.", [["false positives", "PROBLEM", 40, 55], ["false positives", "OBSERVATION", 40, 55]]], ["In 2002, the two positive Interior pups had antibody titers just over the positive titer cutoff value (Positive antibody titer: $16), in contrast to marked increases in the titers observed among NR pups in 1999 and 2005 ( Figure S1 ).", [["pups", "ORGANISM", 35, 39], ["antibody titers", "TEST", 44, 59], ["antibody titer", "TEST", 112, 126], ["the titers", "TEST", 169, 179], ["marked", "OBSERVATION_MODIFIER", 149, 155], ["increases", "OBSERVATION_MODIFIER", 156, 165]]], ["Adult titers in the Interior and NR were not particularly high in 2002, either.", [["Adult titers", "TEST", 0, 12], ["titers", "OBSERVATION", 6, 12], ["high", "OBSERVATION_MODIFIER", 58, 62]]], ["In the absence of larger samples and more conclusive evidence (e.g. virus isolation or identification via PCR), we cannot be sure that CDV actually swept through the Interior of the park in 2002.Canine distemper virusThe wolf-pup data suggested low rates of seroconversion between the discrete outbreak years of 1999, 2002, and 2005.", [["Canine distemper virus", "DISEASE", 195, 217], ["CDV", "ORGANISM", 135, 138], ["Canine distemper virus", "ORGANISM", 195, 217], ["Canine distemper virus", "SPECIES", 195, 217], ["CDV", "SPECIES", 135, 138], ["Canine distemper virus", "SPECIES", 195, 217], ["larger samples", "PROBLEM", 18, 32], ["virus isolation", "TREATMENT", 68, 83], ["PCR", "TEST", 106, 109], ["Canine distemper virus", "PROBLEM", 195, 217], ["The wolf-pup data", "TEST", 217, 234], ["low rates of seroconversion", "PROBLEM", 245, 272], ["larger", "OBSERVATION_MODIFIER", 18, 24], ["distemper virus", "OBSERVATION", 202, 217], ["low rates", "OBSERVATION_MODIFIER", 245, 254], ["discrete", "OBSERVATION_MODIFIER", 285, 293]]], ["Once a wild or domestic canid is infected with CDV, the animal either recovers rapidly (mean time from infection to recovery [including latency and infectiousness] = 21 days, maximum 120 days) with life-long immunity or dies [15, 16] .", [["infection", "DISEASE", 103, 112], ["CDV", "ORGANISM", 47, 50], ["CDV", "SPECIES", 47, 50], ["CDV", "TREATMENT", 47, 50], ["infection", "PROBLEM", 103, 112], ["latency", "PROBLEM", 136, 143], ["infectiousness", "PROBLEM", 148, 162], ["infected", "OBSERVATION", 33, 41]]], ["Thus, CDV requires a large population of susceptibles to persist, a population likely larger than YNP's canid community [69] .", [["CDV", "ORGANISM", 6, 9], ["CDV", "SPECIES", 6, 9], ["CDV", "PROBLEM", 6, 9], ["a large population of susceptibles", "PROBLEM", 19, 53], ["large", "OBSERVATION_MODIFIER", 21, 26], ["population", "OBSERVATION", 27, 37], ["likely", "UNCERTAINTY", 79, 85], ["larger", "OBSERVATION_MODIFIER", 86, 92]]], ["The low seroconversion between epizootics, if representative of true positives, suggests reexposure from some wild or domestic host outside YNP or mistaken assumptions about the disease.", [["epizootics", "DISEASE", 31, 41], ["YNP", "CANCER", 140, 143], ["The low seroconversion between epizootics", "PROBLEM", 0, 41], ["true positives", "PROBLEM", 64, 78], ["the disease", "PROBLEM", 174, 185], ["low", "OBSERVATION_MODIFIER", 4, 7], ["seroconversion", "OBSERVATION", 8, 22], ["disease", "OBSERVATION", 178, 185]]], ["For example, although no evidence exists for carrier states, loss of immunity, or imperfect protection against novel strains of CDV among canids, loss of CDV immunity has been documented in raccoons (Procyon lotor) [70] .", [["loss of immunity", "DISEASE", 61, 77], ["CDV", "DISEASE", 128, 131], ["CDV", "ORGANISM", 128, 131], ["CDV", "ORGANISM", 154, 157], ["CDV", "SPECIES", 128, 131], ["CDV", "SPECIES", 154, 157], ["loss of immunity", "PROBLEM", 61, 77], ["novel strains of CDV among canids", "PROBLEM", 111, 144], ["loss of CDV immunity", "PROBLEM", 146, 166], ["no evidence exists", "UNCERTAINTY", 22, 40]]], ["If any of these factors pertained to canids, that could help explain the apparent persistence of CDV in YNP.", [["CDV", "DISEASE", 97, 100], ["CDV", "ORGANISM", 97, 100], ["YNP", "CANCER", 104, 107], ["CDV", "SPECIES", 97, 100], ["CDV in YNP", "PROBLEM", 97, 107], ["CDV", "OBSERVATION", 97, 100]]], ["Perhaps more likely, as there are multiple competent hosts for CDV within the GYE (e.g. short and long-tailed weasels, American martens, striped skunks, and raccoons), multi-host transmission might allow localized CDV persistence within the GYE.Canine distemper virus exposure and wolf-pup survivalAlthough a thorough analysis of factors influencing wolf-pup survival would evaluate multiple hypotheses such as population density and food availability, the strong negative correlation between NR CDV seroprevalence and NR wolf-pup survival supports the hypothesis that CDV may have contributed to high NR pup mortality in 1999 and 2005.", [["CDV", "ORGANISM", 63, 66], ["CDV", "ORGANISM", 214, 217], ["Canine distemper virus", "ORGANISM", 245, 267], ["pup", "ORGANISM_SUBDIVISION", 286, 289], ["pup", "ORGANISM_SUBDIVISION", 355, 358], ["NR CDV", "ORGANISM", 493, 499], ["pup", "ORGANISM_SUBDIVISION", 527, 530], ["CDV", "ORGANISM", 569, 572], ["pup", "ORGANISM_SUBDIVISION", 605, 608], ["Canine distemper virus", "SPECIES", 245, 267], ["CDV", "SPECIES", 63, 66], ["striped skunks", "SPECIES", 137, 151], ["CDV", "SPECIES", 214, 217], ["Canine distemper virus", "SPECIES", 245, 267], ["CDV", "SPECIES", 496, 499], ["CDV", "SPECIES", 569, 572], ["CDV within the GYE (e.g. short and long-tailed weasels", "PROBLEM", 63, 117], ["multi-host transmission", "TREATMENT", 168, 191], ["Canine distemper virus exposure", "PROBLEM", 245, 276], ["a thorough analysis", "TEST", 307, 326], ["multiple hypotheses", "PROBLEM", 383, 402], ["NR CDV seroprevalence", "TREATMENT", 493, 514], ["NR wolf-pup survival", "TREATMENT", 519, 539], ["CDV", "PROBLEM", 569, 572], ["high NR pup mortality", "PROBLEM", 597, 618], ["more likely", "UNCERTAINTY", 8, 19], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["CDV", "OBSERVATION", 214, 217], ["distemper virus", "OBSERVATION", 252, 267]]], ["Although $8 young wolfpup carcasses were located in 2005, all were too degraded for CDV isolation.", [["CDV", "ORGANISM", 84, 87], ["CDV", "SPECIES", 84, 87], ["CDV isolation", "TREATMENT", 84, 97]]], ["We found several pup mandibles (n = 4) and handled two live pups during the winter of 2005-2006 displaying the distinctive tooth-enamel hypoplasia diagnostic of CDV [12, 71, 72] .", [["pup mandibles", "ANATOMY", 17, 30], ["tooth", "ANATOMY", 123, 128], ["enamel", "ANATOMY", 129, 135], ["enamel hypoplasia", "DISEASE", 129, 146], ["CDV", "DISEASE", 161, 164], ["pup mandibles", "MULTI-TISSUE_STRUCTURE", 17, 30], ["pups", "ORGAN", 60, 64], ["tooth", "ORGAN", 123, 128], ["enamel", "ORGAN", 129, 135], ["CDV", "ORGANISM", 161, 164], ["CDV", "SPECIES", 161, 164], ["several pup mandibles", "PROBLEM", 9, 30], ["the distinctive tooth-enamel hypoplasia", "PROBLEM", 107, 146], ["several", "OBSERVATION_MODIFIER", 9, 16], ["pup", "OBSERVATION", 17, 20], ["tooth", "ANATOMY", 123, 128], ["enamel hypoplasia", "OBSERVATION", 129, 146]]], ["Furthermore, several coyote dens appeared to experience high pup loss in 2005, with pups displaying neurologic symptoms consistent with late-stage CDV infection (E. Almberg, personal observation) [16] .", [["neurologic", "ANATOMY", 100, 110], ["pup loss", "DISEASE", 61, 69], ["neurologic symptoms", "DISEASE", 100, 119], ["infection", "DISEASE", 151, 160], ["pup", "ORGANISM_SUBDIVISION", 61, 64], ["pups", "ORGANISM_SUBDIVISION", 84, 88], ["CDV", "ORGANISM", 147, 150], ["CDV", "SPECIES", 147, 150], ["several coyote dens", "PROBLEM", 13, 32], ["high pup loss", "PROBLEM", 56, 69], ["neurologic symptoms", "PROBLEM", 100, 119], ["late-stage CDV infection", "PROBLEM", 136, 160], ["pup loss", "OBSERVATION", 61, 69], ["consistent with", "UNCERTAINTY", 120, 135], ["stage CDV", "OBSERVATION_MODIFIER", 141, 150], ["infection", "OBSERVATION", 151, 160]]], ["More recent data suggests that CDV swept through the park again in 2008, and in addition to observing the same patterns of high CDV seroprevalence and very low wolfpup survival, we recovered CDV ribonucleic acid via PCR from 3 dead wolves, all of which had been born after 2005 and thus presumably had no acquired immunity against CDV (Almberg, unpublished data).", [["ribonucleic acid", "CHEMICAL", 195, 211], ["CDV", "ORGANISM", 31, 34], ["CDV", "ORGANISM", 128, 131], ["CDV", "ORGANISM", 331, 334], ["CDV", "SPECIES", 31, 34], ["CDV", "SPECIES", 128, 131], ["CDV", "SPECIES", 191, 194], ["CDV", "SPECIES", 331, 334], ["high CDV seroprevalence", "PROBLEM", 123, 146], ["CDV ribonucleic acid via PCR", "PROBLEM", 191, 219], ["CDV", "PROBLEM", 331, 334], ["high CDV", "OBSERVATION", 123, 131]]], ["Despite the negative correlation between CDV exposure and pup survival, however, the ultimate causes of death could have been due to synergistic effects of CDV and another pathogen (e.g. CPV, CAV-1, canine coronavirus, or protozoan or helminth infections), such as with CDV and Babesia in Serengeti's lions [73] .", [["pup", "ANATOMY", 58, 61], ["death", "DISEASE", 104, 109], ["canine coronavirus", "DISEASE", 199, 217], ["protozoan or helminth infections", "DISEASE", 222, 254], ["CDV", "ORGANISM", 41, 44], ["pup", "ORGANISM_SUBDIVISION", 58, 61], ["CDV", "ORGANISM", 156, 159], ["CPV", "ORGANISM", 187, 190], ["CAV-1", "ORGANISM", 192, 197], ["canine coronavirus", "ORGANISM", 199, 217], ["CDV", "ORGANISM", 270, 273], ["canine coronavirus", "SPECIES", 199, 217], ["CDV", "SPECIES", 41, 44], ["CDV", "SPECIES", 156, 159], ["CPV", "SPECIES", 187, 190], ["CAV-1", "SPECIES", 192, 197], ["canine coronavirus", "SPECIES", 199, 217], ["CDV", "SPECIES", 270, 273], ["death", "PROBLEM", 104, 109], ["CDV", "PROBLEM", 156, 159], ["another pathogen", "PROBLEM", 164, 180], ["CPV", "TEST", 187, 190], ["CAV", "TEST", 192, 195], ["canine coronavirus", "PROBLEM", 199, 217], ["protozoan", "PROBLEM", 222, 231], ["helminth infections", "PROBLEM", 235, 254], ["CDV", "PROBLEM", 270, 273], ["Babesia", "PROBLEM", 278, 285]]], ["Population impacts of pup mortality were short term, for the wolf population rebounded in both years following the 1999 and 2005 lows [27] .Canine distemper virus exposure and wolf-pup survivalWe found no relationship between Interior CDV seroprevalence and Interior wolf-pup survival.", [["pup", "ORGANISM_SUBDIVISION", 22, 25], ["Canine distemper virus", "ORGANISM", 140, 162], ["pup", "ORGANISM_SUBDIVISION", 181, 184], ["CDV", "ORGANISM", 235, 238], ["pup", "ORGANISM_SUBDIVISION", 272, 275], ["Canine distemper virus", "SPECIES", 140, 162], ["Canine distemper virus", "SPECIES", 140, 162], ["CDV", "SPECIES", 235, 238], ["Canine distemper virus exposure", "PROBLEM", 140, 171], ["pup", "OBSERVATION_MODIFIER", 22, 25], ["mortality", "OBSERVATION_MODIFIER", 26, 35], ["distemper virus", "OBSERVATION", 147, 162], ["no relationship", "UNCERTAINTY", 202, 217]]], ["Aside from the hypothesis that the timing of CDV introduction into the Interior either happened to be too early (e.g. 1999 and 2005) or too late (e.g. in 2002) to cause significant pup mortality, other plausible explana-tions for this lack of relationship include 1) that there was no CDV outbreak in 2002, and thus insufficient variation in exposure to detect a relationship with survival, and 2) that we failed to detect pup mortality due to bias in our sampling methods.", [["CDV", "ORGANISM", 45, 48], ["pup", "ORGANISM_SUBDIVISION", 181, 184], ["pup", "ORGANISM_SUBDIVISION", 423, 426], ["CDV", "SPECIES", 45, 48], ["CDV", "SPECIES", 285, 288], ["CDV introduction", "TREATMENT", 45, 61], ["significant pup mortality", "PROBLEM", 169, 194], ["CDV", "PROBLEM", 285, 288], ["pup mortality", "PROBLEM", 423, 436], ["no", "UNCERTAINTY", 282, 284]]], ["The Interior packs' dens were remote and only visible from the airplane, and thus, on average, we made our first pup observations and obtained our first high counts of pups over a month later than those made on the NR (First pup observations, NR: m date = 5/24, sd = 21 days, Interior: m date = 6/26, sd = 27 days; First high pup count, NR: m date = 6/19, sd = 34 days, Interior: m date = 7/22, sd = 37 days).", [["pups", "ORGANISM_SUBDIVISION", 168, 172], ["pup", "ORGANISM_SUBDIVISION", 326, 329], ["The Interior packs' dens", "TREATMENT", 0, 24], ["First high pup count", "PROBLEM", 315, 335], ["Interior", "OBSERVATION_MODIFIER", 4, 12], ["packs", "OBSERVATION_MODIFIER", 13, 18], ["dens", "OBSERVATION_MODIFIER", 20, 24]]], ["Because much microparasite-induced (e.g., viruses and bacteria) pup mortality takes place following weaning (i.e., at 10-12 weeks of age) in late June through early July, it is quite possible that we failed to detect most Interior pup mortality, yielding artificially high survival estimates.Evidence for multi-host CDV outbreaksThe results of two previous studies on pathogen exposure in YNP carnivores further support the patterns of CDV exposure that we observed in wolves and coyotes.", [["pup", "ANATOMY", 64, 67], ["pup", "ORGANISM_SUBDIVISION", 64, 67], ["pup", "ORGANISM_SUBDIVISION", 231, 234], ["multi-host CDV", "ORGANISM", 305, 319], ["YNP carnivores", "ORGANISM", 389, 403], ["CDV", "ORGANISM", 436, 439], ["CDV", "SPECIES", 316, 319], ["CDV", "SPECIES", 436, 439], ["viruses", "PROBLEM", 42, 49], ["bacteria", "PROBLEM", 54, 62], ["pup mortality", "PROBLEM", 64, 77], ["artificially high survival estimates", "PROBLEM", 255, 291], ["multi-host CDV outbreaks", "PROBLEM", 305, 329], ["two previous studies", "TEST", 344, 364], ["pathogen exposure", "TREATMENT", 368, 385], ["CDV exposure", "PROBLEM", 436, 448], ["high survival", "OBSERVATION", 268, 281], ["CDV exposure", "OBSERVATION", 436, 448]]], ["Gese et al. [47] suggested that YNP coyotes experienced a CDV outbreak between 1989 and 1991, which fits with the ,50% seroprevalence we detected in adult coyotes sampled during 1991.", [["YNP coyotes", "ORGANISM", 32, 43], ["YNP coyotes", "SPECIES", 32, 43], ["CDV", "SPECIES", 58, 61]]], ["Also, cougars in YNP appeared to experience isolated outbreaks of CDV in 1991 and 1999 [74] , lending support to the pattern of discrete, multi-host, CDV epizootics.", [["CDV", "DISEASE", 66, 69], ["epizootics", "DISEASE", 154, 164], ["CDV", "ORGANISM", 66, 69], ["CDV", "ORGANISM", 150, 153], ["CDV", "SPECIES", 66, 69], ["CDV", "SPECIES", 150, 153]]], ["Our own extremely limited fox data at least did not contradict the pattern of discrete CDV outbreaks; the single positive animal sampled in 1996 was $5 years old and thus could have been exposed as a kit during the 1989/90 outbreak, and the only other two positive animals were sampled in 2005.", [["CDV", "ORGANISM", 87, 90], ["CDV", "SPECIES", 87, 90], ["discrete CDV outbreaks", "PROBLEM", 78, 100], ["a kit", "TEST", 198, 203], ["discrete", "OBSERVATION_MODIFIER", 78, 86], ["CDV outbreaks", "OBSERVATION", 87, 100]]], ["Furthermore, mustelids are highly susceptible to CDV, and the badger population on the NR appeared to have crashed in 2005 (E. Almberg, personal observation).", [["CDV", "ORGANISM", 49, 52], ["CDV", "SPECIES", 49, 52], ["CDV", "PROBLEM", 49, 52]]], ["However, there are no data on CDV exposure or survival patterns among mustelids in YNP.Evidence for multi-host CDV outbreaksThese correlations among multiple hosts suggest regular CDV spillover but might also suggest multi-host transmission contributing to CDV persistence in the larger region.", [["CDV", "ORGANISM", 30, 33], ["CDV", "ORGANISM", 111, 114], ["CDV", "ORGANISM", 180, 183], ["CDV", "ORGANISM", 257, 260], ["CDV", "SPECIES", 30, 33], ["CDV", "SPECIES", 111, 114], ["CDV", "SPECIES", 180, 183], ["CDV", "SPECIES", 257, 260], ["CDV exposure", "TREATMENT", 30, 42], ["multi-host CDV outbreaks", "PROBLEM", 100, 124], ["regular CDV spillover", "PROBLEM", 172, 193], ["multi-host transmission", "PROBLEM", 217, 240], ["CDV persistence in the larger region", "PROBLEM", 257, 293], ["no", "UNCERTAINTY", 19, 21], ["host CDV", "OBSERVATION", 106, 114], ["CDV spillover", "OBSERVATION", 180, 193], ["CDV persistence", "OBSERVATION", 257, 272], ["larger", "OBSERVATION_MODIFIER", 280, 286]]], ["Domestic animals cannot be ruled out as a reservoir for CDV.", [["CDV", "ORGANISM", 56, 59], ["CDV", "SPECIES", 56, 59], ["CDV", "PROBLEM", 56, 59], ["cannot be ruled", "UNCERTAINTY", 17, 32]]], ["However, reported CDV cases in Montana's domestic animals are uncommon, with 18 possible cases recorded between 1994 and 2008 (Montana Veterinary Diagnostic Lab, Bozeman, MT, USA, unpublished data).", [["CDV", "ORGANISM", 18, 21], ["CDV", "SPECIES", 18, 21]]], ["Furthermore, while the percentage of local domestic animals vaccinated for CDV is unknown, it is probably safe to assume that the unvaccinated population of dogs and cats is too small to serve as a CDV reservoir [69] .Evidence for multi-host CDV outbreaksYNP and the GYE are not closed biological systems.", [["CDV", "DISEASE", 75, 78], ["CDV", "ORGANISM", 75, 78], ["dogs", "ORGANISM", 157, 161], ["cats", "ORGANISM", 166, 170], ["CDV", "ORGANISM", 198, 201], ["CDV outbreaksYNP", "ORGANISM", 242, 258], ["dogs", "SPECIES", 157, 161], ["cats", "SPECIES", 166, 170], ["CDV", "SPECIES", 75, 78], ["CDV", "SPECIES", 198, 201], ["CDV outbreaksYNP", "SPECIES", 242, 258], ["CDV", "PROBLEM", 75, 78], ["a CDV reservoir", "TREATMENT", 196, 211], ["multi-host CDV outbreaksYNP", "PROBLEM", 231, 258], ["multi-", "OBSERVATION_MODIFIER", 231, 237], ["host CDV", "OBSERVATION", 237, 245]]], ["There is currently no proof of dog health or immunization required for entry into the national parks.", [["dog", "ORGANISM", 31, 34], ["immunization", "TREATMENT", 45, 57], ["no proof", "UNCERTAINTY", 19, 27]]], ["Visiting domestic animals certainly constitute a plausible route for new or emerging pathogens (particularly those that are vector-borne or indirectly transmitted) to enter into local, wild canid populations.", [["canid populations", "CELL", 190, 207]]], ["Furthermore, YNP is a small fraction of the overall GYE, and pathogen dynamics within YNP may be in part a product of much larger-scale dynamics driven by inter-connected canid and carnivore populations in the Rocky Mountains.Evidence for multi-host CDV outbreaksIn summary, the constant high canid exposure to CPV, CAV-1, and CHV in YNP suggest that these pathogens are established in the wolf and coyote populations and that they are unlikely to be causing acute mortality in their hosts [50, 51] .", [["YNP", "CHEMICAL", 13, 16], ["YNP", "GENE_OR_GENE_PRODUCT", 13, 16], ["GYE", "GENE_OR_GENE_PRODUCT", 52, 55], ["YNP", "GENE_OR_GENE_PRODUCT", 86, 89], ["multi-host CDV", "ORGANISM", 239, 253], ["CPV", "ORGANISM", 311, 314], ["CAV-1", "GENE_OR_GENE_PRODUCT", 316, 321], ["CHV", "GENE_OR_GENE_PRODUCT", 327, 330], ["YNP", "GENE_OR_GENE_PRODUCT", 334, 337], ["coyote", "ORGANISM", 399, 405], ["YNP", "PROTEIN", 13, 16], ["CDV", "SPECIES", 250, 253], ["CPV", "SPECIES", 311, 314], ["CAV-1", "SPECIES", 316, 321], ["CHV", "SPECIES", 327, 330], ["multi-host CDV outbreaks", "PROBLEM", 239, 263], ["the constant high canid exposure", "PROBLEM", 275, 307], ["CPV", "TEST", 311, 314], ["CAV", "TEST", 316, 319], ["these pathogens", "PROBLEM", 351, 366], ["acute mortality", "PROBLEM", 459, 474], ["small", "OBSERVATION_MODIFIER", 22, 27], ["fraction", "OBSERVATION", 28, 36], ["overall GYE", "ANATOMY", 44, 55], ["carnivore", "OBSERVATION_MODIFIER", 181, 190], ["populations", "OBSERVATION_MODIFIER", 191, 202], ["Rocky Mountains", "OBSERVATION", 210, 225], ["CAV", "ANATOMY", 316, 319], ["pathogens", "OBSERVATION", 357, 366]]], ["Although N. caninum is unlikely to impact canid health, wolf exposure indicates a sylvatic cycle in the park, which may or may not be related to the parasite's dynamics among regional livestock.", [["N. caninum", "DISEASE", 9, 19], ["N. caninum", "ORGANISM", 9, 19], ["N. caninum", "SPECIES", 9, 19], ["N. caninum", "SPECIES", 9, 19], ["caninum", "OBSERVATION", 12, 19], ["unlikely to", "UNCERTAINTY", 23, 34], ["sylvatic cycle", "OBSERVATION", 82, 96]]], ["Canine distemper appears to cycle through YNP's carnivores in periodic epizootics, and may have contributed to low wolf-pup survival in 1999 and 2005 on the NR.", [["distemper", "DISEASE", 7, 16], ["epizootics", "DISEASE", 71, 81], ["Canine distemper", "ORGANISM", 0, 16], ["YNP", "GENE_OR_GENE_PRODUCT", 42, 45], ["pup", "ORGANISM_SUBDIVISION", 120, 123], ["Canine", "SPECIES", 0, 6], ["Canine distemper", "SPECIES", 0, 16], ["Canine distemper", "PROBLEM", 0, 16], ["periodic epizootics", "PROBLEM", 62, 81], ["distemper", "OBSERVATION", 7, 16]]], ["Although CDV does not appear to jeopardize the long-term population survival of YNP wolves, it can cause short-term population decreases.", [["CDV", "ORGANISM", 9, 12], ["CDV", "SPECIES", 9, 12], ["CDV", "PROBLEM", 9, 12], ["short-term population decreases", "PROBLEM", 105, 136]]], ["Additional information on how and where CDV is maintained and the frequency with which future epizootics might be expected would be useful for regional managers working on canids in the Northern Rocky Mountains.", [["epizootics", "DISEASE", 94, 104], ["CDV", "ORGANISM", 40, 43], ["CDV", "SPECIES", 40, 43]]], ["(K = number of estimable parameters, increasing differences from the best model (h) indicate decreasing model adequacy, and Akaike weights (w) express model support relative to all other models in the set.", [["K", "TEST", 1, 2], ["estimable parameters", "TEST", 15, 35], ["increasing differences", "PROBLEM", 37, 59], ["decreasing model adequacy", "PROBLEM", 93, 118], ["model support", "TREATMENT", 151, 164], ["increasing", "OBSERVATION_MODIFIER", 37, 47], ["decreasing", "OBSERVATION_MODIFIER", 93, 103], ["model adequacy", "OBSERVATION", 104, 118]]], ["Found at: doi:10.1371/journal.pone.0007042.s002 (0.14 MB DOC) Table S3 Wolf and coyote canine distemper seroprevalence and associated 95% score confidence intervals.", [["DOC", "CHEMICAL", 57, 60], ["canine", "ORGANISM", 87, 93], ["canine", "SPECIES", 87, 93], ["coyote canine distemper", "SPECIES", 80, 103]]], ["Sample sizes and the number of packs (for wolves) or regions (for coyotes) sampled are noted.", [["Sample sizes", "TEST", 0, 12], ["sizes", "OBSERVATION_MODIFIER", 7, 12]]], ["Found at: doi:10.1371/journal.pone.0007042.s003 (0.14 MB DOC) Figure S1 Mean wolf antibody titers to canine distemper virus in Yellowstone National Park, 1997 Park, -2007 .", [["canine distemper", "DISEASE", 101, 117], ["DOC", "CHEMICAL", 57, 60], ["canine distemper virus", "ORGANISM", 101, 123], ["canine distemper virus", "SPECIES", 101, 123], ["canine distemper virus", "SPECIES", 101, 123], ["MB DOC", "TEST", 54, 60], ["Figure S1", "TEST", 62, 71], ["Mean wolf antibody titers", "TEST", 72, 97], ["canine distemper virus", "PROBLEM", 101, 123], ["distemper virus", "OBSERVATION", 108, 123]]], ["Mean log 2 (antibody titers) are displayed with corresponding 95% confidence intervals for Northern Range (NR) and Interior pups (A) and adults (B).", [["Mean log", "TEST", 0, 8], ["antibody titers", "TEST", 12, 27], ["Northern Range", "TEST", 91, 105]]], ["Found at: doi:10.1371/journal.pone.0007042.s004 (7.71 MB DOC)", [["DOC", "CHEMICAL", 57, 60], ["DOC", "CHEMICAL", 57, 60]]]]}